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ABSTRACT 
 
Background: The noble gases xenon and argon are neuroprotective in models of brain 
injury. This thesis investigated the neuroprotective mechanisms of the inert gases xenon, 
argon, krypton, neon and helium in in vitro models of traumatic brain injury and ischemia.  
Methods: This study used an in vitro model of focal mechanical trauma and oxygen and 
glucose deprivation using mouse organotypic hippocampal brain slices. Injury was quantified 
by propidium iodide fluorescence.  
Results: Xenon (50.6 kPa) and, to a lesser extent, argon (50.6 kPa) are neuroprotective 
against traumatic injury when applied after injury (xenon 0.43 ± 0.03 protection at 72 h after 
injury [N = 104]; argon 0.30 ±0.0% protection [N = 44] vs control injury 1.0±0.05 [N=144]; 
mean ± SEM). Helium, neon, and krypton are devoid of neuroprotective effect. Xenon (50.6 
kPa) prevents development of secondary injury after trauma. Argon (50.6 kPa) attenuates 
secondary injury, but is less effective than xenon (xenon 0.50 ± 0.05 reduction in secondary 
injury at 72 h after injury [N = 104]; argon 0.34 ± 0.08 reduction [N = 44] vs control 
0.86±0.05 [N = 144]; mean ± SEM). Glycine reverses the neuroprotective effect of xenon, 
but not argon in both models of TBI and OGD, consistent with competitive inhibition at the 
N-methyl-d-aspartate receptor glycine site mediating xenon neuroprotection against traumatic 
brain injury.  
Conclusions: Xenon neuroprotection against traumatic and ischemic brain injury can be 
reversed by elevated concentrations of glycine, indicating a key role of inhibition of the 
NMDA receptor glycine co-agonist site in mediating neuroprotection against these injuries. 
Argon does not appear to have any effects on NMDA receptors and is neuroprotective via a 
mechanism distinct to that of xenon. Krypton and neon are devoid of neuroprotective effects 
in either injury model.  
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CHAPTER 1 
INTRODUCTION 
 
1.1      Traumatic Brain Injury  
1.1.1  Traumatic brain injury as a clinical condition 
 
Traumatic brain injury (TBI) occurs as a result of an external force causing mechanical 
disruption of brain tissue and delayed pathogenic events which collectively exacerbate the 
damage [1]. The requirement of an external force is what differentiates TBI from other types 
of brain injury, such as neurodegenerative brain conditions. Common examples of an external 
force includes the head being struck or penetrated by a foreign object, rapid acceleration or 
deceleration and exposure to blast forces [2].  
TBI is considered a global health concern as it is one of the leading causes of death and 
disability in people aged 15-44 in economically developed countries [3]. TBIs occur most 
commonly in men where they make up 75% of cases [4]. The main causes of TBI include 
motor vehicle accidents, falls and assaults. Epidemiological data from the European Union 
quotes  the incidence of hospitalisation for serious or fatal TBI to be an estimated 235 per 
100,000 of the population per year [3].  Survivors of TBI face a lifetime of care and 
rehabilitation due to physical, cognitive and psychological consequences of the injury. As a 
result many survivors suffer negative impacts on their relationships, independence and 
employment [5]. Worryingly, incidence rates for TBI worldwide are increasing  but overall 
mortality rates have only slightly improved since 1990 [5].  One reason for this rising 
incidence is due to the increased use of motor vehicles  in lower and middle-income countries 
[4]. 
TBI is included among the top three causes of injury-related medical costs in the USA and 
Europe with approximately 10-15% of patients that incur a TBI requiring long-term specialist 
care and treatment. The financial costs of TBI are great; in the USA alone they have been 
estimated at over $60 billion annually. However in his letter to the BMJ Ian Roberts is quoted 
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as saying trauma research has received ‘less funding than any other cause of human misery’ 
[6]. Indeed, TBI research is known to have one of the highest unmet financial needs within 
neuroscience research [4, 7].  
There is a requirement for continued research into markers of pathogenic processes after TBI 
and targeted treatments in order to refine diagnosis and improve prognosis for the patient. 
The lack of understanding of the pathophysiological mechanisms following severe head 
injury is a major reason for the slow progress in this field, which has been hindered further by 
the highly heterogeneous nature of head injuries. It is clear that the worldwide burden of TBI 
is vast, and the lack of available treatments only seeks to exacerbate this problem.  
 
1.1.2   Pathophysiology of traumatic brain injury 
 
1.1.2.1 Primary injury 
TBI is a highly heterogeneous disorder that presents differently depending on the type and 
force of impact. However, in all cases of TBI two major phases of injury can be identified, 
known as primary and secondary injury. A primary mechanical injury occurs abruptly upon 
impact and may be accompanied by skull fracture and disruption of brain parenchyma with 
the tearing of the brain tissue and surrounding blood vessels [4, 8]. Mechanical perturbation 
of neurones is associated with a massive release of neurotransmitters,  particularly glutamate 
and other excitatory amino acids, that contribute significantly to the secondary phases of 
injury [2]. Focal cerebral contusions are the most common form of primary injury [4].  
 
1.1.2.2 Secondary injury  
The sequence of pathological events that occur in the hours, days and weeks following the 
primary injury is known as secondary injury, and is considered in many cases to represent the 
major burden of injury. Support for the concept of a ‘delayed’ secondary damage has been 
provided by findings that 30-40% of patients who died after sustaining a head injury had a 
duration whereby they could obey commands or speak, known as a ‘lucid interval’ [9].  
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Secondary injury is an evolving, active process that involves many biochemical pathways. 
These pathways, often act concurrently and synergistically and include excitotoxicity 
pathways, ischemia, free-radical generation and inflammatory responses [4]. The figures 
below attempt to simplify these processes firstly by the order of occurrence after the primary 
injury (figure 1.1) secondly by where these processes occur within various neuronal and glial 
cells (figure 1.2) and lastly by the specific role of the NMDA receptor (figure 1.3) 
 
 
 
Figure 1.1: Events that occur following the initial primary injury that eventually culminate 
in cell death after a period of time that can span weeks. Figure adapted from McAllister 
(2011) [2] 
 
 
(NMDA 
receptors 
involved here) 
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Figure 1.2: The location within neurones and glial cells where pathogenic processes 
relating to secondary injury take place. Figure taken from Rosenfeld et al. (2011) [5] 
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Figure 1.3: The specific role of the NMDA receptor in mediating downstream excitotoxic 
pathways following traumatic brain injury. 
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It is clear that the development of secondary injury involves a complex interplay between 
many biochemical processes. The following sections will focus on the excitotoxic component 
of secondary injury development since this is most relevant to the current study, however 
other factors involved in its development will also be mentioned.  
1.1.2.3 Excitotoxicity  
A major component of the catastrophic neuronal death that occurs after TBI is believed to be 
mediated via the activation of excitatory ionotropic glutamate receptor ion channels, in a 
process known as excitotoxicity.  
NMDA receptors; structure and function 
Glutamate receptor ion channels are classified into N-methyl-D-aspartate (NMDA) receptors, 
α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate acid receptors (AMPA) and kainate 
receptors. All are permeable to positively charged ions; however AMPA and kainate 
receptors mediate fast excitatory transmission whereas NMDA receptors mediate the slow 
phase of excitatory transmission. NMDA receptors are usually located postsynaptically and 
require an initial rapid depolarisation mediated by AMPA/kainate receptors in order to be 
activated to remove the magnesium that blocks the channels at resting membrane potentials. 
An additional requirement of NMDA receptor activation is the presence of two agonists, 
glutamate and glycine, which bind at separate and distinct sites. Once activated NMDA 
receptors allow influx of calcium ions. Structurally NMDA receptors are tetrameric channels, 
made up of four subunits in what has been described as a ‘dimer of dimers’. The most 
abundant NMDA receptor subunit arrangement consists of two NR1 and two NR2 subunits 
[10]. Four isoforms of the NR2 subunit exist, known as NR2A, NR2B, NR2C and NR2D, 
each with a different intracellular C-terminal domain. NR2B subunits predominate in the 
postnatal brain but this switches to NR2A subunit predominance during development. 
Glutamate or NMDA binds to the NR2 subunit in a three dimensional structure formed by the 
extracellular N-terminus and the loop between the third and fourth transmembrane domains 
[10]. Glycine binds to a similar site on the NR1 subunit. A third NMDA receptor subunit, 
NR3 has been described, but its role (if any) in the brain is as yet uncharacterised [11]. 
Permeability to calcium ions underlies the physiological role of the NMDA receptor in 
mediating synaptic plasticity, an essential component of memory formation. NMDA 
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receptors are also involved in pathological processes. Glutamate is released in an 
uncontrolled manner during ischemic and traumatic injury leading to excessive NMDA 
receptor activation in a process known as excitotoxicity [8].  
NMDA receptors and excitotoxicity 
Numerous studies in clinical patients and animal models have shown that a traumatic impact 
to the brain is immediately followed by a massive extracellular release of glutamate [12, 13]. 
Glutamate levels in the brain increase after impact through a number of sources, including via 
enhanced exocytosis, via structural damage to the synaptic terminal, through a disrupted 
blood brain barrier from the blood and by astrocytic glutamate transporter impairment or 
reversal [14]. This increase in the levels of glutamate in the brain cause an over-stimulation 
of glutamate receptors (AMPA, kainate and NMDA), leading to prolonged depolarization and 
a resultant increase in intracellular calcium. Due to the higher permeability to calcium ions, 
NMDA receptors are thought to play an important role in excitotoxic development (see figure 
1.3) [13].  
Calcium overload and the activation of calcium-activated neutral proteases (calpains) is one 
of the key events in excitotoxicity. Calpain activation leads to the proteolysis of a number of 
intracellular proteins, including those of the cytoskeleton [15]. In addition to calpain 
activation, elevated intracellular calcium can also lead to an increase in oxidative stress and 
the activation of lipases and endonucleases which can damage DNA, cell proteins and lipids 
[8] and ultimately leads to death of the cell (see figure 1.3).  
Cortical spreading depression 
A process known as cortical spreading depression is thought to play a role in the spread of 
injury following traumatic impacts and involves a wave of depolarisation that propagates 
throughout the brain. The wave of depolarisation causes a massive release in excitatory 
amino acids including glutamate. Furthermore the voltage dependant magnesium block of 
NMDA receptors is removed by the depolarisation wave. This sensitises the NMDA 
receptors to small increases in extracellular glutamate which contributes to further neuronal 
depolarisation which propagates to neighbouring regions and continues the process [16].  
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1.1.2.4  Ischemia and free radical generation  
Following a traumatic injury the area around the direct trauma site often suffers reduced 
blood flow due to damaged blood vessels, haemorrhage and vasoconstriction, creating 
conditions of ischemia (see section 1.2.2). Under ischemic conditions the amount of nitric 
oxide (NO) in the brain increases due to upregulation of the enzyme that produces NO; 
neuronal nitric oxide synthetase (nNOS). The NO produced reacts with reactive oxygen 
species (ROS), for example, the superoxide anion, to produce peroxynitrite. A further source 
of free radical generation occurs after prolonged elevation of intracellular calcium (part of the 
excitotoxic response, see figure 1.3) whereby superoxide anions are formed by the respiratory 
chain. ROS production leads to lipid peroxidation and oxidation of thiol groups on critical 
proteins and ultimately cell death. The brain is particularly vulnerable to oxidative stress as it 
has a high rate of metabolic activity (which generates ROS), low antioxidant capacity, lack of 
cellular repair/regeneration mechanisms, a high membrane surface to cytoplasm ratio and 
high concentrations of transition metals, which are redox-active and capable of generating 
ROS through the Haber-Weiss reaction [8]. The Haber Weiss reaction occurs in cells and 
involves the generation of highly reactive hydroxyl radicals from hydrogen peroxide and 
superoxide anions in a reaction catalysed by iron.  
1.1.2.5 Inflammation  
The neuroinflammatory response to TBI occurs minutes after the initial injury and involves 
the activation of glial cells (microglia and astrocytes) and the infiltration of blood leukocytes 
[5, 17]. Immune system mediators are secreted from glial cells following injury. These 
include inflammatory cytokines (IL-1, IL-6-, TNF), the anti-inflammatory cytokines (IL-4, 
IL-10, TGF-beta) and the chemokines which drive the infiltration of activated blood 
leukocytes into the brain [5, 17]. These infiltrated leukocytes (neutrophils and monocytes) 
sustain the immune response to injury, causing an impairment in the integrity of the blood 
brain barrier. This in turn leads to an increase in extracellular fluid which, combined with cell 
swelling, leads to oedema and an increase in intracranial pressure. Despite their fast induction 
after injury, the activation of microglial cells can be sustained for several months following 
injury [17]. 
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In excess the inflammatory response is harmful and can contribute to secondary injury 
spread, but is also necessary for the ‘clean up’ of cellular debris after injury and may be a 
trigger for cellular regeneration [18]. It is unclear whether anti-inflammatory therapies could 
improve outcome after TBI in humans [19].  
 
1.1.3  Cell death mechanisms following TBI 
 
Secondary injury following TBI leads to cell death via apoptotic or necrotic mechanisms. 
There is evidence for both necrotic and apoptotic cell death in the brain following trauma, 
with apoptosis estimated to be responsible for around 50% of trauma induced cell death. 
Whether a cell undergoes apoptosis or necrosis has been postulated to involve factors such as 
the nature/severity of the injury itself and ATP availability, as apoptosis is an active, energy 
dependant process [15]. The following table summarises some of the morphological 
characteristics of cells undergoing apoptotic or necrotic cell death. 
 
Apoptosis Necrosis 
Single cells or small clusters of cells 
Cell shrinkage and convolution 
Pyknosis and karyorrhexis 
Intact cell membrane 
Cytoplasm retained in apoptotic bodies 
No inflammation 
Often contiguous cells 
Cell swelling 
Karyolysis, pyknosis and karyorrhexis 
Disrupted cell membrane 
Cytoplasm released 
Inflammation usually present 
 
Table 1.1: Comparison of the morphological characteristics of cells following apoptotic 
and necrotic cell death. Adapted from Elmore, 2007 [20] 
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Apoptotic ‘markers’ have been identified following trauma for both the intrinsic 
(mitochondrial) apoptotic pathway and the extrinsic death receptor pathway [15]. The 
extrinsic pathway involves the activation of death domains and caspase recruitment via TNF 
super family receptors. The intrinsic apoptotic pathway is triggered by mitochondrial 
dysfunction and involves a number of signalling pathways, which can include the NFκB 
dependant pathway, the p53 dependant pathway and activation of the pro-apoptotic bcl-2 
proteins (e.g. bak, bax, bcl-2). Induction of these factors leads to cleavage of the proenzyme 
caspases to their active form, subsequent release of cytochrome-c from mitochondria and 
activation of executioner caspases 3 and 9 (‘the executioner’). These activate DNA breaking 
enzymes such as endonucleases which leads to apoptotic cell death [8]. Once caspases are 
activated there appears to be an irreversible commitment to cell death, which occurs rapidly 
after activation [20].  
However, the brain does possess a number of endogenous protective mechanisms against a 
traumatic insult which attempt to counteract the damage and improve neuronal survival.  
These include heat shock proteins [21], anti-inflammatory cytokines and growth factors [18], 
antioxidants (e.g. superoxide dismutase and glutathione) [22], endocannabinoids [23], 
erythropoietin [24] and sex hormones [25].  However the actions of these survival promoting 
processes are limited both temporally and spatially, so in the case of a serious injury are often 
overwhelmed by the death promoting processes.  
 
1.1.4  Long-term pathophysiological consequences of TBI 
 
The debilitating aftermath of a traumatic brain injury extends far beyond the injury itself. 
Sustaining a TBI is considered to be a risk factor in the development of a number of health 
conditions that can persist throughout life or occur during the aging process. Epidemiological 
studies have identified a number of conditions that TBI patients are at increased risk of 
suffering from in the first three years following injury. These include an 11 fold increase in 
developing epilepsy, a 1.5 fold increased risk of developing depression, a 1.8 fold increased 
likelihood of binge drinking, a 2.5 to 4.5 fold increased risk of developing Alzheimer’s  
disease (from moderate and severe TBI respectively) and overall a 7.5 fold increased risk of 
death [26]. TBI is quoted as being “the best established environmental risk factor for 
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dementia’’ [27]. A meta-analysis conducted in 2003 investigating the relationship between 
TBI and dementia concluded that sustaining a TBI of sufficient severity to lose consciousness 
carried a 50% greater risk of developing dementia compared with others [28]. One study has 
identified a significant relationship between TBI and the development of schizophrenia, with 
the largest effect seen in people who are genetically predisposed to psychiatric disorders [29]  
It is estimated that up to one third of TBI survivors experience adverse effects on their mental 
health following the injury [30] .  
 
1.1.5  Clinical Treatment of TBI  
 
1.1.5.1 Current treatment strategies for TBI patients 
TBI patients often present with numerous pathologies, known as ‘polytrauma’, due to the 
accidental and/or violent nature of events that result in a TBI.  Where these injuries are 
potentially life threatening, they have to be dealt with by the emergency care team before 
medical management of the TBI becomes the priority.  
The medical management of TBI includes specialised prehospital care, in-hospital intensive 
care and for serious cases, long term rehabilitation [31]. Prehospital treatment guidelines 
recommend endotracheal intubation with ventilation assistance and blood-pressure treatment 
for shock (hypotension) where required. Patients with major trauma should be transported as 
soon as possible to a specialised trauma centre for further treatment [32].  
In the hospital TBI is traditionally classified by mechanism (closed or penetrating), by 
assessment of structural damage using neuroimaging techniques and by clinical severity 
using the Glasgow Coma Scale (GCS) [4, 33]. The GCS (table 1.2) is a graded assessment of 
the level of consciousness of the patient ranging from mild to severe that was once a 
universal classification system, but more recently its use is becoming limited due to the 
increasing awareness of additional factors that may influence level of consciousness and 
therefore overall score [34].  
 
Chapter 1 Introduction 
 
 
Page 24 of 170 
 
Eye Opening Motor Response Verbal Response 
 
4    Spontaneous                          
3    To speech  
2    To pain  
1    None 
 
6    Obeys                                  
5    Localises                             
4    Withdraws  
3    Abnormal flexion                
2    Extensor response              
1    None                                   
 
5    Oriented 
4    Confused 
3    Inappropriate 
2    Incomprehensible 
1    None 
 
Table 1.2: Glasgow coma scale. Mild traumatic brain injury (GCS 13-15) usually presents 
as a concussion and in most cases patients make a full neurological recovery albeit with 
some memory loss. In moderate TBI (GCS 9-13) the patient presents as being lethargic and 
in a state of near unconsciousness or insensibility. In severe TBI (GCS 3-8) the patient is 
in a comatose state and is unable to open their eyes or follow commands. These patients 
have a high risk of brain swelling, hypotension or hypoxaemia [32]. 
 
Within the hospital environment the major focus is to prevent ongoing brain damage inflicted 
by secondary injury by reducing brain swelling and treating raised ICP by sedation and 
artificial ventilation. Raised ICP can also be managed by osmotherapy, where rapid infusion 
of mannitol creates an osmolar gradient and improves ICP, however this treatment cannot be 
used for long periods [4]. A craniotomy to reduce pressure from swelling is performed in 
around 30% of patients [31].  Blood perfusion, temperature and oxygen and glucose levels 
are monitored as in normal intensive care treatment and prophylactic antiseizure steps may be 
taken. After these emergency steps patients are simply monitored for development of 
progressive damage and ICP and cerebral perfusion pressure managed as well as possible. 
Continuous EEG monitoring takes place to identify asymptomatic seizure activity which 
occurs in 15-18% of patients [4]. A more recently proposed neuroimaging method using a CT 
scan to focus on the presence or absence of a mass lesion has been described [35]. 
Furthermore using this method diffuse injuries can be differentiated by signs of increased 
intracranial pressure. However this technique is not without limitations, as CT can only 
capture a brief momentary snapshot of the dynamic and evolving processes following head 
injury and certain processes such as ischemic injury cannot be visualised. There are currently 
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no pharmacological therapies for the treatment of TBI that specifically target the secondary 
injury cascades.   
 
1.1.5.2  What does the future hold for TBI treatment?  
As far as treating TBI pharmacologically is concerned there are a number of compounds 
currently undergoing preclinical research for the treatment of secondary damage following a 
TBI. These include AMPA receptor antagonists, apoptosis inhibitors (e.g. caspase inhibitors), 
immunophilin ligands (e.g. MPTP suppressors; cyclosporine A [36]), ovarian hormones (e.g. 
oestrogen) and erythropoietin (for a review of these treatments see [37]).  
A lot of interest has been paid in recent years as to the effectiveness of hypothermia as a 
treatment for TBI, although its actual efficacy as a treatment is controversial.  It has shown 
promise in a variety of animal species and models and is believed to work via multiple 
mechanisms. These include a reduction in oxygen consumption and ATP depletion, a 
decrease in EAA levels, blood brain barrier stabilisation and subsequent reduction in 
infiltration of inflammatory cytokines and free radicals which also reduces cerebral oedema 
[38-42]. Numerous clinical meta-analyses’ addressing the effectiveness of hypothermia 
following TBI have been carried out, which have resulted in inconclusive results [43-45]. 
One study concluded that hypothermic therapy provides no significant benefit 6 months after 
treatment [45] whereas another found hypothermic therapy to reduce mortality and 
unfavourable outcomes (e.g. severe disability) but was also associated with a higher risk of 
developing pneumonia [44]. It still remains to be determined which types of TBI hypothermia 
treatment may show efficacy for and which is the best technique for inducing hypothermia in 
injured patients (surface cooling vs endovascular cooling) [39]. 
No new treatments for TBI have been approved for more than 30 years due to a number of 
factors. The most significant of these is that most drugs that make it through to phase III of 
clinical trials fail due to intrinsic neurotoxicity, failure to reach the site of injury and/or 
inappropriate design of clinical trials [31, 46, 47] (for an extensive list of these compounds 
see [9]). From a clinical perspective there is often much uncertainty over the stage of injury 
development the patient is at or whether the pathophysiological mechanism being targeted by 
a specific drug is actually present in the patient [4]. Despite this somewhat bleak prognosis 
for the future of TBI treatment in March 2010 progesterone entered phase 3 clinical trials for 
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the treatment of TBI. It is believed to exert its neuroprotective effect via reduction of cerebral 
oedema [48, 49]. Results of this study are not expected until 2014-2016. This, along with the 
various other compounds (mentioned above) with potential for treating this devastating 
condition, provides hope for researchers in the search for an effective treatment for TBI. 
In particular, potent neuroprotection by the noble gases xenon and argon has been 
demonstrated in in vitro models of TBI although only a single study for each has been 
published [50, 51]. It is therefore of great interest to investigate these gases, and the other 
noble gases, further in order to further characterise their neuroprotective potential and 
investigate their mechanism of action.  
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1.2  Ischemic Brain injury 
 
1.2.1  Ischemic brain injury as a clinical condition 
 
Cerebral ischemia occurs when an interruption of cerebral blood flow (CBF) leads to the 
deprivation of oxygen and glucose to brain tissues [8, 52]. Cerebral ischemia can arise via a 
number of mechanisms; via blockage of cerebral and extracerebral blood vessels, following 
cardiac arrest or after a period of prolonged  hypotension [53]. Cerebral ischemia is 
responsible for 88% of strokes. The duration of ischemia largely determines the extent of 
tissue damage and death of neuronal cells and thus the extent of the neurological deficit [52]. 
Brain cells at the ischemic core are at the highest risk of cell death, which occurs within the 
first few minutes of ischemia [8]. The tissue surrounding the core, known as the prenumbra, 
also suffers reduced blood perfusion. The cells in this region are at risk from various 
pathological processes that can be fatal to the cells. As such they only have a limited time 
frame for survival, however this does create an opportunity for therapeutic intervention [8].   
Like TBI, cerebral ischemia represents a major global public health problem. A stroke is the 
second most common cause of death (after heart disease) in most economically developed 
countries and is responsible for the deaths of approximately 6.2 million people (WHO 
statistics, 2011) worldwide each year [53]. Stroke is more common in men than women, 
although the risk of mortality is higher in women [53]. Risk factors for stroke include 
hypertension, diabetes mellitus and a family history, although the greatest risk factor is old 
age [52].   
The only currently approved stroke therapy is tissue plasminogen activator (tPA), which has 
been proven effective if administered to a subpopulation of patients within 3 hours of 
showing neurological symptoms. TPa is a thrombolytic drug which acts by enzymatically 
catalysing the conversion of plasminogen to plasmin, which is the principal enzyme involved 
in breaking down clots [53].   
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1.2.2  Shared mechanisms of injury between ischemic and 
traumatic brain injury 
 
Ischemic brain injury and traumatic brain injuries can occur in very different circumstances 
or concurrently (due to disruption of cerebral blood flow following TBI). A number of the 
molecular and cellular mechanisms that leads to cell death are shared between the two 
conditions [53]. These include excitotoxicity, reactive oxygen species generation, 
inflammation and apoptotic cell death.  
Following a reduction in cerebral blood flow, energy failure occurs due to a shortage of 
oxygen and glucose. These are the main sources of energy production via oxidative 
phosphorylation [54]. Reduced ATP levels impede the functioning of Na-K ATPase resulting 
in a loss of normal ionic gradients. Cytosolic Na
+
 increases in concentration and K
+
 
decreases, causing a depolarisation of the neuronal membrane which activates voltage gated 
Ca
2+
 channels [54]. A rapid influx of calcium results in the release of glutamate which binds 
NMDA and AMPA receptors leading to further calcium entry. Under normal conditions the 
excess glutamate is cleared by astrocytes and presynaptic uptake systems but this response is 
disrupted following ischemia [54]. Excessive calcium influx leads to the activation of 
numerous downstream signalling pathways, including activation of enzymes such as 
phospholipases and proteases and endonucleases which decreases cellular integrity and 
ultimately affects survival of the cell [54]. This process of excitotoxicity progresses similarly 
to that seen following a TBI.  
Oxidative stress occurs after ischemia when reactive oxygen species are produced by 
dysfunctional mitochondria [55]. The excess calcium entering cells during ischemia enters 
mitochondria and triggers the opening of the permeability transition pore and cytochrome c 
release; an early event in the apoptotic pathways. Production of reactive oxygen species leads 
to peroxidation of plasma membranes and organelle membranes, damage to the endoplastic 
reticulum and mitochondria and induces DNA fragmentation [54, 55]. 
In terms of the inflammatory reaction, ischemic onset leads to a rapid accumulation of 
microglia, followed by an influx of inflammatory cells such as granulocytes, leukocytes, T 
cells and monocytes and proinflammatory mediators such as cytokines and chemokines are 
released from the damaged tissue [54]. Infiltration of leukocytes complicates the injury 
Chapter 1 Introduction 
 
 
Page 29 of 170 
 
further by causing the release of additional cytokines and chemokines when in the brain 
tissue. This leads to an oxidative stress reaction and activation of matrix metalloproteinases (a 
family of endopeptidases involved in apoptosis) [54]. Activation of matrix metalloproteinases 
enhances the breakdown of the blood brain barrier and allows further entry of inflammatory 
cells into the damaged brain tissue. As with TBI there is also evidence that the inflammatory 
reaction can also be helpful as well as harmful, however to what extent is unclear [54].  
Apoptotic cell death is a feature shared by both ischemic and traumatic brain injury. As with 
a trauma, the cells at the core of the injury where ATP is heavily depleted most likely die via 
a necrotic mechanism (as with primary injury in TBI) [56]. The cells in the ischemic 
prenumbra die predominantly by apoptotic cell death. One pathway of apoptosis involves the 
previous mentioned opening of the mitochondrial permeability transition pore and 
cytochrome c release. Cytochrome c release triggers a series of events that ultimately leads to 
activation of proteolytic caspases. A second pathway of apoptosis involes the activation of 
pro-apoptotic proteins of the Bcl-2 family, such as bax. The extrinsic death receptor pathway 
of apoptosis involving the fas death receptor is also involved in cell death following ischemia 
[54] 
When considering shared pathways of injury it is important to remember that ischemic injury 
itself can form part of the secondary injury following a TBI. In conditions of a severe TBI, 
local damage to the vasculature and subsequent reductions in cerebral blood flow have been 
reported to result in ischemia [53].   
 
1.2.3  What does the future hold for treatment of ischemic 
brain injury 
 
There are generally two therapeutic approaches that are considered when seeking to improve 
outcome following ischemic brain injury. The first aims to improve blood flow to affected 
areas of the brain to target the metabolic issues that arise by increasing local concentration of 
oxygen and glucose available to the tissue. The second approach is via pharmacologic 
neuroprotection, by targeting a pathological process and selectively blocking it to protect 
tissue from further damage [57] 
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Previous attempts to translate experimental efficacy into clinically beneficial effects have so 
far not been hugely successful. Drugs that target excitotoxic cascades, antioxidants, anti-
apoptotic and anti-inflammatory therapies have all failed to produce clinically significant 
improvements in patients [8]. However there could be numerous reasons for their failure, 
including inadequate drug delivery, unrealistic therapeutic time windows and poor study 
designs.  Combination therapy has been gaining interest, as it is thought targeting multiple 
mechanisms may provide a greater benefit than targeting a single pathway, as blocking one 
pathway only may allow the other death promoting pathways to continue unhindered [8]. 
Good progress in the experimental setting has been made with combination therapy, for 
example combining the NMDA receptor antagonist xenon with hypothermia [58]. Other 
avenues to explore for neuroprotection includes further characterising the glial cell response 
to ischemia to make those cells (e.g. astrocytes) a possible target for neuroprotection or 
shifting attention towards repair of damaged tissues with the use of stem cells [54]. 
Along with neuroprotective strategies, advances in brain imaging techniques, such as 
magnetic resonance imaging and PET will allow for more accurate determination of tissues 
that are at risk of impaired blood supply following an ischemic attack which will therefore 
assist in the selection of appropriate neuroprotective strategies [57].   
Given the many shared mechanisms of injury progression between ischemia and traumatic 
brain injury, neuroprotective strategies that are found to be useful following one type of 
injury may hopefully prove beneficial for use in both conditions if certain pathogenic 
pathways are targeted.  
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1.3    Xenon as a Neuroprotectant 
 
1.3.1  The history and clinical profile of xenon 
 
Xenon is the 54
th
 element in the Periodic Table and exists as a monoatomic gas. It is 
categorised as a Noble gas due to its full outer shell of electrons. Xenon was first discovered 
in 1898 by the British chemists William Ramsay and Morris Travers. Its biological effects 
were reported many years later by Lawrence and colleagues in 1946 who reported 
behavioural effects including sedation and ataxia when mice were exposed to 0.4-0.8atm 
xenon [59].  
Xenon was first used clinically as a general anaesthetic agent in the early 1950s [60] and has 
been used experimentally in clinical anaesthetic practise for more than 60 years. In humans 
the published minimum alveolar concentrations of xenon for immobilisation (MACimmobility) 
are between 63% vol [61] and 71% vol [62]. Xenon possesses many of the properties 
characteristic of an ‘ideal’ anaesthetic. These include a rapid and smooth inhalational 
induction and emergence (regardless of anaesthetic duration) due to its very low blood/gas 
partition coefficient of 0.115 and low solubility in lipids (oil/gas partition coeffient; 1.9). 
Xenon is known to have an excellent cardiovascular stability profile (no change in heart rate 
or peripheral vascular resistance). It is also known to possess profound analgesic properties 
and seemingly no toxic, foeto-toxic, carcinogenic, mutagenic or allergic properties. Xenon is 
not metabolised by the kidney or liver and is excreted unchanged via the lungs [63]; this is 
advantageous as it eliminates the potential risk of toxic metabolite production and reduces 
usage costs as xenon can be recycled. Xenon’s safety and efficacy profile as an anaesthetic 
has been described as “unequalled” [64] . Xenon is manufactured by fractional distillation of 
air at a cost of £25 a litre which has thus far limited its widespread clinical use.  
Xenon has been shown to exert organoprotective properties, notably in the brain and heart. 
Indeed there is considerable interest in the use of xenon as a neuroprotectant after ischemic or 
traumatic brain injuries [50, 58, 65-68]. Its potential use in this setting is described more fully 
in section 1.3.3.  
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1.3.2  Molecular targets of xenon; binding properties and 
sites of action       
 
Noble gases are described as being ‘inert’ due to their inability to form covalent bonds with 
other molecules, thus it might be thought that noble gases would be incapable of biological 
interactions. However, some noble gases are capable of producing a biological effect via 
interactions with amino acids in the active site of enzymes or receptors [69]. The electron 
shell of xenon is capable of being polarised by surrounding molecules which induces a 
dipole, thereby enabling interactions with proteins via Van Der Waals interactions. This type 
of weak intermolecular force is also known as London dispersion forces or an ‘induced 
dipole-dipole attraction’, and underlies xenons ability to exert pharmacological effects 
despite its lack of reactivity.  
Many inhalational and intravenous anaesthetics potentiate inhibitory synaptic transmission 
via allosteric modulation of the ligand-gated GABAA receptor. Numerous studies have agreed 
that xenon has no substantial effects at GABAA receptors or other inhibitory (glycine) 
receptors [70-73]. Xenon also has no effect on N-type voltage-gated calcium channels [71, 
74, 75] and appears to target the NMDA receptor component of glutamatergic transmission 
[71, 76]. Based on this evidence it appears that xenon exerts its actions predominantly 
postsynaptically. 
The NMDA receptor was first discovered to be one of the targets of xenon when in 1998 it 
was found to inhibit NMDA evoked currents in hippocampal neurones by around 60% when 
applied at a clinically relevant concentration of  80% xenon [71]. Mechanistically, xenon is 
thought to exert its effects at the NMDA receptor via competitive antagonism at the glycine 
binding site [68, 71].  Electrophysiological studies identified the co-agonist glycine site as the 
target of xenon binding, and it is believed that xenon stabilises the open confirmation of the 
glycine binding domain, preventing the closure of these domains and subsequent NMDA 
receptor channel opening [76]. Consistent with competitive antagonism at the glycine site, 
xenon inhibits NMDA receptors more potently at low glycine concentrations than at high 
glycine concentrations (see figure 1.2a) [76]. Further work in this lab identified an amino acid 
(phenylalanine 758) that is essential for the interaction by xenon at the glycine site of NMDA 
receptors [77]. Lineweaver Burk analysis of NMDA receptor inhibition by xenon identified 
an additional non-competitive component of xenon inhibition (see figure 1.2b). 
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Figure 1.4 (a) Inhibition by 80% xenon in HEK cells transfected with the NR1/NR2A 
NMDA receptor subunits increases as glycine concentration is reduced. (b) Lineweaver-
Burk analysis shows a mixed competitive and non-competitive inhibition by xenon. White 
circles indicates 80% xenon, black circles indicate no xenon present.  The insets show 
example traces of the current produced in the absence and presence of 80% xenon at 
glycine concentration of 100µM (left) and 1µM (right).  Both figures from Dickinson et al. 
(2007) [76] 
 
Additional studies have identified possible non-NMDA receptor targets of xenon as the two-
pore domain K+ channel TREK-1 [78] Channels of this type act normally to modulate 
neuronal excitability by providing a background leak potassium conductance. Activation of 
these channels can cause hyperpolarisation of the cells and therefore reduce excitability [74]. 
Other targets include the ATP sensitive K+ channel (KATP) [79] which is thought to play a 
role in the preconditioning neuroprotective effect of xenon. A study in 2009 by Trapp and 
colleagues used neuronal-glial co-cultures exposed to 75% xenon in a preconditioning 
paradigm (15 minutes prior exposure) before being subjected to 75 minutes of oxygen and 
glucose deprivation 24 hours later. Exposure to xenon prevented cell death after the OGD 
procedure as measured by the MTT reduction test and this neuroprotection was reversed by 
the presence of 0.1mM of the KATP channel inhibitor tolbutamide.  Patch clamp 
electrophysiology experiments on HEK293 cells expressing the Kir6.2/SUR1 KATP channel 
revealed that xenon acts as a KATP channel opener as shown by an increased K
+
 current [79]. 
Further work by this group demonstrated that xenon targets the Kir6.2 pore forming subunit 
of the KATP channel [80]. Some subtypes of nicotinic acetylcholine receptors [81] and 5-HT3 
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receptors [82] are also thought to be targets of xenon, however the role (if any) of these 
channels in xenon’s pharmacological properties remains to be fully determined.  
Inhibition of NMDA receptors is thought to underlie a number of xenons pharmacological 
properties, including general anaesthesia and neuroprotection following brain injury (which is 
explained in greater depth in the following section). NMDA receptor glycine site antagonists 
are known to be well tolerated in patients.  
 
1.3.3  The neuroprotective properties of xenon and its 
potential use following traumatic brain injuries 
 
NMDA receptors are known to play a pivotal role in the progression of injury after a 
traumatic or ischemic brain injury (as outlined in section 1.1.2.3), hence it has long been 
postulated that NMDA receptor antagonists may be useful as neuroprotective agents. Xenon 
has been shown to be neuroprotective in in vitro [47, 68, 79, 83-86] and in in vivo [58, 65-67, 
87, 88] models of ischemic brain injury and in an in vitro model of TBI [50].  
A recent study by Banks et al. [68] investigated the mechanism of xenon neuroprotection in 
an in vitro model of ischemic brain injury, using hippocampal organotypic slice cultures 
exposed to OGD for 30 minutes followed by incubation with  50.6 kPa xenon for 24 hours. 
They found application of xenon to provide around 68% protection from OGD induced 
injury; which was not significantly different from a slice that received no injury. This 
neuroprotective effect was mediated by xenon’s competitive inhibition at the co-agonist 
glycine site of the NMDA receptor as addition of 100μM glycine abolished xenon 
neuroprotection entirely. Numerous studies have confirmed xenon’s efficacy as a 
neuroprotectant in in vivo models of ischemia, including middle cerebral artery occlusion [84, 
89, 90] and carotid artery ligation [66, 67, 91]) and direct injection of NMDA [47] with a 
reported lack of neurotoxic effects compared to other NMDA receptor antagonists (e.g. MK-
801) [87].  A number of studies have additionally investigated the synergistic neuroprotective 
effects of combining hypothermia with xenon administration in models of ischemia [58, 65, 
66, 69]. It is plausible that xenon binding is increased at lower temperatures which would 
correlate with its increased potency during hypothermia as it has been established that the 
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binding of volatile general anaesthetics increases at lower temperatures due to favourable 
enthalpic reactions [74, 92-94].  
In models of ischemic injury the therapeutic time window of xenon has been approximated at 
around 3 hours post injury [38, 67, 86, 97]. This is highly encouraging for the clinical 
implications for the potential use of xenon to treat these conditions, as it allows a window of 
opportunity for emergency services to reach the patient, assess their condition and move them 
to an appropriate location for treatment. From a further clinical perspective xenon’s 
pharmacological properties (outlined in section 1.3.1), particularly its lack of metabolism and 
good cardiovascular stability, allow for prolonged and repetitive dosing in the critical period 
after injury has been sustained. This provides xenon with an advantage over other agents that 
require IV infusion into the body which may require constant dosing.   
More recently xenon has entered into phase III clinical trials as a neuroprotectant following 
ischemic brain injuries, including cardiopulmonary bypass, neonatal asphyxia and brain 
damage following cardiac arrest. Previous clinical trials involving xenon have only 
investigated its safety and efficacy as a general anaesthetic [74]. As yet none of the 
neuroprotection trials involving xenon have been completed or have reported results. Any 
clinical benefits that xenon may possess would greatly outweigh the initial cost of xenon 
treatment in terms of financial costs of long term rehabilitation following brain injuries.  
A study by Coburn et al. [50] using in vitro model of focal traumatic brain injury found 75% 
xenon provide marked neuroprotection against the development of secondary injury. The 
mechanism of this neuroprotection is currently unknown, although it may involve 
interference with NMDA receptor signalling similar to that observed in ischemic injury. As 
yet only a single in vitro study and no in vivo studies investigating xenons neuroprotective 
potential after TBI have been carried out.                                                                        
1.4  Other noble gases as potential neuroprotectants 
 
The discovery of xenon’s neuroprotective properties has prompted researchers to investigate 
the potential of other noble gases helium, neon, argon and krypton as neuroprotectants [95] 
(radon is excluded as it is radioactive). As mentioned previously, the binding forces created 
by the formation of a temporary dipole relies on the ability of the gas to be polarised, which 
in itself it determined by the electronic configuration. It is therefore reasonable to predict that 
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other noble gases aside from xenon to have the capability of binding to proteins, receptors or 
molecules and thus exert some kind of biological effect.  
Helium and neon are known as non-immobilisers [96], that is, they are unable to cause 
anaesthesia even at elevated pressures. Argon and krypton possess anaesthetic properties, 
albeit at elevated pressures (4.5 atm krypton and 15 atm argon [74]). The difference in (or 
lack of) anaesthetic activity between the noble gases may be due to the ability of the gas to 
become polarised. The ability of the gas to interact with proteins arises from London 
dispersion forces and/or charge induced dipole interactions. Both of these are proportional to 
the polarizability. The binding energy must be sufficiently large to overcome the 
unfavourable (repulsive) entropy term associated with binding [74, 97]. Helium and neon can 
be distinguished from the other noble gases by the unfavourable balance between the binding 
forces and the repulsive forces [97].  Table 1.3 lists some of the key properties of the noble 
gases.  
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Physical Property Helium Neon       Nitrogen Argon Krypton Xenon 
Atomic number 2 10 7 18 36 54 
Atomic mass (g/mol) 4.0 20.2 14.0 39.9 83.8 131.3 
Density (g/l) (0
o
C) 0.1785 0.900 1.251 1.784 3.736 5.887 
Thermal conductivity 
(W/m/K) (300k) 
0.1499 0.0491 0.0260 0.0178 0.0094 0.0056 
Polarizability α (Ǻ3) 0.21 0.39 1.74 1.64 2.48 4.04 
Water/gas partition 
coefficient at 25
0
C 
0.0085 0.010 0.015 0.031 0.053 0.095 
Oil/gas partition coefficient at 
25
0
C 
0.016 0.019 0.07 0.14 0.44 1.9 
General anesthesia (atm) N/a N/a 39 15.2 4.5 0.95 
(mouse) 
0.6-0.7 
(human) 
 
Table 1.3: Physical properties of the inert gases and nitrogen. Reproduced from Dickinson 
and Franks 2010 [74].  
 
1.4.1  Helium as a neuroprotectant 
 
Helium is widely considered to be inert and lacking any intrinsic pharmacological activity 
and is often used in experiments to test the effects of pressure on biological systems [50, 74, 
96]. With regard to the neuroprotective properties of helium, numerous studies in different 
models and preparations of brain injury have yielded contrasting results. One in vitro study of 
ischemia found 50.6 kPa helium to have no effect on cell survival or death [68], whereas 
another in vitro study of ischemia found 75% helium to be detrimental to cell survival [95]. 
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To further complicate the matter, an in vivo model of focal ischemia found 75% helium to 
reduce infarct volume and improve functional outcome 24 hours post injury [98]. It is 
currently unknown why these differing results were found. David and colleagues [99] found 
that the neuroprotection afforded by helium following MCAO was temperature dependent, 
that is, when the inspired temperature was 25
0
C neuroprotection was seen, but when the 
temperature of the inspired helium was raised to 33
0
C this effect was abolished. They 
therefore propose that helium causes hypothermia when inspired, which is responsible for the 
neuroprotection. The high thermal conductivity of helium compared to nitrogen (0.1499 
W/m/k vs 0.0260 W/m/k) makes this theory entirely plausible [74], as breathing in helium 
below normal body temperature will cause a reduction in core temperature. This may also 
provide an explanation for differing findings in different models of brain injury if 
temperature of the model during experimentation was not strictly monitored or regulated 
[74].  
 
1.4.2  Neon as a neuroprotectant 
 
Neon has received very little attention with regard to biological activity, as it appears to 
possess none. Only a single in vitro study of ischemic brain injury has been carried out 
involving neon, which found it to have no effect [95].  Neon has a thermal conductivity that 
is twice that of nitrogen (0.0491 W/m/k) therefore may induce hypothermia upon inhalation, 
although to a much lesser degree than helium. Further studies in different models of brain 
injury are required to assess neon’s potential as a neuroprotective gas.  
 
1.4.3  Argon as a neuroprotectant 
 
Argon, another of the noble gases capable of causing anaesthesia (at elevated pressures) has 
been found to be neuroprotective in certain in vitro and in vivo models of ischemic and 
traumatic brain injury at both elevated and normobaric pressures [51, 95, 100-102]. Argon 
has been found to be less potent as a neuroprotectant than xenon [95]. However argon has an 
advantage over xenon in that it is more abundant in the atmosphere (0.93%) and is thus 
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substantially cheaper to obtain and would not require a closed circuit delivery system [103]. 
The molecular targets of argon and its mechanism of neuroprotective action are currently 
unknown.  
1.4.4  Krypton as a neuroprotectant 
 
Krypton is another of the noble gases that has received very little attention thus far, despite 
the fact it does appear to possess some biological properties. Krypton is an anaesthetic under 
hyperbaric conditions (4.5 atm) although no molecular targets for anaesthesia have been 
identified [74]. To date only a single study has investigated the neuroprotective effects of 
krypton. Jawad and colleagues [95] used pure neuronal cultures exposed to OGD for 90 
minutes in order to determine whether noble gases, including krypton, displayed any 
neuroprotective properties. They found exposure to krypton (at the same effective 
concentration of xenon, 75%) did not have a protective effect, but instead krypton was found 
to be injurious to uninjured cells.  
Given the conflicting results on the efficacy of inert gases (other than xenon) as 
neuroprotectants, one aim of this study was to investigate the effects of all the inert gases 
under identical conditions.  
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1.5  Aims of research 
1.5.1  Research outline 
 
It is clear from the literature that there is a critical need for effective compounds to treat 
secondary injury development following a traumatic brain injury, as there are currently no 
treatments approved for this condition. The aim of this thesis is to investigate the 
neuroprotective efficacy of the noble gases xenon, argon, krypton and neon in an in vitro 
model of TBI, the first of its kind.  Once a neuroprotective effect has been established, this 
project aims to investigate the mechanism by which this is achieved focusing on the 
involvement of the glutamatergic NMDA receptor. Knowing the mechanism of a 
pharmacological compound is important for a number of reasons. It can answer some 
important questions as to when administration of the drug is required in order to achieve 
maximum efficacy, what potential side effects the drug may have, how long administration is 
required for, which combination therapies may enhance its effects and what other pathologies 
it may be useful for which share a similar injury mechanism, among others.  
The method chosen to model TBI in vitro uses organotypic hippocampal slice cultures 
subjected to a weight-drop injury to create a primary focal contusion injury. These cultures 
allow long term maintenance of the slices to monitor the development of secondary injury. 
Injury in the slices will be assessed via fluorescence imaging in the days following the initial 
injury. Treatment with gases will be applied via a custom built chamber following the initial 
injury and maintained throughout the experimental protocol.  
Further to addressing neuroprotection following TBI, this project will also investigate the 
mechanism of neuroprotection by the noble gases in an in vitro model of ischemic brain 
injury. Targeted treatments for the reduction of secondary injury development following 
ischemic brain injury represents another unmet clinical need thus research into 
neuroprotective strategies is of great interest. The same hippocampal organotypic slice 
culture model will be utilised for this investigation, with injury inflicted via 30 minutes of 
oxygen and glucose deprivation prior to treatment.  
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1.5.2  Hypotheses   
 
Given previous findings and the available evidence the hypotheses for this project are as 
follows: 
1. Given the wealth of data regarding the efficacy of xenon as a neuroprotectant in 
various models of acquired brain injury it is hypothesised that xenon will provide 
neuroprotection against secondary injury development following TBI in vitro. 
2. Glutamate excitotoxicity is a well-established mechanism involved in the 
development of secondary injury following TBI. Given that xenon acts as an 
antagonist of the NMDA receptor at its glycine binding site [76] it is reasonable to 
hypothesise that this mechanism may also be responsible for the neuroprotection 
observed after TBI.   
3. I will test the hypothesis that the other noble gases helium, neon, argon and krypton 
are neuroprotective following traumatic brain injury in vitro.  
4. If these gases are found to be neuroprotective, then I will test the hypothesis that the 
other gases provide neuroprotection via the same mechanism as xenon.  
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1  Preparation and maintenance of neonatal 
C57BL/6 mouse hippocampal organotypic slice cultures 
 
Organotypic cultures are slices of tissue which are cultured whole, without dissociation of the 
individual cells. Organotypic slice cultures maintain normal structural, organisational, and 
functional features of native brain tissue with preserved synaptic and chemical signalling, 
which allows for functional analysis of the properties of nervous tissue [104-106]. 
Organotypic slices maintained in culture from neonatal mice closely mimic developmental 
events that occur in vivo [106]. The spatial orientation and complex electrophysiological 
pathways between cell types of particular brain regions are maintained in three dimensions in 
this system, with greater fidelity to the in vivo state than is possible with other systems. (A 
detailed description of the similarities between organotypic slices and the in vivo brain 
appears in Discussion section 7.1.1).  
The hippocampus was chosen as the brain region under investigation for a number of reasons. 
Bilateral loss of hippocampal neurons has been observed in 85% of fatal head injury cases as 
soon as 48 hours following the initial traumatic event [107]. This is suspected to be due to the 
high density of NMDA receptors in this brain region, making it particularly at risk of 
excitotoxic damage especially in the CA1 region where density is highest. A study by 
Watanabe et al. of adult wild type C57BL/6 mouse brain found distribution of the NR2 
subunit of the NMDA to have the highest levels of expression in the hippocampus (see figure 
2.1). High levels are also detected in the cerebral cortex and granular layer of the cerebellum 
[108]. The hippocampus is therefore an obvious choice of brain region when investigating a 
pharmacological compound that possibly targets the NMDA receptor.   
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Figure 2.1: NMDA NR2A subunit distribution in the brain of adult wild type C57BL/6 
mice visualised using immunohistochemistry. Image adapted from Watanabe et al. [108]. 
Scale bars indicate 1mm.  
Hippocampal slices were obtained from 5-6 day old neonatal C57/BL6 mouse pups using a 
modified interface method of Stoppini et al. [109]. All experiments were performed in 
compliance with the United Kingdom Animals (Scientific procedures) Act of 1986 and have 
been approved by the Ethical Review Committee of Imperial College London.  Mice were 
purchased as a dam with a litter averaging 5 pups (Charles River, UK) and all efforts were 
used to minimise suffering and the number of animals used. 
 
2.1.1  Preparation of laboratory prior to dissection.  
 
It was not possible to carry out the dissection and slicing procedure in a laminar flow hood so 
every care was taken to sterilise the environment in which the slices were prepared and a 
number of steps were taken to prevent contamination. A labcoat, latex gloves, hairnet and 
PPE mask were worn and all surfaces wiped down with 70% ethanol.  Sterile autoclaved 
paper towels were laid down in all areas of the bench and culture hood and all dissection 
equipment treated with Virkon (VWR International, Leicestershire, UK) before being 
autoclaved and sprayed with 70% ethanol before use. Dissection dishes (150mm glass petri 
dishes containing a base of Sylguard elastomer (Dow Corning, MI, USA)) and individual 
razor blades (Wilkinson Sword, Bucks, UK) were autoclaved and sprayed with 70% ethanol 
before use.  The plastic chopping disk for the tissue chopper was also sterilised by immersion 
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in 70% ethanol for at least 1 hour. All equipment was allowed to dry fully before use.  
Solutions necessary for the procedure (dissection media and growth media) were kept on ice 
and all petri dishes that would contain brain tissue at any point were placed on a large metal 
heat-sink on ice to ensure temperatures were kept as low as possible throughout. Unless 
indicated all solutions were purchased from Sigma Aldrich (Dorset, UK).  
 
2.1.2  Dissection of mouse brain, slicing and isolation of 
hippocampus.  
 
Organotypic cultures were prepared from 2 or 3 pups at a time. Any more than 3 would 
extend the time taken to complete the procedure which may compromise the health of the 
hippocampal slices. Pups were culled by schedule 1 euthanasia (cervical dislocation) 
followed by decapitation with the head handled using sterile paper towels.  Surgical scissors 
were used to cut the skin from the neck to the nose along the midline to allow the peeling 
back of the skin to access the skull. Using Vannas scissors an incision was made at the caudal 
end of the skull above the cerebellum across the left and right hemispheres. A second incision 
was then made along the midline in a rostral direction before a third incision was made above 
the olfactory bulbs. This ‘I’ shape that was cut created two panels of the skull which were 
pulled back carefully using forceps to reveal the brain beneath. The brain was gently removed 
using a small spatula and transferred to a dissection dish containing ice cold dissection media 
(Gey’s balanced salt solution with 5gl-1 D-glucose (Sigma G8270) and 1% antibiotic-
antimycotic suspension (Amphotericin B, penicillin, streptomycin, Sigma A5955)). Using a 
razor blade (Wilkinson Sword, Bucks, UK) a coronal cut was made at the caudal end of the 
brain removing the cerebellum and a second cut was made along the midline to separate the 
two hemispheres. These were then transferred to a 35mm petri dish on a cold heat-sink and 
taken to the culture hood. In the hood the hemispheres were transferred again to a dissection 
dish under a light microscope and the olfactory bulbs removed with a razor blade. This 
created a flat surface on which to stand the hemispheres on allowing for easily removal of the 
midbrain by gently teasing apart the midbrain from the cortex using ultra-fine forceps. 
Flipping the cortex back into its side revealed the hippocampus running obliquely through the 
middle.  
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The pre-cooled plastic chopping disk was then attached to the cutting table of the McIlwain 
Tissue Chopper (Mickle Laboratory Engineering Co., Surrey, UK) and an excess of ice cold 
dissection medium added to its surface. A clean sterile razor blade was affixed to the blade 
holder and dropped against the chopping disk to confirm they sat flush against one another 
during slicing. The brain tissue was transferred using a spatula and orientated so that the axis 
of the hippocampus was parallel to the chopper blade. The excess medium was removed with 
a fine tipped Pasteur pipette and the tissue chopper switched on immediately. Tissue was 
sliced at 400μm thick at 50% chopping speed and force (arbitrary units). After slicing ice 
cold dissection media was re-applied to the slices before transferring them to the dissection 
dish with the flat of a scalpel blade. Using ultra-fine forceps the slices were gently teased 
apart (with care being taken to avoid touching the hippocampus) and the hippocampus 
removed from the surrounding cortex with ultra-fine vannas scissors. A cut off Pasteur 
pipette was used to transfer the individual hippocampal slices to a fresh 35mm petri dish 
containing ice-cold dissection media.   
A p5 mouse brain generated on average 10-12 hippocampal slices per hemisphere.  
 
Figure 2.2: Bright field photograph of a typical p5 hippocampal slice prior to plating on 
membrane.  
 
2.1.3  Plating of slices onto membrane 
 
The petri dish containing the hippocampal slices was transferred to a sterile laminar flow 
hood where it was placed in a pre-cooled heat sink to prevent warming of the slices during 
plating. A cut-off Pasteur pipette was used to transfer 5-6 slices to each tissue culture insert 
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(Millicell CM, Merck Millipore, Darmstadt, Germany) which were themselves placed inside 
sterile 35mm petri dishes, with care being taken to distribute the slices evenly around the 
membrane and with suitable distance from the membrane edge. The excess dissection 
medium was removed with a fine-tipped Pasteur pipette. Around 1ml of ice cold growth 
media (50% Minimum essential media with Earle’s salts, L-glutamine and bicarbonate Sigma 
M4655, 25% Hank’s balanced salt solution Sigma H9269, 25% heat-inactivated horse serum 
Sigma H1138, 2mM L-glutamine Sigma G7513, 5mg ml
-1
 D-glucose Sigma G8270, 10mM 
HEPES VWR 441485H, 1% Antibiotic-antimycotic suspension Sigma A5955; pH 7.2) was 
then added to the petri dish; enough so that it completely covered the base of the membrane 
but without overflow or ‘floating’ of the insert. Following plating all dishes were transferred 
to a humidified incubator at 37
0
C with 5% CO2.  
                
 
Figure 2.3: Schematic diagram of hippocampal organotypic slices plated on a membrane 
at the ‘air-medium’ interface, allowing the slices access to both growth media and oxygen.  
 
2.1.4  Maintenance of organotypic slices 
 
Medium was replaced with prewarmed (37
o
C) growth medium the day after plating, and at 
least every 3 days thereafter for around 10-14 days before experiments were began. Old 
media was removed from beneath the membrane using a fine-tipped pipette and replaced with 
fresh growth media. Care was taken not to disturb or stretch the membrane in any way during 
37
O
C, 5% CO2 
Growth media  Membrane insert 
35mm Petri dish 
Organotypic slice 
Chapter 2 Materials and Methods  
Page 47 of 170 
 
media changing, as a ‘stretch’ of the slice itself is considered an injury paradigm for TBI 
[110].  
 
2.2  Traumatic brain injury in vitro 
 
In vitro models of TBI provide researchers with a platform on which to perform well 
controlled, repeatable and environmentally isolated experiments [111] whilst allowing 
investigation of specific pathways without systemic or vascular influences. Numerous in vitro 
models of TBI exist all of which aim to recreate distinct components of injury cascades 
following injury. This study aimed to recreate conditions of a focal contusion (compression) 
injury, which in itself is characterised by a region of primary injury followed by a secondary 
spread of injury. Primary injury was inflicted upon the slices by dropping a weight onto them 
using a custom built impact device.  
 
2.2.1  Building the traumatic impact device 
 
The traumatic impact device was custom built in house. The design was inspired by the in 
vitro TBI device used by Coburn et al. [50] and others [112, 113] to model primary injury 
followed by secondary injury development after TBI. The device was designed to drop a 
small weight (hereafter referred to as a ‘stylus’) onto the slice at a defined energy to inflict a 
focal injury in the CA1 region. The mechanism of the weight drop device was simple; an 
electrical current (4 x 6V batteries) was delivered to an electromagnet upon which the stylus 
would suspend due to the magnetic force. By switching a relay switch momentarily the 
current was interrupted and the stylus was allowed to make brief contact with the surface of 
the hippocampal slice with a selected energy (see figure 2.4). Impact energy (J) was 
determined by the height above the slice and calculated using the equation mass (kg) x 
acceleration (m/sec
2
) x height (m) [113].  
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Figure 2.4: Schematic diagram of electrical circuit for impact device. Current supplied to 
an electromagnet suspends the stylus above the surface of the slice. The relay switch allows 
for a brief interruption to the current allowing the stylus to drop.  
 
The stylus had a diameter of 1.3 mm and mass of 70 mg with the distal part of the stylus 
smooth and rounded to prevent perforation of the slice. The stylus was held in a glass 
capillary for support which was mounted within a plastic support allowing for the easy 
removal of the stylus from the electromagnet for sterilisation. The electromagnet was 
attached to a three-axis micromanipulator for easy positioning of the stylus over the CA1 
region and for accurate determination of drop height (see figure 2.5). After building the 
circuit and stylus and mounting them on a micromanipulator the supporting structure of the 
TBI device was built. This included a stereomicroscope to visualise regions of the slices and 
monitor impact, and a support platform for the slices which consisted of an upturned large 
glass petri dish (see figure 2.4) under which a fibre optic light source was positioned to 
enable illumination of the slices from beneath (not pictured).   
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Figure 2.5: (A) Traumatic impact device including supporting structures and power supply 
and (B) a close up of the electromagnet with the stylus (circled) suspended above the slices. 
 
2.2.2  Preparation of slices for experimental procedures 
 
After 10-14 days in culture the slices were ready to begin experimentation. Each experiment 
consisted of 6 membranes per 6-well plate, half of which were assigned into a sham group 
and the other half were assigned to receive a TBI. This was done so that sham slices received 
exactly the same conditions (besides TBI injury) as the TBI slices in the same 6-well plate. 
All membranes contained slices that were dissected on the same day from the same litter and 
each membrane contained on average 5-6 slices. Assignment into sham or TBI groups was 
carried out before initial imaging to avoid potential bias when the health status of the slices 
was already known. The membranes were transferred into a 6 well plate with custom-made 
metal rings inserted into the wells to raise the membrane into the magnification range of the 
2x objective of the florescence microscope. Each well contained ≈8mL of pre-warmed (37oC) 
experimental media containing Propidium iodide (PI) (75% Minimum essential media with 
Earle’s salts, L-glutamine and bicarbonate, 25% Hank’s balanced salt solution, 2mM L-
glutamine, 5mg mL
-1
 D-glucose, 10mM HEPES, 1% Antibiotic-antimycotic suspension, 
4.5μM propidium iodide; pH 7.2). PI is a membrane impermeable dye that only enters cells 
with damaged cell membranes, where it forms an irreversible bond principally to DNA [114]. 
When bound it becomes highly fluorescent with a peak emission in the red region of the 
A B 
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Plastic support 
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24V electrical 
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visible spectrum. PI is known to be non-toxic to neurons (as interaction with DNA can only 
occur in a cell with a compromised membrane) and is used frequently as an indicator of 
neuronal integrity and cell viability [115]. 
Membranes were transferred with the aid of forceps and the level of experimental media 
beneath the membrane topped up using a fine tipped pipette to ensure no bubbles remained. 
Slices were incubated for 1 hour at 37
o
C in this medium to allow PI to equilibrate, as 
previous studies have found PI binding to reach maximum after 30 minutes exposure [50]. 
For experiments where exogenous glycine and strychnine were added to the experimental 
media, these agents were present in the media at the time of transfer to completion of the 
experiment. 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: A study by Coburn et al. [50] found PI binding following permeabilisation with 
70% ethanol to be rapid, with a half time of 7 minutes and complete by 30 minutes. Image 
from Coburn et al. 2008 [50] 
 
2.2.3  Fluorescence imaging of organotypic slices 
 
One hour after transfer into experimental media slices were transferred in an insulated 
polystyrene box to the fluorescence microscope for imaging (Nikon Eclipse 80). Imaging was 
carried out before experimentation (referred to as t=-1 imaging) to identify any slices whose 
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viability was compromised in order to exclude them from experimental analysis (see section 
2.4 for exclusion criteria).  
Slices were imaged using a Nikon Eclipse 80 florescence microscope with a super high 
pressure mercury lamp. Due to the lamp intensity dropping over time, the exposure time of 
each set of slices per session was adjusted using a glass slide standard (Fluor-Ref Texas red, 
Omega Optical, VT, USA) as a reference. Exposure time was adjusted depending on the 
mean intensity of the red channel in the glass slide standard which was exposed for 4ms 
under a 10x objective.  The text on the slide was used to gain focus. The ratio of the 
maximum intensity of 126.6789 (previously measured) to the intensity measured in each 
session was multiplied by the exposure time for the slices (1.2 seconds) to calculate the 
relative exposure time for that session ((126.6789/measured intensity)*1.2). This exposure 
time was selected as it did not cause a saturation of the image at any level of injury (be it 
uninjured t-1 slices or maximally damaged 70% ethanol treated slices).  Slices were imaged 
using the calculated exposure time for that session.  A hairdryer was used to gently heat the 
lid of the plate if condensation built up inside which would attenuate the signal from the PI. 
The hairdryer was held at a distance of around 2 ft to avoid damaging the slices. After 
imaging slices were transferred back into the incubator for 1 hour to equilibrate temperature 
back to 37
o
C.  
2.2.4  Traumatic impact procedure   
 
Before starting the impacting procedure the hood and equipment (figure 2.5) were cleaned 
and sterilised with 70% ethanol. During the procedures a face mask, hair net and gloves were 
worn to avoid contamination of the slices. The stylus was pre-sterilised by spraying liberally 
with 70% ethanol before being placed under a UV lamp for 1 hour before impacting. It was 
essential that the stylus be sterilised thoroughly as it comes into direct physical contact with 
the slices. The slices were transported from the incubator to the impactor in an insulated 
polystyrene box, the lid removed and the slices placed on the glass platform. The well which 
was to be impacted was positioned below the stylus with a cold light source focused beneath 
it. Using the micromanipulator the stylus was lowered and positioned under the microscope 
so that it just touched the membrane in a region where there were no slices in close 
proximity. This was assigned the 0’ position and the height of this read off the 
micromanipulator and recorded. The stylus was then raised 1-2mm from the surface of the 
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slice and positioned above the CA1 region using the microscope; this allowed accurate 
determination of where the stylus would drop. The stylus was then raised to the full height 
(5mm) and the relay switch pressed briefly to allow the stylus to drop and then retract 
instantly. This process was monitored under the microscope to ensure all slices were hit in the 
correct region. Once all slices in a well had been impacted the entire procedure was repeated 
for each well until all slices (except shams) had been impacted. Previous experiments during 
calibration of the device determined that the 0’ position did not change within each well 
(ensuring all slices were impacted from the 5mm height) but did change between wells, thus 
its position was determined for each individual well. The impacting procedure was carried 
out with both accuracy and efficiency in mind; typical impacting experiments took less than 
10 minutes to complete fully. Half of the wells in each 6 well plate was assigned as a sham 
group, and half of the wells the TBI group. Assignment into sham or TBI groups was carried 
out before the initial t0 imaging.  
 
2.2.5  Hyperbaric chamber procedure and application of 
experimental gases following TBI 
 
Immediately after impacting slices were carried to the custom made hyperbaric gas chamber 
in the heat box and sealed inside. The chamber (figure 2.7) had a volume of 0.925 litres and 
was capable of maintaining pressures of up to 6 atm for several days. With the inlet and outlet 
valves both open the chamber was flushed with humidified gas (20.2 kPa O2/76.0 kPa 
N2/5.0kPa CO2) for 5 minutes at 5 l min
-1 
(determined by a flow meter); this ensured better 
than 99.99% gas replacement. The gas was humidified by bubbling through a sealed beaker 
of autoclaved H2O. Following flushing the outlet valve was sealed and 50.6 kPa experimental 
gas (helium/neon/argon/krypton/xenon) was added slowly over >1minute before sealing the 
inlet valve. The chamber had an integrated pressure gauge for accurate determination of 
pressure within the chamber. Following addition of experimental gas the high speed chamber 
fan was switched on for 5 minutes to allow for rapid mixing of gases. Some concentration 
response experiments involving argon and xenon required 30.4 kPa or 70.9 kPa of 
experimental gas added. No blinding took place to the treatment condition as analysis of the 
injury levels in the slices was purely quantitative from this point on, that is, no part of the 
analysis had any subjective element that could be affected by subconscious bias.  
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The chamber was housed inside an incubator set at 37
o
C. This temperature was maintained 
throughout all experiments. Previous experiments using the chamber (conducted by Paul 
Banks) found that the flushing and pressurisation procedures had negligible effects on 
temperature within the chamber. Opening of the chamber was found to cause a transient 1
o
C 
drop in temperature and pressurisation  with 50.6 kPa experimental gas was found to cause a 
transient temperature increase of 0.5
o
C (when pressurisation was carried out >1minute) which 
returned back to 37
o
C within 30 minutes. Temperature was maintained at 37
o
C inside the 
chamber throughout all experiments.  
 
 
 
 
Figure 2.7: Custom made hyperbaric chamber with integrated pressure gauge and mixing 
fan.   
After 24 hours of exposure to experimental gases, slices were removed from the chamber by 
slowly releasing the pressure (over >1 minute) and carried to the florescence microscope in 
an insulated polystyrene box. Slices were imaged as outlined in section 2.2.3 before being 
immediately returned to the chamber. Flushing, addition of experimental gas and mixing was 
repeated every time the slices were removed from the chamber.  Slices were imaged again at 
48 and 72 hours to monitor the development of injury. Injury was quantified and 
High speed chamber fan 
Pressure gauge  
Outlet valve 
Inlet valve 
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subsequently analysed as outlined in section 2.4. A full schematic representation of the TBI 
protocol is shown in figure 2.8.  
 
Figure 2.8: Schematic timescale of TBI protocol. After 14 days in culture slices are 
transferred to experimental medium containing PI and reincubated for 1 hour to allow PI 
binding to equilibrate. Slices are then imaged to assess general viability before another 
reincubation period of 1 hour to equilibrate temperature back to 37
O
. Slices are then 
impacted and sealed in the chamber for 24 hours before imaging and returned to the 
chamber. Subsequent imaging takes place at 48 and 72 hours.  
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2.3  Oxygen and glucose deprivation in vitro 
 
Preparation of organotypic slices for the oxygen and glucose deprivation (OGD) protocol 
were prepared as outlined in section 2.1. Additionally, the preparation of slices for 
experimental procedures and the florescence imaging of slices before experimentation were 
carried out as described in sections 2.2.2 and 2.2.3.  
 
Immediately after imaging slices were taken to a laminar flow hood and transferred to 
Ringers solution (120mM NaCl, 5mM KCl, 1.25mM NaH2PO4, 2mM MgSO4, 2mM CaCl2, 
25mM NaHC03, 10mM sucrose, 20mM HEPES, pH 7.25). For sham experiments sucrose 
was replaced with 10mM D-glucose but all other ingredients remained the same. Ringers 
solution was deoxygenated for OGD experiments by bubbling for 45 minutes at 50 mL min
-1
 
with 96.3 kPa N2/5.0 kPaCO2. The sham ringers was bubbled with (20.2 kPa O2/76.0 kPa 
N2/5.0kPa CO2) for the same time and at the same flow rate. After bubbling, the solution was 
transferred to a sterile laminar flow hood where it was immediately drawn into a 50mL 
syringe using a 5” kwill filling tube (Smiths medical supplies, Kent, UK), the tube was then 
detached and filtered through a 0.2µm cartridge filter and injected into the bottom of a 15ml 
falcon tube using another 5” kwill filling tube. Kwill tubes were used to limit reoxygenation 
of the solution by exposure to air. Falcon tubes were filled to the brim and inverted to check 
for bubbles. Ringer’s solution was always bubbled and filtered on the day of use, usually 
around 60 minutes before required and pre-warmed to 37
O
C.  
 
For the transfer, a 6 well plate that had been prepared previously with rings warmed to 37
O
C 
was removed from the incubator and one individual 15ml Falcon tube of deoxygenated 
Ringers solution was poured into a well.  Using forceps the membrane was carefully removed 
from the plate containing experimental media and the underside of the membrane briefly 
washed in a petri dish containing Ringers solution to remove residual experimental media 
that might contain traces of D-glucose. The membrane was transferred into the well 
containing Ringers solution and topped up to remove any bubbles beneath. This process was 
repeated for the remaining 5 wells. The slices were immediately transferred to the chamber 
which was then flushed with 96.2 kPa N2/5.0 kPa CO2 for 5 minutes at 5 L min
-1
 (or (20.2 
kPa O2/76.0 kPa N2/5.0kPa CO2) for sham experiments). After flushing the inlet and outlet 
valves were sealed and a timer started for 30 minutes. After this period of OGD the slices 
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were removed from the chamber and transferred back into the plate containing experimental 
media which had been stored in the incubator at 37
O
C. No extra wash steps took place. After 
transfer the slices were sealed back inside the chamber which was flushed for 5 minutes at 5 
L min-1 with (20.2 kPa O2/76.0 kPa N2/5.0kPa CO2). After flushing 50.6 kPa of experimental 
gas was added to the chamber over >1minute. The high speed mixing fan was switched on for 
5 minutes to allow rapid mixing of the gases. After 24 hours the slices were removed from 
the chamber and imaged as outlined in section 2.2.3.  
 
For OGD experiments it was important that all 6 wells were filled with media and a 
membrane, in order to avoid empty wells acting as a reservoir for oxygen during the 
procedure. A full schematic representation of the OGD protocol is shown in figure 2.9. 
 
Figure 2.9: Schematic timescale of OGD protocol. After 14 days in culture slices are 
transferred to experimental medium containing PI and reinsulated for 1 hour to allow PI 
binding to equilibrate. Slices are then imaged to assess general viability before transfer to 
Ringers solution. Slices are then sealed in the chamber for 30 minutes with 96.2 kPa 
N2/5.0kPa CO2 or 20.2 kPa O2/76.0 kPa N2/5.0kPa CO2 (for sham experiments). Slices are 
then transferred back to experimental media and sealed in the chamber for 24 hours 
before imaging. 
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2.4 Data analysis and statistical testing  
 
During the imaging procedure images of the slices were captured as an RGB 24-bit TIF 
image using a digital video camera and software (Micropublisher 3.3 RTV camera and 
Qcapture Pro software, Burnaby, BC, Canada). Each image contained a total of 3145728 
pixels distributed across 256 intensity levels (0-255). Using ImageJ software it was possible 
to split the images into the red, green and blue channels. Using only the red channel, 
histograms were plotted showing pixel distribution over 256 intensity levels. The background 
of the image contained a large number of pixels in the 0-25 range of intensity level, creating a 
large peak in the intensity histogram. PI fluorescence in the slices caused a shift in the 
number of pixels towards the higher intensity levels. By integrating the number of pixels 
above a certain threshold intensity level, injury in the slices could be quantified (see figure 
2.10). For the TBI experiments a threshold of 50 was selected. The reason for this choice of 
threshold is explained in further detail in chapter 3.  
Slices were assessed for viability before experimentation in order to exclude any slices from 
analysis whose health was already compromised. Reasons for exclusion from analysis 
included any slices where the distribution of pixels reached 20 or more pixels at intensities 
above a threshold of 80 (a reliable indicator of poor survival throughout the experimentation 
procedure) or where a qualitative assessment deemed them unhealthy (e.g. visible focal lesion 
present).  Additionally slices that had other slices/cell debris visible in frame or where the 
impact was not in the CA1 region at t=24 were also excluded from analysis. Approximately 
10-20% of slices were excluded from analysis in each experiment due to a combination of the 
above factors.  
Sample sizes for each condition were from a minimum of 3 experiments per condition. It was 
kept in mind that larger sample sizes yield more accurate results but cost and time constraints 
meant there were limitations in the number of experiments which could be performed. Three 
repeats yielding the same result was considered suitable to demonstrate reproducibility of the 
result. Statistical analysis of the data was carried out using 2-way ANOVA with Bonferroni’s 
post-hoc test with significance defined as a P value of less than 0.05. Factor one was 
treatment (helium, xenon, glycine addition etc.) and factor 2 was the time after injury (24 
hours, 48 hours and 72 hours). A repeated measures ANOVA was used with factor 1 as the 
repeated factor. Significance was defined as a P value of less than 0.05. All TBI data 
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presented is normalised to the helium control injury at 72 hours after injury, unless otherwise 
stated.  
For measurements of the area of the slice and the area of the primary injury site ImageJ 
software was used. A graticule was used to apply an appropriate scale to each image. Images 
were split into the red channel and the colours inverted. The impact area or slice was 
manually drawn around using a drawing tool and the area filled using a paintbrush tool. The 
images were then converted to binary images and an analysis macro applied which allowed 
an outline to be drawn and the area calculated using the area tool.   
For the OGD experiments a threshold of 100 was used as this allowed for a clear distinction 
between sham and OGD injury. Since OGD experiments were only carried out for 24 hours a 
one-way ANOVA with post-hoc Bonferroni’s test was used to test significance between 
groups, with significance defined as a P value of less than 0.05. All OGD data presented is 
normalised to helium (control) injury at 24 hours, unless otherwise stated.  
Statistical tests were implemented using the SigmaPlot (Systat Software Inc., California) for 
two-way repeated measures ANOVA tests and the Origin (OriginLab Inc., Northampton, 
MA) software package for one-way ANOVA tests. All graphs were produced using the 
Origin software.  
 
 
TBI 
Sham 
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Figure 2.10: Example histogram traces of an impacted (red line) and sham (black line) 
slices. A scale of red intensity from 0-255 is shown underneath the traces. Threshold of 50 
has been indicated and the shaded section represents the area under the curve that would 
be integrated to obtain quantification of injury in a particular slice. Images are actual 
images of the slices that the individual histogram traces were obtained from. Both sham 
and TBI slices were exposed to 50.6 kPa helium and injury quantified at 72 hours.  
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CHAPTER 3 
Modelling traumatic brain injury in vitro; calibration of 
the custom built impact device 
 
3.1  Impact energy  
 
The device used to impact the slices was custom built in the laboratory and required 
calibration in order to achieve an injury in the slices that would meet certain criteria. These 
criteria were determined so that the in vitro injury modelled characteristics of in vivo TBI. 
The criteria were:  
 
- The injury should not cause catastrophic cell death in the entire slice but instead have 
a distinct primary injury site observable after impact.  
- The primary injury itself should be robust and reproducible. 
- Injury should develop significantly over a period of time that mirrors secondary injury 
development in in vivo models and in clinical TBI.  
- The injury produced must be distinct from levels of damage observed in the sham 
slices due to manipulation of the slices.   
 
With these criteria in mind the calibration of the device primarily assessed the size of the 
primary injury and its subsequent development over 72 hours. Both of these factors were 
influenced by the energy that the slices were impacted with. As the mass of the stylus and the 
acceleration of the stylus under gravity remained constant, the variable factor in determining 
impact energy was the height the stylus was dropped from. From a technical perspective the 
impact energy chosen had to occur from a drop height whereby the stylus could be easily 
retracted back to the electromagnet when current was restored and did not rebound or stick to 
the slices upon impact. It was also taken into consideration that the higher the drop height the 
lower the error in measuring an accurate distance from the slice. However the maximum 
distance was in turn limited by the retractability of the stylus. Preliminary experiments using 
the impact device determined that the maximum drop height whereby it was possible for the 
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stylus to retract back towards the electromagnet was 6mm. It was noted that using a higher 
drop height caused the stylus to stick to the slices and on manual retraction excessive damage 
was caused to the slices by tearing. Since a manual retraction of the stylus was not a 
condition that could be controlled stringently, that was deemed to be not ideal for use in 
subsequent experiments. The stylus was designed in order for the maximum achievable drop 
height (5mm) to produce an impact energy of ≈3.5µJ as this impact energy had previously 
been shown to produce reproducible injury in similar in vitro models of TBI [50]. This was 
achieved by constructing the stylus at a specific mass of 70mg. The three drop heights 
investigated were 2mm, 4mm and 5mm which gave impact energies of 1.4µJ, 2.7µJ and 
3.5µJ respectively. Had these energies not been ideal for subsequent experiments then the 
mass of the stylus could have been modified in order to achieve higher or lower impact 
energies.   
As expected, there was a correlation between impact energy and damage inflicted in the 
slices; such that the larger the impact energy the greater the progression of injury as shown in 
figure 3.1. A primary impact site is visible in all three impacted groups, however secondary 
injury is most prominent in the slice impacted at 3.5µJ. Secondary injury is visible 
surrounding the primary injury site and at regions distinct to the primary site which is absent 
in the other treatment groups.   At each time point the level of damage in the 3.5µJ impacted 
slices was significantly higher than in the sham treated slices (p<0.001) as shown in figure 
3.2. Although at the lower energies of 2.7µJ and 1.4µJ the mean level of injury was greater 
than the sham, this difference was not significant at any time point.  
With regard to injury progression over time, the 3.5µJ injury developed significantly between 
24 and 48 and 48 and 72 hours (p<0.001) reflecting conditions observed in vivo. However 
this development did not occur in the 2.7µJ, 1.4µJ , or sham treated slices as shown in figure 
3.2. Given these results it was decided that a 3.5µJ injury was ideal for the purposes of the 
investigation as it met the specific criteria for the injury that was being modelled. 
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Figure 3.1: Representative slices from the sham and each of the impact energy groups at 
72 hours post injury. The site of primary injury is approximated in each image by the 
location of the hatched circle. Secondary injury is interpreted as PI fluorescence outside of 
this region. 
 
 
 
1.4µJ TBI 
2.7µJ TBI 3.5µJ TBI 
Sham 
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Figure 3.2: Development of injury with different traumatic impact energies. Uninjured 
sham slices are shown as white bars, compared with injured slices with impact energies of 
1.4µJ (light grey bars), 2.7µJ (grey bars) and 3.5µJ (dark grey bars). Data have been 
normalised to 3.5µJ impact 72 hours after injury. The error bars are standard errors.          
* indicates value significantly different (P<0.001) from sham slices at each time point 
(N=33: sham; N=43: 3.5µJ; N=7: 1.4µJ and 2.7µJ.  
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3.2  Time course of injury development  
 
With the ideal impact energy determined, further experiments were carried out in 
collaboration with Dr Rita Campos-Pires to investigate the development of the secondary 
injury at earlier time points post impact: 30 minutes, 1 hour, 6 hours and 12 hours (followed 
by standard imaging at 24, 48 and 72 hours) as shown in figure 3.3. Dr Campos-Pires was a 
fellow PhD student  in the lab who carried out these experiments in the early stages of her 
PhD. It was my responsibility at this time to train and supervise her during these experiments. 
Data analysis was carried out by Dr Campos-Pires. In these experiments the number of 
imaging sessions for a given slice set was limited to 4 to avoid having slices out of the stable 
temperature and humidity of the chamber for extended periods. The earliest time point that 
injury could be observed in the slices was 30 minutes after impact, which is likely due to the 
time it takes for PI binding to equilibrate. The earliest time point where TBI was found to be 
significantly different from sham treated slices was at 6 hours, and at all subsequent time 
points afterwards (P=0.004). At all time points investigated the injury developed significantly 
from initial t-1 (before injury) imaging (P<0.001), however a significant difference between 
sham treated slices and t-1 slices was only apparent by 24 hours and this was true at all 
subsequent time points. By 1 hour after trauma, the injury had developed to 0.32±0.04 of 
total injury, and by 6 hours the injury development was 0.51±0.08 of the total injury, 
increasing at 12 hours to 0.67±0.10 of the total injury present at 72 hours.  The lower panel of 
figure 3.3 shows the same TBI injury data as the upper panel but plotted on a linear time axis 
to allow a visualisation of the rate of progression of the injury (this interpretation of the data 
was carried out by myself). From this graph it is clear that the greatest rate of injury 
development occurs in the first 12 hours following injury, after which it develops steadily but 
at a less rapid rate, as shown by a decrease in the slope.  
Figure 3.3a: Propidium iodide fluorescent images of slices at 1h before injury, and 30 
minutes, 24h, 48h and 72h after injury. 
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Figure 3.3b: Development of injury (grey bars) compared to sham (white bars) quantified 
by propidium iodide florescence intensity after injury with impact energy 3.5µJ. The error 
bars are standard errors. Data has been normalised to TBI injury at 72 h. *Indicates value 
significantly different (P<0.01) from injured slices at each time point, ** Indicates value 
significantly different (P<0.001) at each time point,  (N=48: traumatic brain injury (TBI), 
t= -1, 24, 48 and 72h; N=33: sham, t=-1, 24, 48 and 72h; N=5 : TBI 0.5h; N=4: sham 0.5h; 
N=11: TBI 1h; N=13: sham 1h; N=19: TBI 6h; N=8: sham 6h; N=13: TBI 12h; N=8: 
sham 12h. (lower panel) Development of injury in TBI slices plotted over time to indicate 
the rate of injury development in the slices. Data is the same as in upper panel. Data is 
courtesy of Dr Rita Campos Pires who kindly gave her permission for the data to be 
included.   
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In parallel to the above experiments the histograms of slices before and immediately after 
injury were studied in order to determine the ideal threshold for pixel integration that 
accurately represented injury levels in the slices. Figure 3.4 shows that before injury almost 
all the pixels in each slice image are distributed within the intensity level range of 
approximately 0-40 (left panel). This sharp peak therefore represents the background of the 
image and does not represent PI fluorescence.  30 minutes after the impact when the PI 
fluorescence at the primary injury site is visible by eye, the histogram reflects this with a 
subtle yet clear shift in the number of pixels between 50 and 100 which appears to be the 
range in which PI fluorescence is detectable.  It was therefore concluded that a threshold of 
50 accurately captured all the PI fluorescence in the slice at a single time point and no 
information was lost which may have been the case if a higher threshold was chosen. 
Furthermore the right panel of figure 3.4 demonstrates that this threshold allows a clear 
distinction between impacted and sham slices.  
 
 
Figure 3.4: (left panel) Histogram showing pixel distribution of slices 1 hour before (black 
line) and 30 minutes after traumatic impact (red line). (right panel) Histogram showing 
pixel distribution 30 minutes after traumatic impact (red line) compared with non-injured 
sham slices (black line) at the same time point. In both panels the blue line indicates the 
threshold above which the numbers of pixels were totalled to provide a quantitative 
measure of injury levels. Error bars are standard errors. Lines represent mean data from 
28 slices before impact and at 30 minutes post impact and 22 slices for sham.  
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A further element of the calibration process was to characterise the size of the primary impact 
and subsequent development of injury with regard to the maximum injury possible to inflict 
in the hippocampal slices. Maximum cell death was achieved in the slices by submersion in 
70% ethanol for several hours and incubation overnight. At 72 hours after traumatic injury 
the level of traumatic injury was 25±1% of the maximum possible injury, indicating that the 
degree of injury inflicted upon the slices was not ‘catastrophic’.  Results are shown in figure 
3.5. Primary injury compromised 3.5±0.2% of the total possible injury. Measurement of the 
area of the primary injury in slice images in relation to the total area of the slice showed the 
primary injury to be 0.34±0.01mm
2 
compared to the average total area of a hippocampal slice 
of 4.80±0.08mm
2 
as measured in 50 slices. This indicates that the area of primary injury 
occupies approximately 7% of the total slice area.  
 
Figure 3.5: Injury development in the slices (grey bars) compared to the maximum 
achievable fluorescence when slices are permeabilised with ethanol (red bar). Primary 
injury indicates slices imaged at 30 minutes post impact. All TBI data is from control (50.6 
kPa helium) data. Data is shown as a percentage of maximum fluorescence. The error bars 
are standard errors. (N=28: TBI primary injury; N=141: TBI 24, 48, 72h; N=6: maximum 
death).  
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3.3  Sentinel slice experiments 
 
The final process in calibrating the traumatic brain injury protocol was to investigate whether 
repeated impacts on a single membrane could exacerbate the damage already received from 
the primary injury. Each membrane contained on average 6 slices, so it was unknown 
whether the primary impact may cause vibrations within the membrane that could be 
damaging. These ‘aftershocks’ could potentially be problematic for experimental design, as 
repeated injuries would not reflect the in vivo state of TBI and would also alter the level of 
damage inflicted on the slices depending on how many slices were plated in each membrane. 
An experiment was designed whereby on each membrane three slices were impacted, and the 
remaining three slices on the membrane were left untouched; these were termed the ‘sentinel’ 
slices. In parallel normal sham treated wells were included in the same experiment so 
comparisons could be made between sham treated and sentinel slices. Figures 3.6 and 3.7 
show that no significant difference was found between the sham treated and sentinel slices at 
any time point. A significant difference was found between impacted slices and both sham 
and sentinel slices at each time point (P<0.001). It was therefore concluded that repeated 
impacts on the membrane had no additional effect on slice injury.  
 
 
Figure 3.6: Representative slices from the sham, sentinel and TBI (3.5µJ) groups at 72 
hours post injury. Sham and sentinel slices show a distinct lack of injury compared with 
traumatically injured slices.  
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Figure 3.7: Development of injury in sentinel slices (hatched bars) compared to sham 
(white bars) and TBI injured slices (grey bars).  Data have been normalised to 3.5µJ TBI 
injury at 72h. The error bars are standard errors. **Indicates value significantly different 
(P<0.001) from sham slices at each time point. N=33: sham; N=15: sentinel; N=43 TBI.  
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3.4  Effects of added pressure 
 
To avoid flushing the chamber with 50% gas/air mixtures (and the subsequent high costs of 
this) gases were added as 50.6 kPa of added pressure, in addition to (20.2 kPa O2/76.0 kPa 
N2/5.0kPa CO2). It first was established that 50.6 kPa of additional pressure would have no 
significant effect on injury development by using helium as a control gas. Helium was chosen 
because it is unlikely to exert any pharmacologic effect of its own at these low pressures and 
any effect observed can be attributed to pressure alone. Figure 3.8 demonstrates that 50.6 kPa 
of helium had no significant effect (P>0.9) on sham or traumatic injury at any time point. All 
subsequent control experiments were carried out in the presence of 50.6 kPa helium gas. 
 
Figure 3.8: The addition of 50.6 kPa helium had no effect on the injured or sham-treated 
slices. Sham treated slices are shown as white hatched bars (no helium) or white bars 
(helium), and injured slices are shown as grey hatched bars (no helium) or grey bars 
(helium). The error bars are standard errors. The data have been normalised to traumatic 
injury with 50.6 kPa helium at 72h after injury. **Indicates value significantly different 
(P<0.001) from injured slices at each time point (N=141: helium TBI; N=105: helium 
sham; N=23: no helium TBI; N=25: no helium sham.  
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For concentration response studies with the inert gases two additional concentrations were 
investigated: 30.4 kPa and 70.9 kPa. It was deemed unnecessary to investigate concentrations 
above 70.9 kPa as a concentration higher than that would be unlikely to be used in clinical 
medicine as it does not allow for sufficient oxygen. It was first investigated whether these 
pressures would affect control levels of injury, as shown in figure 3.9. It was found that 
neither concentration, 30.4 kPa nor 70.9 kPa had any significant effect on injury development 
at any time point (P=0.413). 
 
 
Figure 3.9: Pressures of 30.4 kPa (light grey bars) and 70.9 kPa helium (dark grey bars) 
have no effect on the development of injury compared to the control pressure of 50.6 kPa 
(grey bars) at any time point. The error bars shown are standard errors. The data have 
been normalised to traumatic injury with 50.6 kPa helium at 72h after injury (N=14: 50.6 
kPa helium; N=15: 30.4 kPa helium; N=11: 70.9 kPa helium).  
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CHAPTER 4 
Effect of noble gases on injury development following 
traumatic brain injury in vitro 
 
4.1  Effects of noble gases on traumatic injury  
 
Following calibration of the traumatic impact device and characterisation of the injury, 
experiments investigating the neuroprotective effects of the noble gases xenon, argon, 
krypton and neon were carried out. Representative images of slices exposed to 50.6 kPa 
xenon, argon, krypton and neon are shown in figure 4.1. Figure 4.2 shows normalised data of 
the neuroprotective effect of the inert gases. Only xenon and argon showed a significant 
degree of neuroprotection compared to control. Xenon was found to be a more potent 
neuroprotectant than argon. Xenon reduced injury by 0.57±0.03 at 24 hours, 0.56±0.03 at 48 
hours and 0.43±0.03 by 72 hours compared to the control injury slices. Argon reduced injury 
by 0.38±0.07 at 24 hours, 0.43±0.07 at 48 hours and 0.30±0.07 by 72 hours compared to the 
control injury slices. Krypton and neon (like helium) were devoid of any neuroprotective 
effect.  
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Figure 4.1: Representative images from each treatment group; sham, control injury (50.6 
kPa helium), 50.6 kPa xenon, 50.6 kPa argon, 50.6 kPa krypton and 50.6 kPa neon. Each 
slice is from the 72h time point. Slices were selected on the basis of having a level of injury 
that is most similar to the mean for the group.   
 
 
TBI control Sham 
+ 50% xenon + 50% argon 
+ 50% neon + 50% krypton 
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Figure 4.2: Effect of 50.6 kPa of the inert gases xenon (red bars), argon (blue bars), 
krypton (purple bars) and neon (green bars) on control traumatic injury (grey bars) at 24, 
48 and 72h after injury. Sham treated slices (white bars) were not subject to trauma. Xenon 
and argon provided significant neuroprotection at all time points. Xenon was more 
effective than argon, with xenon treated slices being 0.57±0.03 of control injury compared 
with 0.70±0.07 of control injury for argon treated slices, 72h after injury. None of the other 
inert gases provided significant protection against injury at any of the time points. The 
error bars are standard errors. The data have been normalised to control injury at 72h 
after injury. # Indicates value significantly different (P<0.05) from control injury at each 
time point, **Indicates value significantly different (P<0.001) from control injury at each 
time point. (N=141: control traumatic injury; N=105: sham; N=104: xenon; N=44: argon; 
N=45: krypton; N=22: neon).   
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4.2  Effects of xenon and argon on secondary injury 
 
Having shown that xenon and argon are neuroprotective, the next stage was to characterise 
this property further. The data shown in figure 4.2 represents total injury, that is, both 
primary and secondary injury are included. By definition it is not possible to protect against 
primary injury, only the secondary injury that begins in the moments directly after the 
primary injury has been sustained. With this in mind the neuroprotective potencies of xenon 
and argon were re-addressed by investigating the specific effects on secondary injury. To do 
this, injury was measured at 30 minutes post impact to determine the magnitude of the 
primary injury. This was then subtracted from the total injury at 24, 48 and 72h leaving only 
the secondary injury.  Figure 4.3 shows the primary injury at 0.5hr after impact and shows 
schematically how it was subtracted from the total injury to give the secondary injury.  
 
Figure 4.3: Primary injury measured at 30 minutes post impact was subtracted from total 
injury (indicated by the red line) in impacted (not sham treated) slices to give a measure of 
secondary injury shown in light grey. The error bars are standard errors. The data have 
been normalised to control injury at 72h after injury. 
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When secondary injury was isolated in this way it was found that xenon was particularly 
effective at reducing secondary injury development. This is shown in figure 4.4. With the 
primary component removed xenon treated injured slices were found to have the same degree 
of injury as uninjured sham slices, as demonstrated by a lack of significance difference 
between the two data sets. At 24 hours sham injury was 0.30±0.03 of the secondary injury in 
the controls at the same time point, compared with xenon which was 0.28±0.04. At 48 hours 
sham injury was 0.34±0.03 of control and xenon was 0.33±0.03. By 72 hours sham injury 
was 0.35±0.03 of the control secondary injury at 72hrs whereas xenon was higher at 
0.50±0.05 however this difference was not found to be significant. At all time points xenon 
demonstrated a significant degree of protection compared to control injury slices (P<0.001), 
reducing injury by 0.72±0.04, 0.67±0.03 and 0.50±0.04 compared to control at 24, 48 and 72 
hours respectively. Xenon therefore effectively abolished the development of secondary 
injury in the slices over this time period.  
Figure 4.4: Effect of xenon on secondary injury development. At the 24, 48 and 72h time 
points, xenon treated slices (red bars) were not significantly different to uninjured sham 
slices (white bars). At the 72h time point, secondary injury in the xenon treated slices was 
0.50±0.05 of secondary injury in untreated injured slices (grey bar). The error bars are 
standard errors. Data have been normalised to the control injury at 72h after injury. 
*Indicates value significantly different (P<0.001) from control injury at each time point 
(N=141: control traumatic injury; N=105 sham; N=104: xenon.  
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Argon was also found to reduce secondary injury (figure 4.5) although not to the same extent 
as xenon.  Argon reduced secondary injury significantly when compared  to secondary  injury 
controls by 0.48±0.09 at 24h, by 0.51±0.08 at 48h and by 0.34±0.08 at 72 hours (P<0.05). No 
significant difference was found between argon secondary injury and sham treated slices at 
24 and 48 hours after injury, however by 72 hours this difference had become significant 
(P=0.026). Argon could therefore be said to be attenuating secondary injury development, 
unlike xenon which abolished it.  
 
Figure 4.5: Effect of argon on secondary injury development. At the 24 and 48h time 
points, argon treated slices (blue bars) were not significantly different to uninjured sham 
slices (white bars). At the 72h time point, secondary injury in the argon treated slices was 
0.66±0.08 of secondary injury in untreated injured slices (grey bar). The error bars are 
standard errors. Data have been normalised to the control injury at 72h after injury # 
Indicates value significantly different (P<0.05) from control injury at each time point, 
**Indicates value significantly different (P<0.001) from control injury at each time point 
(N=141: control traumatic injury; N=105 sham; N=44: argon.  
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4.3  Concentration response relationships of xenon and 
argon  
 
The experiments with the series of noble gases used concentrations of 50% (50.6 kPa) of each 
gas. This concentration was chosen because it if often necessary to give additional oxygen to 
the brain trauma patients, and a concentration of 50% would allow for this. Nevertheless, we 
wished to determine whether higher concentrations of xenon and argon would be more 
effective and in addition, whether their efficacy would be retained at concentrations below 
50.6 kPa. The concentrations investigated were 30.4 kPa and 70.9 kPa. It was previously 
established that these pressures had no significant effect on control injury development 
(figure 3.9, previous chapter).At a concentration of 30.4 kPa xenon provided a significant 
level of neuroprotection (P=0.026) at 72 hours compared to argon which was without 
protective effect (figure 4.6). Injury in 30.4 kPa xenon treated slices was 0.54±0.10, 
0.62±0.10 and  0.60±0.13 of the control injury at 24, 48 and 72 hours respectively and  injury 
in the 30.4 kPa argon treated slices was 0.78±0.06, 0.80±0.06 and 0.94±0.07 of the control 
injury at 24, 48 and 72 hours respectively.  
 
Figure 4.6: The neuroprotective effect of 30.4 kPa xenon (red bars) and lack of 
neuroprotection by 30.4 kPa argon (blue bars) on injury progression following traumatic 
injury compared to control injury slices (grey bars) at the same pressure. The error bars 
are standard errors. Data are normalised to 30.4 kPa helium injury at 72h. # Indicates 
value significantly different (P<0.05) from control injury at each time point. (N=6: 30.4 
kPa xenon TBI; N=14: 30.4 kPa argon TBI; N=15: 30.4 kPa helium TBI).  
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In contrast, at a 70.9 kPa concentration of both xenon and argon provided neuroprotection 
which was significant at the 72 hour time point (P=0.023 xenon and P=0.035 argon). Injury 
in 70.9 kPa xenon treated slices was 0.62±0.11, 0.59±0.13 and  0.48±0.12 of the control 
injury at 24, 48 and 72 hours respectively and  injury in the 70.9 kPa argon treated slices was 
0.55±0.12, 0.54±0.11 and 0.60±0.10 of the control injury at 24, 48 and 72 hours respectively.  
 
Figure 4.7: The neuroprotective effect of 70.9 kPa xenon (red bars) and 70.9 kPa argon 
(blue bars) on injury progression following traumatic injury compared to control injury 
slices (grey bars) at the same pressure. The error bars are standard errors. Data are 
normalised to 70.9 kPa helium injury at 72h. # Indicates value significantly different 
(P<0.05) from control injury at each time point. (N=6: 70.9 kPa xenon TBI; N=10: 70.9 
kPa argon TBI; N=11: 70.9 kPa helium TBI).   
 
Figure 4.8 summarises the data shown in figures 4.6 and 4.7 with the addition of the 50.6kPa   
concentrations at the 72 hour time point. A concentration of 30.4 kPa, xenon provided 
protection of 0.40±0.13 whereas argon was without protective effect (0.06±0.07) at the same 
concentration. At 50.6 kPa xenon provided 0.43±0.03 protection whereas argon provided 
0.30±0.07, and at 70.9 kPa xenon provided protection of 0.52±0.12, whereas argon protected 
by 0.40±0.10. These results show that a concentration-response relationship exists with 
regard to neuroprotection by argon whereas xenon appears to be almost equally as potent 
across a range of concentrations.  Xenon is more potent than argon across a range of 
clinically relevant concentrations.  
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Figure 4.8: Concentration-response relationship for neuroprotection by xenon and argon. 
Xenon (filled circles) exhibited a neuroprotective effect at a concentration of 30.4 kPa, 
with 40±8% protection, increasing to 52±13% protection at 70.9 kPa xenon. In contrast 
argon, open circles was not neuroprotective at 30.4 kPa but did exhibit a protective effect at 
concentrations of 50.6 kPa and 70.9 kPa argon. Lines shown were drawn by eye and have 
no theoretical significance. Error bars are standard errors (N=104: 50.6 kPa xenon; N=6: 
30.4 kPa and 70.9 kPa xenon; N=44: 50.6 kPa argon; N=14: 30.4 kPa argon; N=10: 70.9 
kPa argon).  
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CHAPTER 5 
The mechanism of xenon and argon neuroprotection 
following traumatic brain injury in vitro 
 
Previous findings in our lab have shown that inhibition of NMDA receptors by xenon is 
competitive. Xenon has been found to inhibit NMDA receptors more strongly at low glycine 
concentrations (1µM) than at high glycine concentrations (100µM) [76]. This finding was 
used as a tool to investigate whether it was possible to modulate the neuroprotective effect of 
xenon in the same manner by manipulating the glycine concentration in the experimental 
media. Additionally it was investigated whether increased glycine could modulate the degree 
of neuroprotection by argon, as its molecular targets within the brain are unknown.  
 
5.1  Effect of added glycine and strychnine on control 
injury 
 
The first stage of investigation was to investigate whether adding a saturating concentration 
of glycine (100µM) in the experimental media altered the degree of injury observed in 
control impacted or sham treated slices. This concentration was chosen because it is a 
saturating concentration for the GluN1/GluN2A and GluN1/GluN2B subunit concentrations 
that predominate in the hippocampus [76, 77]. Figure 5.1 shows that 100µM glycine had no 
effect on sham or control injury at any time point as shown by a lack of significance (P>0.9) 
between slices exposed to glycine and control slices. Injury in the glycine treated slices was 
0.93±0.11, 0.85±0.11 and 0.98±0.09 of control injury at 24, 48 and 72h respectively.  
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Figure 5.1: The addition of 100µM glycine has no effect on injury development or sham 
treated slices. Sham slices (white bars) were not significantly different in the presence of 
100µM glycine (white hatched bars) at any time point. Similarly, the development of 
control injury (grey bars) was not significantly different in the presence of 100µM glycine 
(grey hatched bars) at any time point. Data are normalised to control injury at 72h. The 
error bars are standard errors (N=141: control traumatic injury; N=105: sham; N=39: 
glycine traumatic injury; N=35: glycine sham).  
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To rule out any involvement of the ligand gated inhibitory glycine receptors in 
neuroprotective mechanistic studies, experiments with additional glycine were also 
performed in the presence of strychnine, a high affinity competitive antagonist of the 
inhibitory glycine receptor. First it was investigated whether strychnine had any effect on 
injury development or on sham treated slices by itself at a concentration of 100nM. This 
concentration was chosen as it has previously been demonstrated that this abolishes inhibitory 
glycine receptor responses at glycine concentrations up to 300µM [116] Figure 5.2 
demonstrates that no significant difference (P>0.9) was found between sham or injured slices 
in the presence or absence of 100nM strychnine at any time point. Injury in strychnine 
exposed slices was 1.04±0.08, 0.95±0.08 and 1.12±0.12 of control injury at 24, 48 and 72h 
respectively. 
 
Figure 5.2: The addition of 100nM strychnine has no effect on injury development or sham 
treated slices. Sham slices (white bars) were not significantly different in the presence of 
100nM strychnine (white crosshatched bars) at any time point. Similarly, the development 
of control injury (grey bars) was not significantly different in the presence of 100nM 
strychnine (grey crosshatched bars) at any time point. Data are normalised to control 
injury at 72h. The error bars are standard errors (N=141: control traumatic injury; 
N=105: sham; N=18: strychnine traumatic injury; N=19: strychnine sham). 
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Next the combined effects of both 100µM glycine and 100nM strychnine were investigated 
(figure 5.3) and this too had no significant effect on either sham injury or control injury at 
any time point (P>0.9). Injury in glycine and strychnine exposed slices was 0.95±0.08, 
0.98±0.09 and 0.93±0.08 of control injury at 24, 48 and 72h respectively.  
 
 
 
Figure 5.3: The addition of 100µM glycine and 100nM strychnine in combination has no 
effect on injury development or sham treated slices. Sham slices (white bars) were not 
significantly different in the presence of 100µM glycine and 100nM strychnine (white 
squared bars) at any time point. Similarly, the development of control injury (grey bars) 
was not significantly different in the presence of 100µM glycine and 100nM strychnine 
(grey squared bars) at any time point. Data are normalised to control injury at 72h. The 
error bars are standard errors (N=141: control traumatic injury; N=105: sham; N=37: 
glycine and strychnine traumatic injury; N=21: glycine and strychnine sham). 
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5.2  Effect of added glycine and strychnine on xenon 
neuroprotection 
 
Having established that neither glycine nor strychnine had any effect on control injury 
development on their own or in combination, this allowed the next stage of mechanistic 
investigations using xenon and argon to be carried out. Figure 5.4 shows the effects of 
100µM added glycine on xenon’s neuroprotective effect. In the absence of added glycine, 
xenon significantly (P<0.001) reduces injury to 0.43±0.03, 0.44±0.03 and 0.57±0.03 of 
control injury at 24, 48 and 72h after injury respectively. The addition of glycine abolished 
xenon’s neuroprotective effect. In the presence of 100µM glycine the xenon treated slices 
were not significantly different to the untreated injury controls at all time points, being 
0.82±0.09, 1.03±0.11 and 1.13±0.14 of the control at 24, 48 and 72h.  
 
 
Figure 5.4: Glycine reverses the neuroprotective effect of 50.6 kPa xenon. In the absence 
of glycine, 50.6 kPa xenon (red bars) protects against trauma (grey bars). The addition of 
100µM glycine abolishes the protective effect of 50.6 kPa xenon. There was no significant 
difference between the injured slices in the absence (grey hatched bars) and presence (red 
hatched bars) of 100µM glycine at any time point.  Data are normalised to control injury in 
the absence of glycine at 72h. The error bars are standard errors. *Indicates value 
significantly different (P<0.001) from control injury at each time point.  (N=141: control 
traumatic injury; N=104: xenon; N=32: xenon glycine; N=39: glycine traumatic injury).  
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In order to carry out further glycine experiments in the presence of strychnine first it was 
investigated whether strychnine alone at a concentration of 100nM altered the level of 
neuroprotection provided by xenon. Figure 5.5 demonstrates that strychnine present in the 
media throughout experimentation did not significantly alter the level of neuroprotection at 
any time point. Slices treated with xenon alone significantly (P<0.001) reduced injury to 
0.43±0.03, 0.44±0.03 and 0.57±0.03 of control injury at 24, 48 and 72h after injury 
respectively. When strychnine was present in the media, xenon treatment reduced injury to 
0.47±0.09, 0.48±0.11 and 0.43±0.16 of the untreated control injury at 24, 48 and 72 h after 
injury respectively.  
 
 
Figure 5.5: The addition of 100nM strychnine has no effect on injury development or on 
the level of neuroprotection observed in xenon treated slices. Neuroprotection by 50.6 kPa 
xenon (red bars) was not significantly different in the presence of 100nM strychnine (red 
crosshatched bars) at any time point. Similarly, the development of control injury (grey 
bars) was not significantly different in the presence of 100nM strychnine (grey 
crosshatched bars) at any time point. Data are normalised to control injury in the absence 
of strychnine at 72h. The error bars are standard errors (N=141: control traumatic injury; 
N=104: xenon; N=45: xenon strychnine; N=18: control strychnine traumatic injury). 
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Having established that the presence of 100nM strychnine did not alter the level of 
neuroprotection by xenon the next stage was to expose injured slices to both 100µM glycine 
and 100nM strychnine in combination, in order to fully exclude any possible involvement of 
inhibitory glycine receptors in xenon’s mechanism of neuroprotection. Figure 5.6 shows the 
effects of 100µM added glycine and 100nM added strychnine on the neuroprotective effect of 
xenon. The addition of glycine and strychnine in combination abolished xenon’s 
neuroprotective effect. In the presence of 100µM glycine and 100nM strychnine the xenon 
treated slices were not significantly different to the injury controls (with glycine and 
strychnine) at all time points, being 1.05±0.11, 1.07±0.14 and 1.18±0.11 of the control at 24, 
48 and 72h. A significant difference was found between slices treated with xenon alone and 
slices treated with xenon and glycine at all time points (P<0.05).   
 
A key feature of these experiments is that at each time point, when glycine was present it 
reversed the effects of xenon to the level of the untreated slices at the same time point, as 
demonstrated visually in figure 5.7. Taken together with the lack of effect of glycine on the 
control injury, this means that the effects of glycine cannot be explained by simply 
exacerbating the injury itself. In addition the lack of effect of strychnine (figures 5.5 and 5.6) 
in both the absence and presence of glycine indicates that inhibitory glycine receptors have 
no role in both injury development or in neuroprotection by xenon. The reversal of xenon’s 
protective effect by glycine is consistent with xenon neuroprotection at the NMDA receptor 
glycine site.  
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Figure 5.6: Glycine and strychnine in combination reverses the neuroprotective effect of 
50.6 kPa xenon. In the absence of glycine and strychnine, 50.6 kPa xenon (red bars) 
protects against trauma (grey bars). The addition of 100µM glycine and 100nM strychnine 
abolishes the protective effect of 50.6 kPa xenon. There was no significant difference 
between the injured slices in the absence (grey squared bars) and presence (red squared 
bars) of 100µM glycine and 100nM strychnine in combination at any time point.  Data are 
normalised to control injury in the absence of glycine at 72h. The error bars are standard 
errors. **Indicates value significantly different (P<0.001) from control injury at each time 
point.  (N=141: control traumatic injury; N=104: xenon; N=19: xenon glycine strychnine; 
N=37: glycine strychnine traumatic injury). 
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Figure 5.7: Addition of 100µM glycine reverses neuroprotection by xenon to the level of 
control injury slices. Glycine itself has no effect on injury progression. Primary injury is 
visible in all slices.  
 
 
 
 
 
 
 
 
 
 
+ 50% helium (control injury)  + 50% helium + 100µM 
glycine 
+ 50% xenon + 50% xenon + 100µM 
glycine 
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5.3  Mechanism of argon neuroprotection 
 
To investigate whether xenon and argon act via the same mechanism, investigations into the 
effect of 100µM added glycine were conducted on argon treated slices. Figure 5.8 shows that 
in the presence of 100µM glycine, 50.6 kPa argon treatment resulted in significant 
neuroprotection at all time points (P<0.05). With no glycine present, argon treatment 
significantly reduced injury in the slices to 0.62±0.07, 0.57±0.07 and 0.70±0.07 of control 
injury slices at 24, 48 and 72 h respectively. When glycine was present argon treatment 
reduced injury in the slices to 0.67±0.09, 0.68±0.09, 0.58±0.07 of control injury at 24, 48 and 
72h respectively. No significant difference was found between slices treated with argon in the 
absence or presence of 100µM glycine at all time points. Figure 5.9 demonstrates visually the 
lack of reversal of neuroprotection by argon in the presence of glycine. This is not consistent 
with argons neuroprotective effect being mediated via the NMDA receptor glycine site and 
indicates that argon has a different mechanism of action to xenon.  
 
Figure 5.8: Glycine does not reverse the neuroprotective effect of 50.6 kPa argon. In the 
absence of glycine, 50.6 kPa argon (blue bars) protects against trauma (grey bars). The 
level of injury in argon treated slices is unchanged regardless of the presence (hatched 
blue bars) or absence (blue bars) of 100µM glycine.   Data are normalised to control injury 
at 72h. #Indicates value significantly different (P<0.05) from control injury at each time 
point. **Indicates value significantly different (P<0.001) from control injury at each time 
point.  The error bars are standard errors (N=141: control traumatic injury; N=44: argon 
TBI; N=37: argon glycine; N=39: control glycine traumatic injury).  
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Figure 5.9: Addition of 100µM glycine has no effect on injury development in both control 
injury slices and slices treated with 50.6 kPa argon. Neuroprotection is shown in the slices 
by a lack of secondary injury development compared to control treated slices. Primary 
injury is visible in all slices. Each experiment contained ‘internal control’ wells whereby 
no glycine was present as an additional control measure.  
 
 
 
 
 
 
 
 
 
+ 50% argon + 50% argon + 100µM 
glycine 
+ 50% helium (control injury)  + 50% helium + 100µM 
glycine 
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Unlike xenon, where a few molecular targets have been identified that could mediate its 
neuroprotective effect, in the case of argon thus far no molecular targets have been clearly 
identified. In order to clarify this situation electrophysiological experiments were performed 
by Scott Armstrong alone (and reproduced here with his kind permission) on HEK-293 cells 
transfected with GluN1/GluN2A NMDA receptors and TREK-1 potassium channels. Figure 
5.10 shows electrophysiological recordings in the absence and presence of argon. 80% argon 
had no effect on NMDA-receptor mediated currents at both high (100µM) and low (1µM) 
concentrations of glycine. In contrast to xenon, these results are not consistent with argons 
neuroprotective effect being mediated via inhibition of the NMDA receptor glycine site, 
indicating a different mechanism of action to xenon.  
 
 
Figure 5.10: 80% argon has no effect on NMDA-activated currents at high glycine 
(100µM) and low glycine (1µM). The traces show typical currents activated by 100µM 
NMDA in HEK cells expressing NMDA receptors containing the GluN1/GluN2A subunit 
combination. Data courtesy of Scott Armstrong. 
 
 
 
 
Chapter 5   Results 
 
 
Page 93 of 170 
 
 
In addition, it was shown that the other noble gases; krypton, neon and helium, also had no 
effect on NMDA receptor currents (figure 5.11) at high (100µM) and low (1µM) 
concentrations of glycine. This shows NMDA receptor inhibition to be a unique property of 
xenon among the noble gases and, besides from argon, may explain a lack of neuroprotective 
effect seen after treatment with these gases.  
 
 
Figure 5.11: NMDA receptor currents were unaffected by 80% argon (light blue bars), 
80% krypton (brown bars), 80% neon (green bars) or 80% helium (black bars). The error 
bars are standard errors. (100µM glycine; N=10: argon; N=9: krypton; N=5: neon; N=9: 
helium. 1µM glycine; N=12: argon; N=9: krypton; N=6: neon; N=6: helium). Data 
courtesy of Scott Armstrong. 
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The data collected regarding the mechanism of argon neuroprotection in studies using the 
organotypic slices and electrophysiology experiments by Scott Armstrong strongly suggests 
that the NMDA receptor is not a molecular target of argon. Therefore an alternate mechanism 
was investigated. The target of investigation was the two-pore domain K+ channel TREK-1. 
This channel acts normally to modulate neuronal excitability by providing a background leak 
potassium conductance. Activation of channels of this type can cause hyperpolarisation of the 
cells and therefore reduce excitability, and possibly lead to neuroprotection [74]. To 
investigate how the noble gases alter activation of TREK-1 channels electrophysiological 
experiments were performed by Scott Armstrong and reproduced here with his kind 
permission.  
 
Cells that were not transfected with TREK-1 channels passed only a few picoamperes or less 
of current when clamped at -50mV (N=3, data not shown). Cells that expressed TREK-1 
channels had an outwardly rectifying current that reversed at -80mV. Halothane was used as 
a positive control in these experiments (figure 5.12) to activate TREK-1 currents. 0.82mM 
halothane was found to potentiate TREK-1 currents by 152±20%. Figure 5.12 shows that 
80% xenon also activates TREK-1 currents by 39±5% of the current measured at -50mV. In 
contrast to this effect by xenon, none of the other noble gases (helium, argon, krypton and 
neon) were found to potentiate TREK-1 currents at a concentration of 80% (figure 5.13). 
Figure 5.13 summarises the results of the TREK-1 experiments using all noble gases. These 
results suggest that TREK-1 channels are not a molecular target of argon and therefore this is 
not a mechanism of neuroprotection. In contrast the potentiation TREK-1 channel currents by 
xenon may or may not contribute to the neuroprotective properties of this gas.  
 
For details on the methods used for electrophysiology experiments see Appendix section A 
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Figure 5.12: Upper panel: Halothane (0.82mM) activates TREK-1 potassium channel currents. 
Traces are recordings from voltage ramps (-120 to 0mV in 250ms) performed in the presence 
(hatched line) and absence (solid line) of halothane. Activation by halothane was used as a positive 
control for the noble gases. Halothane potentiates the current measured at -50mV by 15220% 
(n=10). Lower panel: 80% xenon activates TREK-1 potassium channel currents. Traces are 
recordings from voltage ramps (-120 to 0mV in 250ms) performed in the presence (hatched line) 
and absence (solid line) of xenon. Data were sampled at 20 kHz, with each trace containing 3,000 
data points. Lines are through these individual points. Data courtesy of Scott Armstrong. 
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Figure 5.13: 80% helium, 80% argon, 80% krypton and 80% neon have no effect on TREK-1 
potassium channel currents. Traces are recordings from voltage ramps (-120 to 0mV in 250ms) 
performed in the presence (hatched line) and absence (solid line) of noble gases. Data were 
sampled at 20 kHz, with each trace containing 3,000 data points. Lines are through these 
individual points. Lower panel: 80% xenon potentiates TREK-1 potassium channel currents, 
whereas 80% helium, neon, argon, and krypton do not. Currents were measured at -50mV. Bars 
are mean values, error bars are standard errors (n=3, helium; n=4, neon; n=3, argon; n=9, 
krypton; n=5, xenon). Data courtesy of Scott Armstrong. 
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CHAPTER 6  
Neuroprotection by xenon and argon in an in vitro model 
of ischemic brain injury 
 
6.1  Establishing the OGD protocol 
 
There is a lack of previously published data with regard to neuroprotection by noble gases 
following TBI [50] as the main focus of interest in the past decade has been on 
neuroprotection following ischemic brain injury (particularly focusing on xenon in vitro [47, 
68] and in vivo [58, 65-67, 87, 88]). This final results chapter investigates neuroprotection by 
xenon and argon in an ischemic in vitro model of brain injury, in order to determine if the 
mechanism of neuroprotection is the same as for TBI. Data presented in this chapter was 
collected with the assistance of Mariia Koziakova who was a Masters student under my 
supervision. Approximately half of the data in this chapter was collected by me alone, and the 
other half was collected with the assistance of Ms Koziakova, i.e. experiments were either 
performed by me whilst she observed, or performed by Ms Koziakova whilst I supervised.   
First the OGD protocol was established. Slices were exposed to deoxygenated Ringers 
solution and sealed inside the chamber with 96.3 kPa N2/5.0 kPa CO2 for 30 minutes to 
produce a level of injury at 24 hours as seen in figures 6.1 and 6.2. Sham treated slices were 
exposed to normal Ringers solution and sealed inside the chamber with 20.2 kPa O2/76.0 kPa 
N2/5.0kPa CO2 for 30 minutes. This procedure resulted in a small amount of injury (figure 6.1 
and 6.2) that was 0.27±0.07 of the OGD injury. A significant difference was seen between 
OGD slices and sham treated slices (P=3E-6). Both OGD slices and sham treated slices were 
exposed to 50.6 kPa helium gas in the 24 hour incubation period following injury, to control 
for hyperbaric conditions in the experiments with argon and xenon.  
Generally fewer initial experiments were required for the OGD protocol than the TBI 
protocol as it had already been established in the lab prior to these experiments by Paul Banks 
(PhD thesis 2010, Imperial College London). He established a number of conditions: 
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- 30 minutes of OGD is sufficient to produce a significant level of injury in the slices 
- Injury after 30 minutes of OGD does not develop further after 24 hours following 
injury  
- Addition of 50.6 kPa helium does not significantly alter the level of injury in either 
sham treated or OGD slices compared to slices exposed to no added pressure. 
A threshold of 100 was selected for analysis of the data. This was selected by studying 
the histogram (figure 6.2) of sham and OGD treated slices. The histogram shows very few 
pixels distributed above an intensity level of 50 in healthy, uninjured slices. Following 
OGD and sham procedures, a greater number of pixels are distributed towards higher 
intensity levels. The point at which sham treated and OGD treated slices could be 
distinguished as different from one another occurs at an intensity level of approximately 
75. The threshold was chosen to be 100, as this is above the 75 threshold for 
distinguishing condition and was the point of the histograms where the line became 
smooth with less sharp peaks. Furthermore, this threshold is consistent with the OGD 
study by Paul Banks [68].  
 
Figure 6.1: 30 minutes of oxygen and glucose deprivation in the slices causes a significant 
level of damage compared to sham treated slices. Sham damage (white bar) is 0.27±0.07 of 
control injury (grey bar). Error bars are standard errors. Data is normalised to control 
OGD injury at 24 hours. **indicates value significantly different (P<0.001) from control 
OGD injury. (Sham: N=31; OGD: N=83). 
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Figure 6.2: Histogram showing pixel distribution of slices immediately before OGD (black 
line), 24 hours after OGD (blue line), and sham treated slices at 24h (red line).  
The purple line indicates the threshold above which the numbers of pixels were summed to 
provide a quantitative measure of injury levels. Error bars are standard errors. (T0: 
N=114; Sham: T=31; OGD: N=83). 
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6.2  Mechanism of xenon and argon neuroprotection 
following OGD 
 
With control conditions established the effects of 50.6 kPa xenon and 50.6 kPa argon on 
OGD injury was investigated. Figure 6.3 shows low levels of injury in xenon and argon 
treated slices compared to control OGD slices. Control OGD slices show high levels of 
damage in the CA1 region in particular, with further sensitivity to damage in the DG and 
CA3 regions. Treatment with xenon and argon attenuates the high levels of injury in the CA1 
and CA3, although some sensitivity to DG damage is still apparent. This is also the case for 
sham treated slices. Figure 6.4 shows that both xenon and argon provided a significant 
(P=5E-8) level of neuroprotection when compared to control levels of injury. Xenon reduced 
injury to 0.32±0.05 of control injury, and similarly argon reduced injury to 0.29±0.07 of 
control injury. Both xenon and argon treatment reduced levels of injury in the slices to the 
level of sham treated slices, shown by a lack of significance when compared to sham treated 
slices (P=0.98 xenon P=0.99 argon). Both xenon and argon showed remarkably similar levels 
of neuroprotection in this model, in contrast to the TBI model in which xenon was more 
potent as a neuroprotectant.  
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Figure 6.3: High levels of injury can be seen in slices following 30 minutes of oxygen and 
glucose deprivation (top right panel) compared to sham treated slices. Treatment with both 
50.6 kPa xenon and 50.6 kPa argon provides robust neuroprotection against OGD. Slices 
are typical examples from each group, selected on the basis of having an average injury 
value close to the mean for that group.  
 
OGD + 50% argon OGD + 50% xenon 
OGD control Sham 
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Figure 6.4: 50.6 kPa xenon and 50.6 kPa argon both provide significant neuroprotection 
following oxygen and glucose deprivation. Xenon treatment (red bar) reduces injury to 
0.32±0.05 of control injury. Similarly argon treatment (blue bar) reduces injury to 
0.29±0.07 of control injury. Error bars are standard errors. Data is normalised to control 
OGD injury at 24 hours. **indicates value significantly different (P<0.001) from control 
OGD injury. (Sham: N=31; OGD: N=83; Xenon: N=84; Argon: N=36). 
 
In order to investigate the mechanism of neuroprotection, that is, the involvement of the 
NMDA receptor in neuroprotection, the same technique was adopted as in the TBI model. 
The slices were exposed to 100µM glycine in the experimental media for the 24 hour 
duration of the experiment during xenon and argon treatment. Previous experiments by Paul 
Banks had established that this strategy of reversing xenon neuroprotection following 
ischemic injury was successful in organotypic slices [68]. These experiments were repeated 
in order to confirm that the model being used was sensitive to these changes. Figure 6.5 
shows that the presence of glycine in the media was found to not have any significant effect 
on the extent of injury in the slices (P=0.6), with control injury with glycine present 
1.18±0.17 of the control injury without glycine.  When 100µM glycine is present in the 
media a significantly (P=3E-4) higher level of damage occurs in xenon treated slices. Injury 
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in slices treated with xenon alone was 0.32±0.05 of the control injury, whereas when glycine 
was present this increased to 0.78±0.09 of the control injury.  There was no significant 
difference found between slices treated with xenon and glycine compared to control injury 
(P=0.24), however there was a difference found between control slices with glycine present 
and slices treated with xenon and glycine present (P=0.039). The presence of 100µM glycine 
therefore reversed the neuroprotective effects of xenon almost fully to control levels. Further 
experiments involving strychnine were not carried out for the OGD model as it had been 
previously shown that the inhibitory glycine receptor did not have a role in xenons 
mechanism of neuroprotection following OGD [68]. 
 
 
Figure 6.5: Addition of 100µM glycine reverses neuroprotection by 50.6 kPa xenon. 
Glycine has no significant effect on control levels of injury (grey hatched bars). When 
glycine is present the level of injury in xenon treated slices (red hatched bar) is 0.78±0.09 
of injury seen in control slices (grey bar). With no glycine present the level of injury in 
xenon treated slices (red bars) is 0.32±0.05 of control injury. Error bars are standard 
errors. Data is normalised to control OGD injury at 24 hours. **indicates value 
significantly different (P<0.001) from control OGD injury. (OGD: N=83; Xenon: N=84; 
Xenon + glycine: N=73; Helium + glycine: N=35). 
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Following confirmation that NMDA receptor glycine site inhibition was a shared mechanism 
of xenon neuroprotection in both traumatic brain injury and ischemia, the same was 
investigated for argon. Figure 6.6 shows that neuroprotection by argon is not significantly 
(P=0.69) changed regardless of the presence of glycine in the media. With no glycine present 
the level of injury in argon treated slices is 0.29±0.08 of control injury. When 100µM glycine 
is present the level of injury in argon treated slices is 0.38±0.09 of injury seen in control 
slices. This result provides further evidence that inhibition of the NMDA receptor is not a 
mechanism of argon neuroprotection following either ischemic or traumatic brain injury.   
 
 
Figure 6.6: Addition of 100µM glycine has no significant effect on neuroprotection by 50.6 
kPa argon. Glycine has no significant effect on control levels of injury (grey hatched bars). 
When glycine is present the level of injury in argon treated slices (blue hatched bar) is 
0.38±0.09 of injury seen in control slices (grey bar). With no glycine present the level of 
injury in argon treated slices (blue bars) is 0.29±0.08 of control injury. Error bars are 
standard errors. Data is normalised to control OGD injury at 24 hours. **indicates value 
significantly different (P<0.001) from control OGD injury. (OGD: N=83; Argon: N=36; 
Argon + glycine: N=32; Helium + glycine: N=35).  
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CHAPTER 7 
DISCUSSION 
The results presented in this thesis describe the neuroprotective properties of the noble gases 
xenon and argon following in vitro TBI and OGD, and the lack of neuroprotection by helium, 
neon and krypton following in vitro TBI. Furthermore, this study describes the mechanism by 
which neuroprotection is achieved by xenon and rules out a number of neuroprotective 
mechanisms of argon. This discussion will explore the suitability for the model to mimic a 
human head injury, the consistency of these findings with previously published results and 
most importantly, the significance of these findings with regard to future work in this area.  
 
7.1  The in vitro weight drop device as a model of 
human traumatic brain injury  
 
Before embarking on a comprehensive discussion of the experimental results presented in this 
thesis it is important to first consider the use of the models themselves to mimic traumatic 
brain injury and ischemia.  The initial aim of the current study was to establish a protocol 
whereby the effects of noble gases in a model of TBI and ischemia could be investigated in 
order to prove or disprove the hypothesis challenged in this thesis. Creating a model of a 
complex neurodegenerative disorder such as TBI is not without difficulty, so extreme care 
had to be taken when designing and building the equipment and establishing the protocols 
necessary to model TBI, with the main outcome focused on producing a robust and 
reproducible level of injury. The current study used hippocampal organotypic slice cultures 
from neonatal C57BL/6 mice which were traumatically impacted using a weight drop device 
to create a focal contusion injury or deprived of oxygen and glucose for 30 minutes.  
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7.1.1  Organotypic slice cultures as an in vitro representation 
of the in vivo brain  
 
There are a number of choices of the tissue surrogates used for in vitro studies of brain injury, 
including dissociated primary cultures, acute slices and organotypic slice cultures, which can 
critically determine the translatability of results to the in vivo state [111]. Dissociated cultures 
are cell cultures that are mechanically and enzymatically isolated from brain tissue. Acute 
slices are thin slices of brain tissue that have been freshly isolated, and organotypic slice 
cultures are slices of brain tissue that have been maintained in culture for an extended period 
of time (>7 days). Both acute slices and organotypic slices preserve the anatomical structure, 
neuronal circuitry and heterogeneous cell populations found in an in vivo brain whereas 
dissociated cell cultures typically contain a single cell type [111]. A limitation of acute slice 
preparations is the effect of tissue explantation on the response to a subsequent trauma, as 
experiments have to be performed on the day of explantation and slicing whereas organotypic 
slices are cultured for 14 days before experimentation so they have the opportunity to recover 
and return to a stable state [111]. Organotypic slice cultures allow for longer-term 
investigations of the neuroprotective effects of compounds (in this case, three days post 
injury), whereas acute slices and dissociated cell cultures typically only remain viable for 
experiments for 8 and 24 hours respectively, which was a significant advantage for 
investigations in this study. Organotypic slices maintain the normal structural, organisational, 
and functional features of native brain tissue with preserved synaptic and chemical signalling, 
which allows for functional analysis of the properties of nervous tissue [104-106].  
 
In this study slices were prepared from neonatal P5 C57BL/6 pups. C57s are one of the most 
widely used mice strains in medical research and have been described as a ‘general 
multipurpose model’. Advantageous to this study was their ability to be good breeders, as a 
regular steady supply of pups was required. In addition, C57BL/6 mice have had their entire 
genome sequenced which makes it an ideal choice for knockout and transgenic models. It is 
now of particular interest following this study and the study by Scott Armstrong (which 
discovered an amino acid mutation that eliminated xenons interaction at the glycine site 
without affecting glycines affinity for the receptor) to pursue a transgenic route to dissect out 
the contribution of glycine site inhibition to anaesthesia and neuroprotection by xenon, thus it 
is more suitable to use the same breed in in vitro experiments as subsequent in vivo 
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experiments.  Neonatal mice were used as at this age the tissues show a high degree of 
resistance to the mechanical trauma suffered during dissection and have already established 
basic synaptic connections [117]. During the two week incubation period after explantation, 
organotypic slices mature similarly to the in vivo schedule of development, with the basic 
synaptic connections forming mature synaptic networks. [106, 117]. A study by De Simoni 
and colleagues in 2003 [106] found that in terms of total length and primary branches of 
neurones, outgrowth of apical dendrites and spine density, the organotypic slices cultured for 
varying times in vitro were the developmental equivalent of slices taken from the 
corresponding age of pup in vivo.  They also found that there were no differences between 
organotypic slices and their age matched acute slices in the frequency of action potentials and 
miniature synaptic activities [106, 117].  
 
Glial cell populations are also maintained in organotypic slice cultures [105, 109, 118].  
Oligodendrocyte populations are present in organotypic slices and axons become myelinated 
over the first 14 DIV [105]. Microglial cells become activated during the explanatation 
procedure but return to the resting state after 3 DIV [119]. Morphological characteristics of 
astrocytes are maintained throughout the entire culture period [120], with the typical glial 
scar of hypertrophic astrocytes found from 5DIV onwards [119]. When modelling complex 
brain pathologies it is especially important that all the native cell populations within the brain 
are represented accurately within the model and their relative contributions to injury or 
recovery allowed to contribute to the final outcome.  
 
For this study organotypic slice cultures were chosen over alternative in vitro models and 
indeed over an in vivo model of TBI as they confer a number of advantages over the 
alternatives. An advantage of this technique over alternative in vitro models (such as 
dissociated cell cultures) is the more accurate replication of the distribution of extracellular 
signalling molecules, since their local concentration may be elevated in the intercellular 
spaces within the tissue as opposed to just diffusing away freely after release [121]. As 
mentioned above, OSCs also maintain populations of glial cells [105, 109, 118] which is a 
feature often overlooked in simpler in vitro models. Despite representing a very basic model 
of the in vivo brain, in certain scenarios OSCs can confer an advantage over in vivo models. 
One key example of this is that the extracellular environment can be precisely controlled, that 
is, when investigating the mechanism of action of drugs one can control the concentration of 
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compounds in the surrounding media in order to correlate molecular changes with 
neuropathological outcomes [117]. This was especially useful in the current study as it 
allowed direct control over glycine concentrations in the slice environment, thus allowing a 
saturating concentration to be achieved for competition binding experiments. Direct injection 
of glycine into animals would not have been possible as glycine itself is a major inhibitory 
neurotransmitter in the CNS and thus injection of a bolus dose could have a major impact on 
CNS function. It would also have been difficult to control or determine the extracellular 
concentration of glycine in vivo to know if adequate concentrations for competition 
experiments with xenon had been reached. Another advantage over whole animal models is 
that a single slice can be monitored at multiple time points over an extended period of time, 
whereas in vivo multiple measurements are mostly restricted to behavioural studies and 
pathological assessment of injury can only be carried out once the animal is sacrificed, 
restricting the analysis to only a single time point following injury. Other important 
advantages of OSCs over animal models are the lower associated costs, and lower 
requirement for the animals themselves (one pup typically yields 15-20 slices) which confers 
an ethical advantage to their use.   
The main limitation of the OSCs are, quite obviously, the extent to which they are capable of 
reproducing events that occur in vivo, as is the case with any in vitro model (discussed in 
more detail in section 7.1.2). Currently organotypic slices culture techniques are limited to 
tissue explanted from neonatal pups, usually p5-7 in the case of mice and p8-15 in rats [109]. 
Organotypic slices prepared from adult tissue exhibit poor viability, with 90% of cells dead 
after 15DIV [122]. Further investigations have identified that during the culturing phase adult 
organotypic slices (at 5DIV) display neurons with a severe loss of volume and shrunken, 
pyknotic nuclei and a failure of glial cells to return to a resting state after initial slicing [119]. 
This limitation should be of consideration when translating results from this study into in vivo 
experiments on adult mice and indeed when translating these results to human head injury 
scenarios since the majority of TBI cases occurs in adult humans. Unfortunately as it stands 
OSCs from adult mice exhibit poor viability so neuroprotection experiments on adult models 
will be limited to in vivo models of TBI. A further issue with the use of OSCs was 
highlighted by the aforementioned study by De Simoni who found that there was an increased 
number of branches and higher order dendrites in OSCs which corresponded to an increase in 
glutamatergic miniature synaptic currents, which means the contribution of excitotoxicity to 
outcomes after traumatic or ischemic injury could possibly be over-accentuated [106].  
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Taken together the breadth of published studies which use organotypic slice cultures to 
mimic neurodegenerative events and neuroprotection in vitro justified their use to investigate 
the neuroprotective potential of noble gases.  
7.1.2  How well does the weight drop device model traumatic 
brain injury in vivo?  
 
Models of traumatic and ischemic brain injury can be used as a platform on which to test the 
neuroprotective potential of new compounds in a system that is repeatable, environmentally 
isolated and tightly-controlled [111] as well as being more cost effective and higher 
throughput than whole animal models [121]. There are a number of different in vitro models 
of TBI that each targets a different injury mechanism. These include weight drop and impact 
models to mimic focal contusion injuries, stretch injury, hydrostatic pressure, shear strain and 
fluid shear stress to model diffuse axonal injury as a result of rapid deceleration, transection 
to model penetration injuries and blast to model primary blast injury. For the study presented 
in this thesis a weight drop model was used as it was possible to create a focal primary injury 
which allowed for observation of the development of secondary injury. Secondary injury 
development was a key characteristic for this study to investigate how neuroprotective gases 
may alter its development.  
The weight drop model can be used in both in vitro [50] and in vivo systems [123, 124] to 
model TBI. It is used to produce a largely focal injury via the impact of a free falling weight 
on a slice of brain. This model has the advantage of having control over the severity of the 
insult by adjusting the impact force, shape of impact device  and duration of impact [111]. 
Using this model in this study it was possible to create an area of primary injury which lay 
directly beneath the area weight dropped upon and a surrounding secondary injury, making 
this a good choice for investigating agents that may aid in halting the spread of injury 
following TBI. A limitation of the weight drop model is that the impact energy can be 
calculated theoretically but is difficult to measure forces accurately, so a complete 
characterisation of the biomechanics of injury is difficult [111, 121]. Oxygen and glucose 
deprivation is a widely used model to study acute stroke pathology [117]. Region specific 
death occurs in slices exposed to OGD, with selective death seen specifically in the CA1 
region, similar to what is observed in vivo [125]. A number of characteristics of ischemia 
induced changes in brain activity have been successfully reproduced in organotypic models 
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of OGD (where oxygen and glucose deprivation is brief at around 30 minutes). These include 
neurotransmitter release (particularly glutamate), delayed injury development, involvement of 
caspase pathways and post translational modification of proteins [117, 125, 126].  
Some aspects of an in vitro model of a complex injury that could be seen as beneficial to 
pharmacological experiments could also be a limitation of the model itself. For example, the 
extracellular environment can be stringently controlled in vitro; however it may not be an 
accurate representation of the extracellular environment in vivo. Indeed this is almost 
impossible to model in the case of TBI and ischemia as the exact status of the extracellular 
environment at the time of injury is difficult to measure [111]. Certain other systemic aspects 
such as inflammatory response, temperature regulation, oxygenation and local ionic 
concentrations are also not present in in vitro models of injury. The lack of these however 
allows for simpler studies without the complication of such factors.  
The hippocampus was chosen in this model to be cultured and receive a primary injury for a 
number of reasons. From a practical aspect the hippocampus is easy to identify and remove, 
and slices prepared are all of a similar size, meaning quantitative analysis could not be 
skewed by larger slices giving off larger signals. From an experimental aspect the 
hippocampus has a high distribution of NMDA receptors and thus is highly sensitive to 
excitotoxic damage.  However in the case of a human head injury, a direct impact to the 
hippocampus is unlikely, which represents a major limitation to this model. Hippocampal 
damage is observed in up to 85% of human head injury cases. This is likely due to a process 
known as cortical spreading depression, which involves a wave of depolarisation that 
propagates throughout the brain. The wave of depolarisation causes a massive release in 
excitatory amino acids including glutamate which could spread to the hippocampus and lead 
to secondary injury development in this region of the brain. Therefore the development of 
secondary injury in the hippocampus is of clinical relevance, whereas primary injury in the 
hippocampus is less relevant to the real life scenario.  It is also important to note that due to 
the high density of NMDA receptors in this particular brain region, results obtained using this 
model could be bias toward NMDA receptor mediated mechanisms of action and other 
neuroprotective targets could be seen as being less dominant.  
Another limitation to consider, not with the model itself but with this particular study, is 
highlighted in a review paper by Morrison and colleagues [111] who state that “the 
underlying mechanism that is addressed by a protective compound can be shown to be 
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relevant by comparing in vitro results with in vivo results”. That is, one can validate the 
model chosen to mimic injury development in vitro by confirming that a compound that is 
successful in one model translates to the animal models of injury too. This is a simple way to 
confirm that similar, if not the same, mechanisms are occurring both in vitro and in vivo. A 
wealth of in vivo data exists for both xenon and argon confirming their efficacy as 
neuroprotectants following ischemic injury [51, 58, 65-67, 87, 88, 95, 100-102] which 
provides a degree of confidence that the same injury mechanisms are present in the in vitro 
model used in this study and in vivo ischemia. There is currently no published data regarding 
the in vivo neuroprotective effects of xenon and argon following TBI to assist in validating 
the in vitro model chosen, however the work in this thesis was carried out in order to provide 
more information on this emerging area of research, so a lack of previously published data 
represents simply a limitation and not a weakness.  
7.1.3  Using a weight drop device it is possible to model 
secondary injury development following a TBI.  
 
The first part of this study involved the characterisation of an in vitro model of traumatic 
brain injury that was capable of being utilised for neuroprotection studies. Although similar 
models had been previously described, it was essential for the subsequent experiments that 
the model was reliable and reproducible. The equipment for creating a focal injury in vitro is 
not commercially available and had be custom built in the lab, with the design aided by 
previously published studies [50, 112, 113]. It would not suffice to simply create a weight 
drop model similar to a published model and begin neuroprotection studies straight away 
without rigorous testing of the reproducibility of the model first, as this was essentially a new 
protocol that had not been previously tested by this or other labs and thus few comparisons 
between this and other studies of neuroprotection following in vitro TBI could be performed. 
It was crucial that all parameters that were possible to measure were investigated and well 
defined, so that changes observed in the slices following impact and following treatment with 
different agents could be attributed to a single manipulation with a high degree of confidence. 
After the device was built, the calibration process aimed to answer the following questions: 
 
- Does a relationship exist between the energy the slices are impacted with and the 
extent to which secondary injury develops? 
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- Where should the threshold is set in order to accurately quantify the level of injury in 
the slices?  
- Can primary and secondary injury be separated into two distinct components of injury 
development? 
- What are the characteristics of the injury development? 
- To what extent does the impact damage the slice with regards to the maximum 
damage that is possible to inflict? 
- Do repeated impacts on the same membrane create an additional element of injury?  
 
The first stage of calibration involved investigating a range of impact energies to assess the 
relationship between impact energy and secondary injury development. The impact energies 
selected for investigation were 1.4µJ, 2.7µJ and 3.5µJ, which corresponded with drop heights 
of 2mm, 4mm and 5mm. With the mass of the stylus fixed at 70mg and the acceleration 
under gravity constant the drop height represented the variable for different impact energies. 
The energies used to inflict damage are somewhat arbitrary, as it would be extremely difficult 
to extrapolate impact forces used in in vivo TBI models to in vitro models involving a thin 
slice of brain tissue. Instead, the ‘ideal’ impact energy for experimentation would be that 
which best models the characteristics of an in vivo TBI, that is, a clear measurable area of 
primary injury that occurs immediately upon impact, followed by subsequent secondary 
injury that develops significantly in the hours and days following the initial impact. With this 
in mind, 3.5µJ was selected as the impact energy for subsequent experiments, as impacts of 
1.4µJ and 2.7µJ produced a level of injury that was greater than in the sham slices, but not to 
a level of a significance, and injury did not develop over the 72 hour experimentation 
procedure. In comparison slices impacted at 3.5µJ exhibited levels of injury that were  
significantly different from sham treated slices at all time points and secondary injury 
developed significantly from 24-72 hours (figure 3.2). The choice of impact energies to 
investigate was based on previous published descriptions of similar weight-drop models of 
TBI in organotypic slice cultures [50, 113]. A study by Adembri and colleagues [113] 
investigated impacts ranging from less than 3µJ to 9µJ. They found that at impacts of 3µJ or 
below, an area of primary injury was apparent but this did not develop significantly between 
24 and 48 hours. In addition, impacts of 9µJ produced a large lesion that was maximal by 24 
hours which did not allow for observation of injury development.  
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The level of injury at 30 minutes post impact was considered a measure of primary injury in 
this study. For subsequent experiments where only secondary injury was analysed, the mean 
value of the primary injury was subtracted from the total injury to give a measure of 
secondary injury (figure 4.3). Primary injury was calculated to make up 14±1% (n=28) of the 
total injury. A fixed value of primary injury made two assumptions: that each impact was of 
the same severity, and each slice did not possess different intrinsic resistance to mechanical 
injury. Drop height and mass of the stylus was the same in each experiment, so theoretically 
the impacts would be of the same severity each time, slices were prepared from pups of the 
same age and breed, and days in culture was kept within a narrow time frame of 10-14 days. 
Coburn et al. [50] used an alternative method to calculate secondary injury in impacted slices. 
They masked the area of primary injury with a circle with a diameter of 1000µm and 
integrated only the pixels that were outside of this masked area. This technique however 
raises a concern that the primary injury is overestimated as any secondary injury that 
develops close to the primary injury in the region of the mask would be excluded from 
secondary injury analysis. Given the nature of secondary injury development it is highly 
likely that a significant proportion of the secondary injury would occur adjacent to the 
primary site. Indeed this may be the case in the study by Coburn [50] who estimated that 
secondary injury made up approximately 40% of the total injury. 50% of the total injury was 
reached in 24 hours, so by definition this could be taken to assume that all injury developing 
within the first 24 hours could be classed as a primary injury. In an ideal world, the exact 
value of primary injury in each individual slice would be determined to allow for a more 
tailored analysis of secondary injury development. However this was not considered 
practical, as imaging the slices at 30 minutes post impact may introduce an element of 
hypothermia to the slices which has been found to be neuroprotective, and would 
undoubtedly interfere with subsequent neuroprotection studies. 
 
To characterise injury development in the slices in the first 24 hours following impact, Rita 
Campos Pires investigated additional time points of 1, 6 and 12 hours post impact (figure 
3.2a) and kindly gave her permission for this data to be used in this thesis. The development 
of injury in the slices was found to increase rapidly in the first 12 hours following injury, with 
51% of the total injury occurring by 6 hours post impact. Injury continued to develop steadily 
after 12 hours but at a reduced rate.  The rapid rate of injury development in the first 12 hours 
following injury found in this study most likely reflects the massive release of 
neurotransmitters (including glutamate) and prolonged depolarisation that follows from 
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mechanical perturbation of neurones [2]. Secondary injury developed in a characteristic 
manner in the slices, specifically affecting the CA1, CA3 and DG regions with the densest PI 
stain seen in the CA1 region. This pattern of selective vulnerability of these hippocampal 
regions is known to occur following in vivo TBI  [127, 128] and is thought to be attributed in 
part to the high density of NMDA receptors found in these regions [129]. A study by 
Kristenson et al. [130] found sensitivity to excitotoxic injury induced by NMDA application 
in organotypic slice cultures to be highest in the CA1 region, followed by the DG and the 
CA3 which is in agreement with the findings of this study.  
A further aspect of the calibration process involved characterising the extent of injury in the 
slices that is produced by impacting in relation to the maximum possible injury. If the injury 
inflicted by the impact was similar to the maximum, this would translate to a lack of 
secondary injury development as the slice would already be dead, making neuroprotection 
studies difficult. Maximum injury was inflicted by submerging the slices in 70% ethanol. It 
was found that primary injury represented 3.5% of the total possible injury (figure 3.5). The 
total TBI injury increased rapidly to 18% of the maximum by 24 hours and reached 25% of 
the maximum injury by 72 hours.  
 
The final stage of calibration focused on determining whether repeated impacts on the same 
membrane could create an additional element of injury that would affect the development of 
secondary injury. This would be an issue for the current study as the model was designed 
whereby the primary injury occurred only once and thus secondary injury could be isolated 
entirely to a single impact. It was considered that perhaps impacting the slice may cause a 
distension of the membrane beneath, creating a form of stretch injury which in itself is 
another form of traumatic brain injury [110]. Experiments were devised whereby on each 
membrane half of the slices were impacted, and half were not; the unimpacted slices were 
termed ‘sentinel slices’. It was found that the sentinel slices did not exhibit a level of injury 
that was significantly different to that of sham treated slices (figure 3.6), thus concerns 
regarding repeated impacts effect could be eliminated. 
 
With the characteristics of the injury fully explored in this model it was possible to proceed to 
experiments involving neuroprotection by the noble gases.  
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7.2  Neuroprotection by the noble gases  
 
7.2.1  Xenon and argon provide neuroprotection following 
TBI and ischemia in vitro 
 
This study investigated the potential neuroprotective effects of the noble gases helium, neon, 
argon, krypton and xenon under identical conditions. Only xenon and argon possessed 
neuroprotective properties (figures 4.1 and 4.2). Xenon was found to be more efficacious as a 
neuroprotectant than argon in this study (figures 4.4 and 4.4).  
 
In this study helium was used as a control gas, to control for the hyperbaric conditions (50.6 
kPa added pressure) that slices were subjected to for experiments involving the other noble 
gases. Helium was chosen because it is considered inert and lacking in any pharmacological 
effect; no molecular targets have been identified and it is often used as a pressuring gas in 
experiments investigating the effects of pressure [74, 131, 132]. It was found that the addition 
of helium at this pressure had no significant effect on injury development when compared to 
TBI slices and sham treated slices under normobaric conditions (figure 3.8). For 
concentration response studies involving xenon and argon, a range of pressures was 
investigated using helium to identify any effects of pressure per se. It was found that over a 
range of added pressures; 30.4 kPa, 50.6 kPa and 70.9 kPa no effect on injury development 
was observed on TBI or sham treated slices (figure 3.9).  Further discussion of helium in the 
literature can be found in the following section 7.2.2.  
 
Neuroprotection by xenon  
In this study, 50.6 kPa xenon was found to be potently neuroprotective following traumatic 
and ischemic brain injury in vitro (figures 4.2 and 6.4). This effect was sustained through the 
72 hour experimentation period for TBI, and the 24 hour experimentation period for 
ischemia. At 72 hours 50.6 kPa xenon reduced total injury (primary and secondary injury 
included) by 0.43±0.03. When the primary injury component was removed from analysis, it 
was calculated that xenon reduced secondary injury by 0.50±0.05 at 72 hours. Most 
remarkably the extent of damage xenon treated injured slices was not found to be 
significantly different from sham treated slices at any time point (figure 4.4). This data 
suggests that this concentration of xenon completely abolished the development of secondary 
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injury in the slices when slices were exposed to xenon for the entire 72 hour experimentation 
procedure. The work produced in this thesis found that exposure to 50.6 kPa xenon was 
found to reduce OGD induced injury by approximately 0.69±0.05, which is comparable to 
that found by Paul Banks [68] using the same in vitro model.  Similarly, Jawad et al. found a 
75% concentration of xenon following ischemic injury in dissociated cells afforded more than 
92% protection [95] and David et al. [84] found that treatment with xenon at concentrations 
ranging from 50%-75% reduced injury levels of brain slices subjected to OGD  to the level of 
control uninjured slices.  
 
Concentration response effects of xenon 
This study in this thesis also addressed possible concentration response effects of xenon 
across a range of concentrations from 30.4 kPa to 70.9 kPa (figure 4.8). At a concentration of 
30.4 kPa xenon provided protection of 0.40±0.13, at 50.6 kPa xenon provided 0.43±0.03 
protection which rose to 0.52±0.12 protection at 70.9 kPa. Overall the concentration studies 
of xenon yielded encouraging results, as it appears that even at lower concentrations the 
neuroprotection afforded by xenon is robust. These results suggest that potent 
neuroprotection may be observed at concentrations below the ones investigated in this study. 
This has clinical advantages in terms of allowing for sufficient oxygen levels during 
treatment, and economic advantages as lower effective concentrations results in a lower 
overall cost of treatment. Concentration dependence of neuroprotection by xenon has been 
investigated  in a number of previous studies [47], Encouragingly, neuroprotection has been 
observed in in vitro models of brain injury at concentrations as low as 10.3 kPa. However an 
in vivo study found 20% xenon to be ineffective as a neuroprotectant whereas 70% xenon 
provided a significant level of protection following carotid artery ligation [85]. This may 
reflect the relative complexity of whole animal models compared to simple in vitro models 
where other factors such as inflammation and blood-brain barrier breakdown may play a 
significant role in the spread of damage.  
 
Neuroprotection by argon 
In this study argon was also identified as possessing neuroprotective properties following 
traumatic and ischemic brain injuries. Following trauma, 50.6 kPa argon was found to reduce 
injury development by 0.30±0.07 (figure 4.2). When secondary injury alone was examined 
argon was observed to reduce secondary injury development by 0.34±0.08 (figure 4.5). In 
this model argon was less effective than xenon at reducing secondary injury development, as 
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secondary injury in argon treated slices was not significantly different from sham treated 
slices at the 24 and 48 hour time points but by 72 hours it was significantly higher than in the 
shams, indicating an attenuation or a delay in the development of secondary injury.  When 
neuroprotection by 50.6 kPa argon was investigated following OGD, it reduced injury 
development to 0.29±0.08 of control injury (figure 6.4) which was not significantly different 
to the level of protection afforded by xenon, thus they appear to have similar potencies 
following OGD. However OGD injury was only assessed up to 24 hours, whereas TBI injury 
was assessed up to 72 hours, so it is possible that if a longer experimental period had been 
implemented following OGD then differences between the potencies of xenon and argon may 
have been observed.  
 
A number of publications have reported similar neuroprotective effects of argon following 
traumatic and ischemic injury both in vitro and in vivo. Loetscher et al. [51] investigated 
argon neuroprotection in a similar model of in vitro TBI to the current study. They found 
50% argon to reduce injury by approximately 86% compared to control injury 72 hours after 
the TBI. The reason for the higher potency observed by argon following TBI in their study 
compared to the data in this thesis may be due to methodological factors; Loetschers study 
used an impact force of 5.26µJ, a threshold for pixel integration of 100 and normobaric 
conditions. On the other hand, their study observed a lower potency of argon following OGD 
than in this thesis (44% Loetscher study vs. 71% in this study) despite a similarity between 
the protocols, although the OGD slices in Loetschers study were observed for 72 instead of 
24 hours. In vivo studies of middle cerebral artery occlusion [97], neonatal asphyxia [135] 
and NMDA injection [101]  exposed to argon concentrations ranging from 37.5-70.9 kPa 
argon (respectively) observed reduced infarct volumes and improved functional recovery 
following treatment. These results indicate that in vitro neuroprotection observed by argon 
has been successfully translated to the in vivo setting when given at the investigated 
concentrations, which is encouraging.  
 
Concentration response effect of argon  
This study investigated the concentration response effect of argon following TBI, by 
investigating the neuroprotection afforded by argon at concentrations of 30.4 kPa, 50.6 kPa 
and 70.9 kPa (figure 4.8). It was found that argon was devoid of neuroprotective effects at a 
lower concentration of 30.4 kPa, with a reduction in injury of only 0.06±0.07 (figure 4.6). A 
significant neuroprotective effect of argon was observed at concentrations of 50.6 kPa and 
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70.9 kPa, providing 0.30±0.07 and 0.40±0.10 neuroprotection respectively at 72 hours. In 
comparison to xenon there appears to be a concentration dependence of argon 
neuroprotection. Concentration dependence of argon neuroprotection has recently been 
demonstrated by Brucken and colleagues [133] who reported that rats receiving 70.9 kPa 
argon following cardiac arrest had significantly less neurological impairment than rats 
receiving 40% argon. David and colleagues [101] found that both in an in vivo model of 
excitotoxic injury, and an in vitro model of OGD injury, argon provided a significant level of 
neuroprotection when administered at concentrations of 37.5 kPa or above (50.6 kPa and 70.9 
kPa was also investigated), but injury returned to control levels when argon was administered 
at a concentration of 25.3 kPa. Interestingly, they found that in vivo, argon was not 
neuroprotective when administered at a 70.9 kPa concentration, whereas it was significantly 
neuroprotective at this concentration in vitro [101]. This may be of concern, as the target of 
argon neuroprotection may be one which is easily overwhelmed by other death promoting 
mechanisms in vivo compared with in vitro studies.   
 
Comparing the relative potencies of xenon and argon  
The reasons for the differing concentration dependence between xenon and argon may be due 
to different potencies between the gases, which are most likely accounted for by the different 
mechanism of neuroprotection (see section 7.3.1). In terms of potency, this study found that 
following TBI xenon was more potent at a 50.6 kPa concentration when assessing the 
reduction of secondary injury development, whereas following OGD both xenon and argon 
were equally as effective as neuroprotectants although the OGD procedure was limited to 
assessing cell injury at 24 hours post injury. The reason for limiting the experimental 
procedure to 24 hours was based on observations by Paul Banks who reported no further 
injury development after 24 hours using this model of OGD. There are two published studies 
in which xenon and argon have both been assessed in the same model; the in vitro dissociated 
cell model of OGD by Jawad et al. [95], and the in vivo model of neonatal asphyxia by 
Zhuang et al.  [134]. These studies found conflicting results, with Jawad’s study concluding 
that at a 75% concentration xenon was more effective as a neuroprotectant, whereas Zhuang’s 
study found that whereas xenon and argon (at a 70.9 kPa concentration) both decreased 
infarct volume to the same extent, only argon improved cell survival to naïve levels, 
indicating argon was more effective. Coburn and colleagues used an in vitro model of TBI to 
assess both argon [51] and xenon [50] in separate studies, although the methods are very 
similar. In these studies argon was found to be a more effective neuroprotectant following 
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TBI, reducing total cell death to 14% of control, whereas xenon reduced it to 50% (both at a 
75% concentration). There are a number of subtle differences between the two studies 
however, including different impact energies (5.26µJ argon study and 3.5µJ xenon study) and 
different thresholds for pixel quantification (100 argon study, 150 xenon study). It is clear 
that there is a requirement for more studies investigating both xenon and argon in the same 
controlled models both in vitro and in vivo in order to further assess the relative potencies of 
both. In terms of economic costs, if argon were found to be equally as effective as xenon but 
only when given at higher concentrations, then this would potentially make argon a more 
clinically feasible option as it would negate the requirement for expensive closed circuit 
delivery systems.  
 
7.2.2  Helium, neon and krypton do not provide 
neuroprotection following TBI in vitro 
 
The work described in this thesis found that helium, neon and krypton were all devoid of 
neuroprotective effects when administered for 72 hours following TBI in vitro.  
 
Helium  
The general consensus regarding heliums neuroprotective effect, or lack of, is disputed in 
other publications, most of which focus on ischemic brain injury. The findings of the current 
study are in agreement with that of Banks et al. [68] who determined that 50.6 kPa of 
additional helium had no significant effect on injury development in organotypic 
hippocampal slices in an in vitro model of ischemic brain injury (the same model as 
employed in chapter 6). Another in vitro model of ischemic brain injury  [95] using 
dissociated cortical cells exposed to 90 minutes of oxygen and glucose deprivation found that 
exposure to 75% helium actually worsened the injury when cells were assessed 24 hours 
later. In in vivo studies of ischemia helium appears to have consistently neuroprotective 
effects. A study by Pan et al. in 2007 [135] found 75% helium to reduce infarct volume and 
improved neurological deficits 24 hours after focal ischemia. Another in vivo study of MCAO 
by Pan et al. [136] several years later found 70.9 kPa helium to reduce infarct size and 
improve neurological deficit scores but only if it was administered immediately after the 
injury. The neuroprotective effect was lost if treatment with helium was delayed by 30 
minutes or longer [136]. Interestingly one in vivo study [134] found that 70.9 kPa helium was 
Chapter 7 Discussion 
 
 
Page 120 of 170 
 
protective after 90 minutes of ischemia in rats, but this neuroprotection was lost in a more 
severe insult of 120 minutes of ischemia (in comparison to xenon and argon that were 
significantly protective in both).  
 
The reasons for the discrepancies between different studies concerning helium 
neuroprotection are unclear, although it can most likely be attributed to the different models 
employed in each study and differing concentrations of helium. Helium is very unlikely to be 
exerting neuroprotective effects via a pharmacological mechanism (due to unfavourable 
binding enthalpies) and is more likely to be due to a physical mechanism [74]. David and 
colleagues [99] propose that the neuroprotection observed by helium in vivo is due to the 
induction of hypothermia on account of the high specific heat in comparison to normal air 
(thermal conductivity of helium and nitrogen are 0.1499 and 0.0260 W/m/K respectively 
[74]). They found that when 75% helium was administered following MCAO at 25
O
C 
neuroprotection was observed, whereas when the temperature of the inspired helium was 
adjusted to 33
O
C then this neuroprotective effect was abolished. This does provide a plausible 
explanation for neuroprotection by a gas that is seemingly devoid of biological targets, and 
goes some way towards explaining the lack of effect observed by helium in this study as 
temperature was controlled at 37
O
C throughout the experimental procedure. Despite the 
conflicting evidence in the literature regarding potentially neuroprotective effects of helium, 
this study found both helium and hyperbaric conditions to have no significant effect on injury 
development. It was assumed that the effects of helium and pressure were not exactly equal 
and opposite, and helium was considered a suitable control gas for this investigation.  
 
Neon  
No effect was observed following treatment with 50.6 kPa neon following TBI in this study 
(figure 4.2). Similar to helium, the unfavourable balance between binding energies and 
repulsive forces means neon is unlikely to interact with binding cavities in proteins [103] and 
thus unlikely possess any biological activity. Although never investigated before in a model 
of TBI, this finding is in agreement with that of Jawad and colleagues [95] who found neon to 
be devoid of neuroprotective effects in a dissociated cell culture model of oxygen and glucose 
deprivation. A thorough literature search found a single paper suggesting neon possessed 
biological activity [137]. Pagel and colleagues found that preconditioning with 70.9 kPa neon 
significantly reduced myocardial infarct size by 20±3% after 30 minutes of left anterior 
coronary artery occlusion in rabbits, which they suggest is due to activation of prosurvival 
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signalling kinases and inhibition of the MPTP opening [137]. These exact mechanisms 
remain unclear, as does the existence of any biological activity of neon in brain tissues.  
 
Krypton 
This study found that krypton was devoid of neuroprotective effects in an in vitro model of 
TBI (figure 4.2). As a molecule krypton possesses a polarizability that is favourable for the 
formation of London dispersion forces and thus the interaction with protein binding cavities 
[74, 97]. In contrast to the findings of this study Jawad and colleagues [95] found that the 
presence of 75% krypton was actually detrimental to cell survival in a dissociated neuronal 
cell culture model in the naïve state, and not after OGD, as shown by a reduction in MTT 
reducing ability [95], suggesting an intrinsic toxic effect of krypton to cells in their normal, 
uncompromised state. However experiments carried out for this thesis found that krypton 
treated sham slices did not show a significantly higher level of damage than sham slices 
treated with any other noble gas (data not shown). However, despite a lack of observed 
neuroprotection, krypton may possess biological targets and the capability to exert a 
physiological response, but these may not be involved in neuroprotection.  
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7.3  Mechanism of xenon and argon neuroprotection 
 
7.3.1  Xenon provides neuroprotection via inhibition of the 
NMDA receptor at the glycine co-agonist site 
 
Following identification of xenon and argon as neuroprotectants following in vitro TBI and 
OGD, subsequent experiments were devised to investigate the mechanism of neuroprotection. 
The primary focus of investigation was the involvement of the glycine co-agonist site of the 
NMDA receptor. The reason for this was twofold. Firstly, the NMDA receptor is known to 
have an important role in excitotoxic cell death following traumatic brain injuries, and 
secondary, the NMDA receptor is a known target of xenon, with glycine site inhibition 
believed to form a major component of the neuroprotective profile of xenon following 
ischemic brain injury [68].  
To investigate the role of glycine site inhibition in the neuroprotective effects of xenon and 
argon, experiments were devised whereby 100µM glycine was present in the media 
throughout the experimental period, with the rationale that it may compete with xenon and 
argon at the glycine binding site and reduce the effectiveness of these agents. This 
concentration of glycine was used as it has been shown electrophysiologically to maximally 
inhibit the competitive component of NMDA receptor inhibition by 80% xenon in 
concentration response experiments [76]. Furthermore, this concentration of glycine was used 
in the experiments by Banks et al. [68] to demonstrate reversal of neuroprotection by xenon 
following in vitro OGD. It was found that addition of glycine at this concentration had no 
significant effect on traumatic injury development or on sham injury (figure 5.1 and 5.3). 
This is in agreement with previous published reports that this concentration of glycine is not 
toxic to cells in vitro [138-142] or in vivo [143], with glycine toxicity only reported at 
concentration of 10mM and higher [138, 139] To rule out any involvement of the ligand 
gated inhibitory glycine receptors (GlyRs) on injury development or neuroprotection control 
experiments were performed in the presence of 100nM strychnine. This concentration was 
chosen as it has been shown to completely inhibit GlyRs even in the presence of high 
concentrations of glycine [116]. The presence of strychnine at this concentration had no 
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significant effect on traumatic injury development or sham injury when applied alone (figure 
5.2) or in combination with 100µM glycine (figure 5.2c).  
 
Reversal of neuroprotection by glycine site antagonists with the addition of glycine is a 
technique that has been employed successfully in a number of previous studies using glycine 
concentrations ranging from 10µM-1mM [141, 144-147]. Of note is the study by Paul Banks 
[68] which reversed the neuroprotective effects of 50.6 kPa xenon and 0.5µM and 5µM 
gavestinel (a competitive NMDA receptor glycine site antagonist) by addition of 100µM 
glycine in a model of ischemic injury in organotypic hippocampal slice cultures. D-serine has 
been proposed as an alternative endogenous modulator for the glycine site of the NMDA 
receptor. Glycine and d-serine are regulated by distinct uptake and release pathways and both 
are believed to have a role in activating synaptic NMDA receptors, and in the development of 
excitotoxic events [142]. In studies where the effects of d-serine depletion are investigated, 
the effects can be rescued by the addition of glycine [148, 149]. In addition knockout mice 
lacking serine racemase (an enzyme that generates d-serine from l-serine) have been observed 
to retain normal functioning of synaptic NMDA receptors [149, 150].  In this study it was 
proposed that xenon competes for the same site as glycine and/or d-serine and not a direct 
interaction with the molecule themselves so, providing the receptors respond in the same way 
to the co-agonist, its endogenous identity is of less relevance. The primary reasons for 
selecting glycine over d-serine in this study is due to the fact that concentration response 
relationships between glycine concentration and xenon inhibition of the NMDA receptor 
have previously been performed [76] and reversal of xenon neuroprotection by glycine has 
previously been observed following OGD in hippocampal organotypic slices [68].  
This study found that when 100µM glycine was present in the media the neuroprotective 
effect of xenon was abolished (figure 5.4). This effect was sustained when slices were 
exposed to 100µM glycine and 100nM strychnine in combination (figure 5.6), with the 
presence of 100nM strychnine alone not having a significant effect on the level of 
neuroprotection by xenon (figure 5.5). These observations lead to two conclusions. Firstly, 
inhibition of NMDA receptors via the glycine site forms a major component of the 
neuroprotective profile of xenon following TBI, and secondly, inhibitory glycine receptors 
play no role in xenons neuroprotective profile. It was also observed that addition of 100µM 
glycine reversed the neuroprotection by 50.6 kPa xenon in a model of in vitro OGD (figure 
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6.5). This had been previously established by Banks and colleagues [68], but in this 
experiment it was performed to act as a control for the argon experiments, that is, to prove 
that elevated glycine is capable of reversing a neuroprotective effect.  
 
Given the diversity of NMDA receptors it is of interest to consider whether subunit 
composition or location of the NMDA receptor may affect xenons ability to interact with the 
receptor. The glycine binding site is found on the NR1 subunit, however the NR2 subunit is 
differentially expressed during neuronal development and is found predominantly in 
extrasynaptic NMDA receptors. In early developmental stages the NR2B subunit is 
predominantly expressed and the NR2A/NR2B ratio increases during development with an 
NR2A predominant expression in mature neurons [151]. A study by Dickinson and 
colleagues [76] established in electrophysiological experiments that 80% xenon inhibited 
NMDA receptor currents to the same extent in HEK cells transfected with the NR1-NR2A 
and NR1-NR2B subunits (see figure 7.1). Further studies by Haseneder et al. [152] and 
Kratzer et al. [153] have confirmed that inhibition of NMDA receptors by xenon is not 
subunit-selective for NR2A or NR2B containing receptors. Synaptic NMDA receptors are 
activated by the release of glutamate from the presynaptic membrane. In contrast 
extrasynaptic NMDA receptors are located outside of synapses and do not respond to 
synaptically released glutamate [153]. Extrasynaptic NMDA receptors have been proposed to 
play an important role in neuronal degeneration as they respond to increased ambient 
glutamate concentrations, such as those experienced during ischemic and traumatic brain 
injury [154]. Work by Kratzer and colleagues [153] investigating the effect of 65% xenon on 
mouse hippocampal slices found that xenon reduced NMDA receptor mediated excitatory 
postsynaptic currents by approximately 65% and extrasynaptic NMDA currents by 
approximately 59%, thus they concluded that xenon antagonises both synaptic and 
extrasynaptic NMDA receptors with the same potency.  
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Figure 7.1: Concentration–response curves for activation of receptors by N-methyl-D-
aspartate (NMDA) in the absence (black circles) and presence (white circles) of 80% xenon 
for NR1/NR2A receptors (A) and NR1/NR2B receptors (B). The concentration of the co-
agonist glycine was 100µM throughout. Each point represents the mean value from, on 
average, 7 cells (NR2A), or 6 cells (NR2B). The error bars are SEs; where not shown, 
these are smaller than the symbol. The curves are fitted to the Hill equation, as described 
in the text. (C) There was no significant difference (P > 0.05) in the inhibition of NR1/ 
NR2A or NR1/NR2B receptors by 80% xenon. The data shown are at an NMDA 
concentration of 100 µM. The values are means from 11 cells (NR2A) and 8 cells (NR2B). 
The error bars are SEs. Figures and legend reproduced from Dickinson et al. 2007 [76]. 
 
That glycine site inhibition makes up a significant proportion of the neuroprotective 
properties of xenon provides an encouraging basis for its use following in vivo TBI. A 
microdialysis study by Stoffel and colleagues investigated levels of glutamate and glycine 
release in the first 24 hours following focal cortical lesion in rats [155]. They measured 
glycine concentrations of 0.84±0.11µM glycine at baseline, which then peaked at 
3.82±0.56µM directly after the primary injury and fell rapidly back to baseline levels. 
Glutamate levels were measured at 1.45±0.61µM at baseline, which rose to 9.16±3.32µM 
following trauma and remained elevated for around two hours before returning back to 
baseline (figure 7.2). This result is particularly interesting for a number of reasons. Firstly, a 
concern with the use of xenon in human patients would be that extracellular glycine levels 
would rise to a high enough concentration following injury which could potentially eliminate 
xenon binding at the glycine site, in the same manner as observed in this study. Stoffels work 
shows that the peak in glycine concentration is very rapid and that the baseline levels of 
glycine would be sufficiently low to allow xenon inhibition of the NMDA receptor. 
Secondly, the rise in glutamate levels that persisted for several hours following injury may 
provide an explanation for why xenon has been observed to have a 3 hour therapeutic 
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window for neuroprotection. That is, xenon is at its most effective when glutamate levels are 
at a toxic high.  
 
 
Figure 7.3: Course of extracellular glycine (top) and glutamate (bottom) levels in the depth 
of the parietal cortex directly adjacent to the traumatic tissue necrosis (open circles; sham 
group; filled circles; trauma group). The first sample after trauma revealed a sharp 
increase of these excitotoxins in the extracellular space of the penumbra zone. Glycine 
showed a sudden increase in the sample immediately after injury and went back to baseline 
thereafter. Glutamate remained on a somewhat elevated level for more than 2 hours.  
Figures and legend reproduced from Stoffel et al. 2002 [155] 
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7.3.2  Additional targets of xenon neuroprotection 
 
In addition to NMDA receptor glycine site inhibition a number of other targets of xenon have 
been identified which may contribute to xenon’s neuroprotective properties, including KATP 
channels, TREK-1 channels and apoptotic and inflammatory pathways. The ATP sensitive 
K+ channel (KATP) is thought to play a significant role in the preconditioning neuroprotective 
effect of xenon. [79]. KATP channels are widely distributed in the brain and are activated by 
metabolic stresses such as ischemia leading to a reduction in excitability and increased 
resistance to ischemia [156]  A study in 2009 by Trapp and colleagues found that exposure to 
xenon prevented cell death following OGD in vitro, which could be reversed by the presence 
of the KATP channel inhibitor tolbutamide.  Patch clamp electrophysiology experiments on 
HEK293 cells expressing the Kir6.2/SUR1 KATP channel revealed that xenon acts as a KATP 
channel opener as shown by an increased K
+
 current [79]. Further work by this group 
demonstrated that xenon targets the Kir6.2 pore forming subunit of the KATP channel [80]. 
The role of KATP channels in neuroprotection was further demonstrated in a study by Yamada 
and colleagues [157] who showed that knockout mice lacking the Kir6.2 gene were more 
sensitive to seizures following ischemia. Xenon’s actions at the KATP channel may have 
important implications in its neuroprotective profile following ischemic and traumatic brain 
injuries. A reduction in excitability of the brain would be extremely beneficial in limiting the 
propagation of waves of depolarisation that occur following brain injuries and thus a 
reduction in secondary injury development. Further to this, xenon may provide 
neuroprotection via this mechanism where NMDA receptor involvement is minimal, for 
example where the distribution of these receptors is low, or when glutamate levels have 
returned to normal physiological concentrations.  
   
In this and other studies it has been demonstrated that xenon activates the two pore domain 
potassium channel TREK-1 [78].  Channels of this type act normally to modulate neuronal 
excitability by providing a background leak potassium conductance. Activation of these 
channels can cause hyperpolarisation of the cells and therefore reduce excitability which may 
have a role in neuroprotection [74]. Studies by Heurteaux and colleagues [158]  using TREK-
1 knockout mice found they have a reduced sensitivity to volatile anaesthetics (higher 
concentrations required for loss of righting reflex and longer time to induction of 
anaesthesia). Similarly to KATP channels, a reduction in excitability via xenons actions at 
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TREK-1 channels would be extremely beneficial to reduce spreading waves of depolarisation 
following injury, and thus represents another clinically important mechanism of xenon 
neuroprotection.  
 
Additional studies have proposed that xenon is capable of modulating the immune and 
inflammatory systems following injury which may contribute to its neuroprotective effects. 
Fahlenkamp and colleagues [159] observed that exposure to 74% xenon in cultured 
microglial cells caused an increase in LPS-stimulated IL-1β mRNA and protein levels, 
induced a rapid and persisting ERK 1/2 phosphorylation and inhibited phosphatases. 
Inhibition of phosphatases is likely to underlie the observed ERK 1/2 activation [159] and 
also affect multiple signalling pathways [160]. In support of this is the observation by Fries et 
al. [88] that exposure to 70.9 kPa xenon following cardiac arrest in pigs caused a decrease in 
perivascular inflammation in the caudate and putamen nucleus which translated to an 
improved functional outcome.  Xenon has also been proposed to target apoptotic pathways by 
regulating the calmodulin-activated kinase II (CaMKII) complex [86]. The CaMKII complex 
is involved in the control of presynaptic Ca
2+
 associated events and its activation is associated 
with over release of neurotransmitters and ultimately cell death [86].  
 
In this study it was observed that when glycine site inhibition by xenon is prevented, the 
neuroprotective effect is abolished. This could be interpreted as glycine site inhibition being 
the sole target of xenon neuroprotection, however this is unlikely given the convincing 
evidence for other targets. An alternative hypothesis to glycine site inhibition being the only 
important target of xenon neuroprotection is that xenon acts at more than one target, but 
removing the inhibition of NMDA receptor component from neuroprotection is sufficient for 
the injurious pathways to overwhelm other neuroprotective mechanisms. This model used the 
hippocampus as a platform for neuroprotective studies which has a high NMDA receptor 
density compared to other brain regions. It is therefore reasonable to suggest that NMDA 
reception inhibition will be the dominant mechanism of neuroprotection in this model, but 
this may not be the case for other brain regions in vivo, where other targets such as the KATP 
channel and TREK-1 channels are likely to have a much more dominant role in the 
neuroprotective profile of xenon. This study therefore can only conclude that NMDA 
receptor inhibition by xenon forms a portion of the neuroprotective profile of xenon, and is 
not the sole mechanism, as the model used is somewhat bias towards NMDA receptor 
mediated cell death. Further work investigating the contribution of NMDA receptor inhibition 
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and K+ channel opening on xenon neuroprotective profile in other cultured brain regions 
which are lower in NMDA receptor density would be of great interest. In addition, in vivo 
neuroprotection studies involving genetically altered rodents could aid in determining the 
relative contributions of each mechanism in the neuroprotective profile of xenon, for example 
TREK-1 deficient mice, or mice with selective point mutations rendering the NMDA receptor 
glycine site insensitive to xenon while retaining its affinity for glycine [77]. Whilst this 
would provide more information about xenons mechanism of action, it could also answer 
important questions as to when xenon may be most effective, for how long it should be 
administered for and which patients could be at most benefit from the treatment. This is 
explained further in section 7.4.  
 
Given the evidence presented in this thesis, and previous evidence of xenons targets in the 
brain the figure below presents a proposed mechanism of xenon neuroprotection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3: Schematic representation of neuroprotective mechanisms of xenon 
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7.3.3  Mechanism of argon neuroprotection  
 
Argon also possessed potent neuroprotective properties in this in vitro model of TBI (figure 
4.2) albeit less potently than that of xenon. No molecular targets of argon have been fully 
identified or understood, so at this stage of the investigation it was simplest to rule out (or in) 
targets that xenon possesses, notably the NMDA receptor glycine site and TREK channels. 
Whether xenon and argon shared the same mechanism of neuroprotection was a complete 
unknown so experiments involving the addition of 100µM glycine to the experimental media 
were performed for argon. It was found that additional glycine had no significant effect on 
the neuroprotection afforded by 50.6 kPa argon following both TBI and OGD (figure 5.8 and 
6.6), indicating that glycine site inhibition of the NMDA receptor was not a key mechanism 
of argon neuroprotection following both types of brain injury. To strengthen these 
conclusions electrophysiological experiments were performed by Scott Armstrong on HEK-
293 cells expressing NMDA receptors (NR1-NR2A) to assess whether exposure to argon had 
any effect on NMDA induced currents. These experiments revealed that 80% argon had no 
effect on NMDA currents at high (100µM) and low (1µM) glycine concentrations, providing 
further evidence that the glycine site is not a target of argon, or indeed the NMDA receptor 
itself (at the concentrations investigated). The next target to be investigated was the 2-pore 
domain K
+ 
TREK-1 channels. TREK-1 channels are known to be activated by xenon (figure 
5.12) however their contribution to xenons neuroprotective profile is currently not fully 
understood. Electrophysiological techniques were employed (and performed by Scott 
Armstrong) on HEK-293 expressing TREK-1 channels. It was found that 80% argon (and the 
other noble gases helium, neon and krypton) had no effect on TREK-1 channel currents 
(figure 5.13). These results suggested that TREK-1 channels are not a molecular target of 
argon and therefore this is not a mechanism of neuroprotection. Thus the mechanism of argon 
neuroprotection remains elusive. An obvious future avenue of investigation will be to 
investigate whether argon, like xenon, has any effects at KATP channels.  
 
A number of studies have proposed molecular targets of argon that may underlie its 
neuroprotective effect. A recent paper by Fahlenkamp and colleagues identified the 
extracellular signal regulated kinase (ERK) 1/2 as a possible target for argon neuroprotection 
in neurons and glial cells [161].  Activation of ERK signalling can affect many cellular 
functions, such as cell proliferation and differentiation and activation of gene transcription 
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programs. Exposure to 50% argon caused activation of the ERK pathway in neurons and glial 
cells (microglia and primary astrocytes) after 15-30 minutes of exposure [161]. Zhuang and 
colleagues [134] found that following neonatal asphyxia treatment with argon increased the 
expression of the pro-survival proteins bcl-2 and bcl-xL and decreased expression of the pro-
apoptotic protein bax. Abraini and colleagues [162] suggest that argon may act at the 
benzodiazepine site of the GABAA receptor. This may have an effect on NMDA receptor 
function as GABA receptor stimulation can lead to inhibition of NMDA receptors, and 
GABA receptor activation has been shown to be neuroprotective in in vitro and in vivo 
models of ischemia [163, 164]. Furthermore Zhang et al. [165] provided evidence that GABA 
agonists can attenuate the phosphorylation of the NR2A subunit, decreasing its functionality 
and thus exerting a neuroprotective effect. Other studies investigating the neuroprotective 
effects of GABA agonists unrelated to NMDA receptor function have identified activation of 
the phosphoinositide 3-kinase/protein kinase b cascade [166] and attenuation of cytochrome c 
release [167] as possible mechanisms, although their relationship to argons mechanism of 
neuroprotection is unknown. The reduced ability to form dipoles by argon compared to xenon 
is also likely to limit its number of available protein binding sites compared to xenon [103]. 
Xenon is known to possess multiple targets that are thought to contribute to its 
neuroprotective profile. If argon were to possess fewer targets (or a single target), then it may 
be expected that it would be less effective as a neuroprotectant as alternative injury pathways 
could continue unhindered following injury, although without a full characterisation of all the 
molecular targets of argon and xenon that contribute to neuroprotection, this remains just 
speculation.  
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7.4 What is the clinical importance of these findings?  
 
It has been demonstrated in this thesis and in numerous other pre-clinical studies that xenon 
and argon are neuroprotective following brain injury. This thesis studied the specific 
mechanism of both xenon and argon following identification of them as neuroprotectants 
after in vitro traumatic brain injury.  On the surface, efficacy in human brain injury appears to 
be the most important factor with regards to identifying drugs that are neuroprotective, with 
their specific mechanisms considered a curiosity. However, scratch the surface and there is a 
lot more that mechanistic studies can tell us. These include optimum dosing parameters and 
therapeutic time windows, diagnostic tools that may be useful in determining the success of a 
certain drug in an individual, combination therapies that may produce a beneficial effect, 
other brain pathologies that the drug may be useful for treating and may aid in the design of 
novel compounds that target the same mechanism. 
Previous studies of both xenon and argon in in vitro and in vivo models of have estimated that 
neuroprotection is only achieved if the gases are administered within the first 3 hours after 
the initial ischemic or traumatic injury [50, 51, 68, 84, 100] with the greatest level of 
neuroprotection observed within the shortest time frame to administration (ideally, directly 
after the insult). Time between injury onset and treatment with neuroprotective agents has 
created complications in human clinical trials of NMDA receptor antagonists. This may be 
due to the fact that administration of these agents is too many hours later following the peak 
in glutamate that occurs immediately after the injury where downstream cell death processes 
have already begun, and thus administration of an NMDA receptor blocker after this time is 
almost a case of ‘shutting the gate after the horse has bolted’. By knowing that xenon targets 
the NMDA receptor and the early excitotoxic events after injury this could improve the 
design of clinical trials whereby xenon (or other drugs acting at the same target) must be 
given within a very limited time frame if it is possible.  However, this may be extremely 
difficult to implement clinically especially in the case of stroke and milder head injuries 
which usually don’t present in the first 3 hours after injury. Calculation of the time between 
injury and first dosing may be simpler in the case of severe TBIs as they often occur in 
accidental settings requiring emergency medical treatment, such as in the case of road traffic 
accidents, where witnesses to the injury can approximate when it occurred and relay this 
information to the emergency response team. There is an increasing realisation that mild and 
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moderate head injuries do worse than predicted but they do not present as quickly as severe 
head injuries. NMDA receptor antagonists may not be particularly useful for this subset of 
patients as NMDA receptor over activation is an early event in the secondary injury cascade 
and thus requires early intervention. This could effectively rule out xenon as a treatment 
option in these patients. However the other targets of xenon that contribute to 
neuroprotection, notably the K
+
 channels (TREK-1 and KATP) may be useful in the treatment 
of these patients, particularly with regard to cortical spreading depression, as drugs that target 
these channels would reduce the overall excitability of the brain. Perhaps it is this target of 
xenon neuroprotection that could provide it with a more effective use across a wider subset of 
head injury patients. In addition, imaging techniques that could identify cortical spreading 
depression in patients that present with a head injury later than 3 hours post injury could aid 
in determining who may be most suitable to receive this treatment.  
Xenons properties of providing neuroprotection after preconditioning with the gas also 
provide a potential opportunity in some clinical scenarios. Neonatal asphyxia represents a 
major cause of death and disability worldwide, with an estimated 2-4 per 1000 full-term 
infants experiencing an asphyxial episode either antenatally or perinatally, of which an 
estimated 15-20% die, with 25% of the survivors experiencing severe disability [168]. 
Studies have found xenon preconditioning to provide neuroprotection in models of ischemia 
[79, 169] and neonatal asphyxia [170] which gives rise to a number of possible clinical uses 
of xenon preconditioning, such as before or during birth to provide some pharmacological 
protection to the unborn child against neurological injury caused by asphyxia or in patients 
undergoing surgery where risk of an ischemic episode is high, such as during heart surgery or 
carotid endarterectomy [79]  
 
Combination therapies have been suggested in some publications as ‘the future’ of treating 
TBI and ischemic brain injuries [8], as different drugs that target different aspects of the 
secondary injury cascades could be given in parallel to the patient. Obviously this form of 
treatment requires an understanding of the mechanism being targeted (so the same pathway 
isn’t targeted), so the use of xenon in combination therapies is realistic option. There is a 
growing body of evidence that xenon and hypothermia in combination provides a synergistic 
neuroprotective effect in in vivo studies on rats and pigs following ischemic brain injury [65, 
66, 85, 91, 171]. The binding of volatile general anaesthetics is increased at lower 
temperatures to favourable enthalpic interaction conditions [92-94].  Dickinson and Franks 
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[74] suggested this synergistic effect may be due to increased binding of xenon at lower 
temperatures, although a study by Maze and colleagues [91] found that when xenon and 
hypothermia were administered asynchronously the synergistic effect was still maintained, 
which indicates that the mechanism is not simply physical binding properties. Hypothermia is 
also thought to act presynaptically to reduce glutamate release and interfere with the 
apoptotic cascade [91, 172, 173] and to decrease levels of glycine and p53 protein levels in 
the brain [171, 174, 175]. How these mechanisms specifically account for the synergistic 
relationship with xenon is unclear, but the combination of the two therapies represents an 
exciting treatment option for the future. Another interesting combination therapy to consider 
would be xenon and argon administered together. If xenon and argon act at different targets 
then it would be plausible to suggest combination therapy of the two agents to have an 
additive or synergistic effect, however combining the two would require lowering the 
concentration of both to allow for sufficient oxygen levels. This would in turn reduce the 
neuroprotective efficacy of both agents if in combination their effect was additive, but could 
be viable if their effect in combination was synergistic and thus combination therapy of 
xenon and argon is a possible consideration for the future.  
 
Translation in efficacy across a range of brain injuries is also possible once a mechanism of a 
drug is known. NMDA receptor inhibition was understood first to be one of the key 
mechanisms in neuroprotection following ischemic type brain injuries. Armed with this 
information and the knowledge that glutamate also plays a key role in the development of 
secondary injury following TBI formed the rationale for testing xenon in a model of TBI, 
with success. It is therefore reasonable to hypothesise that where glutamate excitotoxicity 
plays a key role in a progression of a brain injury (e.g. blast injury and neurodegenerative 
conditions such as Alzheimer’s disease [176]), xenon may provide some clinical benefit. 
Xenons actions at potassium channels are also of great importance when considering 
conditions where spreading excitation is a key pathology. Thus mechanistic research can 
open up exciting new avenues of research.  
 
Finally, knowing the mechanism of xenon may aid in the development of novel 
pharmacological compounds that target the same mechanisms. These could be cheaper to 
obtain and administer (i.e. not requiring closed circuit anaesthesia stations). Given that xenon 
is an inhaled gas, new compounds could be designed with alternative routes of administration 
that may be easier to administer where a patient does not require sedation or intubation. 
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Perhaps this is the most important finding of this study; that any drug that possesses a 
mechanism of action the same as that of xenon (NMDA receptor inhibition at the glycine site 
combined with opening of K
+
 channels) may provide clinical benefit in patients following 
head injury.  
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7.5  Why have drugs with similar mechanisms failed 
clinical trials and why might noble gases be different? 
 
The evidence so far supporting the clinical use of xenon following brain injuries is very 
encouraging, with favourable pharmacological properties, lack of toxicity and robust and 
reproducible neuroprotection in numerous models of brain injury. However this promising 
tale is not unfamiliar, as over the years every agent that targeted the excitotoxic component of 
secondary injury development has failed human clinical trials. This could be for a number of 
reasons, which can be broadly broken down into issues with the pharmacology of the 
compound itself, conduction of clinical trials, issues with the role of glutamate itself in 
contribution to brain damage and issues with the pre-clinical models used to model brain 
injuries in vitro and in vivo.  
 
In term of pharmacology of the compounds, they have failed for numerous suggested reasons, 
including high toxicity [177], poor pharmacokinetics, inability to rise to effective 
concentrations in brain tissues (possibly due to metabolism or poor blood  brain barrier 
penetration), short therapeutic time windows and inappropriate receptor subunit selectivity. 
Poor design and execution of clinical trials with inappropriate and insensitive assessments of 
neurological function has also been an issue [46]. Gavestinel is a classic example of a drug 
with a proposed mechanism the same as that of xenon, in that it is a NMDA receptor glycine 
site antagonist, that failed in clinical trials. The reasons for gavestinels failure have been 
proposed as failure to reach the site of action in appropriate concentrations and administration 
outside of the therapeutic time window at 6 hours post ischemia [178-180].  As mentioned in 
the previous section, administration of a glutamate receptor antagonist hours and hours after 
the initial peak in glutamate levels could be futile, as the cell death promoting processes have 
already begun, and using a treatment that targets an early event in the excitotoxic cascade will 
inevitably have little effect.  
 
Ikonomidou and Turski [46] propose an alternative view that the issue lies within the concept 
of glutamate excitoxicity mediating development of injury. They hypothesise that “glutamate 
may be involved in the acute neurodestructive phase that occurs immediately after traumatic, 
or ischemic injury, but that after this period it assumes its normal physiological functions 
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which includes promotion of neuronal survival” [46]. That is, a continued block of NMDA 
receptor function could be harmful to the damaged brain instead of helpful.  
 
One very important aspect to consider when assessing why so many agents fail human 
clinical trials following encouraging pre-clinical success in models of brain injury is the fact 
that pre-clinical models are heavily controlled, that is, injury is usually isolated to the brain. 
In vitro models typically involve isolated brain regions or single cells cultured in conditions 
that are amenable to survival of the slices/cells but with less relevance to the real-life 
scenario, lacking influences from inflammation, blood supply and blood brain barrier 
breakdown. In vivo studies are more useful with regard to these, but the nature of a pre-
clinical model is often far removed from the clinical scenario. Injury is isolated to the brain, 
that is, the poly-trauma that occurs in a large number of head injuries is absent, animals are 
usually anaesthetised at the time of injury and drug treatment is usually began within a time 
window that would be very difficult to achieve in real life.   
 
With regard to these issues, xenons well characterised safety profile and fast induction of 
anaesthesia indicates a rapid delivery to brain tissues. A lack of metabolism eliminates the 
risk of toxic metabolites. Failure to reach the brain in effective concentrations is unlikely with 
xenon, as neuroprotection studies have been conducted at concentrations lower than that 
known to cause general anaesthesia.  Xenon is thought to only be effective if administered 
within 3 hours following the initial injury, so it seems possible that the failure of gavestinel is 
due to administration outside of the therapeutic time window. Since we now know that xenon 
targets the NMDA receptor as one of the key mechanisms of neuroprotection, in which over 
activation is an early event in the injury pathway, clinical trials can progress with specific 
time limits between injury and administration. In terms of extended blockade of NMDA 
receptors being harmful, Dingley and colleagues propose a reason why this issue may be 
circumvented by the use of xenon, as they hypothesise that although it may be true that 
complete NMDA receptor blockade can be pro-apoptotic, a dose of 80% xenon only partially 
antagonises NMDA receptor currents by reducing them to approximately 60% [58, 71]. 
Xenon also has a number of targets within the brain which are thought to contribute to 
neuroprotection. This confers another advantage to its use, as pre-clinical models that target 
limited injury pathways will be biased towards showing robust neuroprotection by agents that 
target that pathway (for example, NMDA receptor antagonists following direct injection of 
NMDA), which may not translate well to the clinical scenario where a large number of 
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chaotic injury pathways are triggered in parallel. It is hopeful that xenons combined NMDA 
receptor blockade and potentiation of K
+
 channel currents could provide a unique 
pharmacological profile to limit secondary injury spread. Possible improvements to the 
techniques of modelling traumatic injury in vitro in discussed in the following section.  
 
A major limitation to the widespread use of xenon is the high cost due to its rarity in the 
atmosphere, currently around £25 per litre. However due to its lack of metabolism, xenon can 
be re-used or recycled if it is delivered to the patient using a closed circuit. Dingley and 
colleagues have developed a closed circuit xenon anaesthesia delivery system that could also 
be used for neuroprotection [181]. A 50% gas mixture of xenon was administered for nearly 6 
hours at a total cost of around £540 ($148.5/hr). This may seem like a pricey treatment 
option, but the NHS figures for long term treatment for a young person sustaining a serious 
head injury to be a staggering £4.89 million over a lifetime for a single patient. This figure 
takes in account the cost of medical care, educational costs, direct social costs, missed 
employment, lost tax revenue, and benefits. Given these massive economic costs that are 
incurred for the long term treatment and rehabilitation of brain injury patients, then the cost 
of xenon treatment would be negated by longer term reductions in spending.  
 
In comparison to xenon, argon is more abundant in the atmosphere (in fact, the most 
abundant noble gas in the atmosphere at 0.93% [161]) and as a result is cheaper to obtain, 
negating the need for a closed circuit delivery system [103]. This is a major advantage of 
argon. Another advantage lies with its property of not being capable of causing general 
anaesthesia at normobaric pressures which may be of benefit in clinical scenarios where 
sedation is not desired, such as acute, focal injury such as stroke [103]. Before its 
neuroprotective properties were discovered, argon has had very limited use as a 
pharmacological agent and thus there is a lack of data regarding its specific pharmacological 
properties, although it is understood to be non-toxic to humans.  
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7.4     Further Studies 
 
Further experiments and improvements to the model  
The work presented in this thesis open up some interesting avenues for further investigation 
in order to characterise xenon and argons mechanism of action further and address some of 
the issues highlighted in this discussion. Firstly, the data presented here demonstrates a robust 
neuroprotection by xenon even at lower partial pressures. It would therefore be of interest to 
lower the concentration of xenon further in these experiments to see if a similar level of 
neuroprotection is achieved, which could have economic advantages to its use clinically. 
Previous studies have suggested that neuroprotection by xenon in vitro can only be achieved 
if the initial treatment is started within 3 hours post injury, which is hypothesised to correlate 
to raised levels of glutamate. It would therefore be interesting to see how the injury 
progresses if the treatment is removed after a certain period of time, for example immediate 
treatment followed by withdrawal of treatment after 3 hours, will the neuroprotective effect 
remain or will it continue? A sustained neuroprotective effect could possibly indicate 
alternative mechanisms of action, for example an inhibition of spreading depression by its 
actions at K
+
 channels. In addition this may be more relevant to the clinical scenario where 
72 hour administration of a drug may not be feasible (xenon is sedative so would not allow 
for assessment of improvement using the GCS during this time, argon is not sedative so may 
be better) and would be expensive to implement.  
Another interesting avenue of investigation would be to culture organotypic slices from other 
brain regions which are lower in NMDA receptor density, to identify the contribution of 
glycine site inhibition and the contribution of K
+ 
channel opening in different regions of the 
brain. One possibly is that lower NMDA receptor density would translate to a lower efficacy 
of xenon as a neuroprotectant. Alternatively, efficacy would be retained but alternative 
neuroprotective targets of xenon (K+ channels) would have a much more dominant role than 
in the current study.   
From a clinical perspective ischemic brain injury occurs as a consequence of the traumatic 
brain injury. This model could therefore be improved to include an element of ischemic brain 
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injury that occurs after the primary injury to see if the neuroprotective effects of these drugs 
are sustained during a more severe insult that is closer to the clinical scenario.  
What is perhaps quite an obvious avenue of investigation following the results of this study is 
the potential effect of argon on KATP channels, as its effects on NMDA receptors and TREK-
1 channels have effectively been ruled out. Experiments performed similar to that of Trapp 
and colleagues [80] could answer this question simply.  
Xenon neuroprotection of oligodendrocytes following in vitro TBI 
With the knowledge that one of the mechanisms of xenon neuroprotection following TBI 
involves inhibition of the NMDA receptor, this opens up an intriguing line of thought that 
xenon may be beneficial for the protection of glial cells, such as oligodendrocytes, as well as 
neurones. Oligodendrocytes are a type of glial cell that are crucial for the function of the 
brain [182]. They are responsible for the myelination of axons and thus the fast propagation 
of action potentials, allowing for rapid transmission of information between brain regions 
[182]. Oligodendrocytes are known to possess functional NMDA receptors at all stages of 
development, which are thought to contribute to the myelination process in a use-dependant 
manner [183, 184]. Myelination begins with the extension of multiple processes from the 
somata of the oligodendrocytes which make contact with the axon. It has been proposed that 
calcium influx through activated NMDA receptors on these processes governs the decision to 
proceed with myelination or retract from the axon [183]. NR1, NR2 and NR3 subunits have 
been detected in myelin [185], however oligodendrocyte NMDA receptors are thought to 
differ from neuronal NMDA receptors in that they possess an unusual combination of 
subunits, thought to be NR1, NR2C and NR3 with a weak Mg
2+
 block [184].   
A number of studies have shown that the presence of NMDA receptors on oligodendrocyte 
processes confers a high sensitivity to damage following various forms of brain injury, such 
as ischemic brain injury, in a calcium dependant manner [183-185]. Under conditions of 
excess glutamate the levels of Ca
2+
 within the myelin is raised which destroys the 
myelinating processes of oligodendrocytes [183, 185, 186]. Furthermore, injured axons 
accumulate intracellular Na
+
, lose K
+
, and depolarise which promotes the release of excess 
glutamate [185]. Oligodendrocyte processes are particularly susceptible to excitotoxic 
damage due to their small dimension and low resistance to oxidative stress [183]. Studies 
investigating NMDA receptor blockade as a neuroprotective strategy for oligodendrocytes 
have found that exposure the MK-801 (an NMDA receptor channel blocker) and 7-
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chlorokynurenic acid (a glycine site antagonist) following ischemic injury can prevent 
calcium mediated damage to oligodendrocyte processes [183, 185, 186].  
 
It has been proposed that the vulnerability of oligodendrocytes to excitotoxicity and the 
subsequent downstream effects on myelination of axons may contribute to the loss of brain 
function following a TBI [187]. Given that the evidence in this thesis proposes that xenon 
provides neuroprotection by antagonism of the NMDA receptor, it seems feasible to 
hypothesise that it may also provide a degree of protection to oligodendrocytes. A study by 
Berger and Frotscher in 1994 [188] identified the presence of functional oligodendrocytes in 
organotypic hippocampal slices from rats, prepared using the Stoppini interface method 
[109]. This implies that the current technique to model TBI in vitro could be adapted to carry 
out these investigations. Immunohistochemical techniques could be employed for detecting 
oligodendrocyte processes. Propidium iodide is not an ideal choice for this type of 
investigation, as it has been proposed that when the processes are damaged the cell seals of 
its membrane to protect the soma, with the possibility of regenerating new processes [182].  
This would be an interesting and potentially clinically relevant avenue of investigation in the 
future, and may provide further evidence that xenon will improve functional recovery after a 
TBI. 
Chapter 7 Discussion 
 
 
Page 142 of 170 
 
 
7.6      Summary 
 
This study investigated the potential neuroprotective effects of the noble gases helium, neon, 
argon, krypton and xenon in a controlled in vitro model of TBI; the first of its kind. The 
initial stages of this study involved the design and calibration of a device capable of 
modelling a traumatic brain injury in vitro which possessed the characteristics of a TBI in 
vivo, specifically the development of a secondary injury.  
 
In neuroprotection studies following TBI, only xenon and argon were found to possess 
neuroprotective properties, with helium, neon and krypton found to possess none. Xenon was 
found to be more efficacious as a neuroprotectant than argon in this study as it was found to 
completely abolish the development of secondary injury in comparison to argon which 
attenuated the injury when both were administered at the same concentration of 50.6 kPa. 
Following OGD in vitro 50.6 kPa xenon and argon were found to be equally potent.  
 
NMDA receptor over-activation forms a key component in the spread of secondary injury 
following a TBI. Mechanistic studies revealed that xenon mediates neuroprotection following 
TBI by competitive inhibition of the glycine co-agonist site of the NMDA receptor, as 
demonstrated by a reversal of its neuroprotective effect when a high concentration of 
exogenous glycine was added to the experimental culture media. Argon neuroprotection 
could not be reversed by elevated glycine, indicating that argon does not act at the NMDA 
receptor glycine site. This finding was confirmed by electrophysiology showing argon does 
not inhibit NMDA receptors or TREK-1 channels.   
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7.7     Conclusions 
 
This thesis has addressed the importance of knowing the mechanism of a pharmacological 
compound as opposed to just whether it works or not. Given that xenon is known to have an 
excellent safety profile and is already in clinical trials for neuroprotection following ischemic 
injury it does seem reasonable to postulate that clinical trials administering xenon to trauma 
patients should be started as soon as possible. However, studies of this kind that seek to 
determine the mechanism of xenon neuroprotection following TBI could impact on the 
success of clinical trials. For example, a characteristic of a head injury involves a sudden 
increase in the extracellular concentration of glutamate that can remain elevated for several 
hours (as demonstrated in a rodent model of TBI [155]). As we now understand one of the 
components of xenons neuroprotective profile following TBI involves inhibition of 
glutamatergic NMDA receptors and this property then indicates a maximum effect by xenon 
may only be achieved whilst glutamate levels remain elevated, that is, within the first few 
hours following the initial injury. When extracellular glutamate returns to normal 
physiological levels treatment may no longer be required, although xenon has other 
pharmacological targets that may provide neuroprotective benefits after glutamate levels have 
decreased via actions at potassium channels. Perhaps the most interesting aspect of 
determining the mechanism of a neuroprotective drug is the fact that it opens up avenues for 
development of compounds that act at the same targets.  
 
Adverse effects are another concern for patients, especially those very vulnerable following a 
severe trauma and glycine site antagonists (such as gavestinel) have been previously shown 
to be well tolerated in patients. Generally, the pharmacological properties of xenon are 
favourable for its use clinically, with a lack of reported toxicity, lack of metabolism, potent 
analgesia and no known adverse effects. Knowing the mechanism of xenon neuroprotection 
may also open up exciting avenues for where combination therapy may be beneficial. Indeed, 
the knowledge that argon targets a separate pathway of injury that does not involve the 
NMDA receptor suggests that the two gases in combination may have enhanced benefits. The 
high costs of xenon which have so far hindered its use as a general anaesthetic can be 
circumvented by the use of closed circuit delivery systems which are commercially available. 
In conclusion, the results of this study form a solid foundation in which to continue to in vivo 
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studies of xenon and argon neuroprotection following traumatic brain injury and to further 
investigate potential other mechanisms of xenon and argon neuroprotection.  
Acknowledgements 
 
Page 145 of 170 
 
ACKNOWLEDGEMENTS 
 
This thesis is dedicated to Bruce Porter 
 
Firstly I would like to thank you, the reader, for making it this far. I hope this thesis has 
instilled some hope in you that the treatment for brain injuries is within our sights.  
Secondly, I would like to acknowledge my supervisor Robert Dickinson for his support and 
intellectual input to this thesis. I am very grateful for everything you have taught me 
throughout my PhD. My gratitude also extends to my co-supervisor Nick Franks and to 
Raquel Yustos for her help over the years.  
To Rita Campos-Pires, Scott Armstrong, Louise Kiru, Alaa Mejaddam, Valeria Bridi, Perrine 
Pluchon, and Mariia Koziakova, I gratefully acknowledge your help on this project and I 
wish you all the best in the future. To Ellie Steinberg and Helen Mount, I thank you for your 
friendship and the many wines consumed in honour of successes or in commiseration of 
failures.  
And last, but by no means least (in fact, the opposite of least) my amazing family. My parents 
John and Philippa Harris, and my sister Charlotte Harris, for their unwavering love and 
support during these 4 years. I absolutely could not have done this without you, and I credit 
you with everything I have ever achieved in life. Thank you xx 
 
References 
 
Page 146 of 170 
 
REFERENCES 
 
1. Albert-Weissenberger, C. and A.L. Siren, Experimental traumatic brain injury. Exp 
Transl Stroke Med, 2010. 2(1): p. 16. 
2. McAllister, T.W., Neurobiological consequences of traumatic brain injury. Dialogues 
Clin Neurosci, 2011. 13(3): p. 287-300. 
3. Tagliaferri, F., C. Compagnone, M. Korsic, F. Servadei, and J. Kraus, A systematic 
review of brain injury epidemiology in Europe. Acta Neurochir (Wien), 2006. 148(3): 
p. 255-68; discussion 268. 
4. Maas, A.I., N. Stocchetti, and R. Bullock, Moderate and severe traumatic brain injury 
in adults. Lancet Neurol, 2008. 7(8): p. 728-41. 
5. Rosenfeld, J.V., A.I. Maas, P. Bragge, M.C. Morganti-Kossmann, G.T. Manley, and 
R.L. Gruen, Early management of severe traumatic brain injury. Lancet, 2012. 
380(9847): p. 1088-98. 
6. Roberts, I., Will we continue to ignore death and injuries from road traffic crashes? 
British Medical Journal, 2001. 323: p. 1. 
7. Sobocki, P., J. Olesen, and B. Jonsson, Brain research has high returns but Europe is 
lagging behind. Eur J Neurol, 2007. 14(6): p. 708-10. 
8. Leker, R.R. and E. Shohami, Cerebral ischemia and trauma-different etiologies yet 
similar mechanisms: neuroprotective opportunities. Brain Res Brain Res Rev, 2002. 
39(1): p. 55-73. 
9. Doppenberg, E.M., S.C. Choi, and R. Bullock, Clinical trials in traumatic brain 
injury: lessons for the future. J Neurosurg Anesthesiol, 2004. 16(1): p. 87-94. 
10. Cull-Candy, S., S. Brickley, and M. Farrant, NMDA receptor subunits: diversity, 
development and disease. Curr Opin Neurobiol, 2001. 11(3): p. 327-35. 
11. Mishina, M., H. Mori, K. Araki, E. Kushiya, H. Meguro, T. Kutsuwada, N. 
Kashiwabuchi, K. Ikeda, M. Nagasawa, M. Yamazaki, and et al., Molecular and 
functional diversity of the NMDA receptor channel. Ann N Y Acad Sci, 1993. 707: p. 
136-52. 
12. Zauner, A. and R. Bullock, The role of excitatory amino acids in severe brain trauma: 
opportunities for therapy: a review. J Neurotrauma, 1995. 12(4): p. 547-54. 
13. Yi, J.H. and A.S. Hazell, Excitotoxic mechanisms and the role of astrocytic glutamate 
transporters in traumatic brain injury. Neurochem Int, 2006. 48(5): p. 394-403. 
14. Chen, Y. and R.A. Swanson, Astrocytes and brain injury. J Cereb Blood Flow Metab, 
2003. 23(2): p. 137-49. 
15. Raghupathi, R., Cell death mechanisms following traumatic brain injury. Brain 
Pathol, 2004. 14(2): p. 215-22. 
16. Lauritzen, M., J.P. Dreier, M. Fabricius, J.A. Hartings, R. Graf, and A.J. Strong, 
Clinical relevance of cortical spreading depression in neurological disorders: 
migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and 
traumatic brain injury. J Cereb Blood Flow Metab, 2011. 31(1): p. 17-35. 
17. Woodcock, T. and M.C. Morganti-Kossmann, The role of markers of inflammation in 
traumatic brain injury. Front Neurol, 2013. 4: p. 18. 
18. Morganti-Kossmann, M.C., M. Rancan, P.F. Stahel, and T. Kossmann, Inflammatory 
response in acute traumatic brain injury: a double-edged sword. Curr Opin Crit Care, 
2002. 8(2): p. 101-5. 
References 
 
Page 147 of 170 
 
19. Kochanek, P.M., R.S. Clark, R.A. Ruppel, P.D. Adelson, M.J. Bell, M.J. Whalen, 
C.L. Robertson, M.A. Satchell, N.A. Seidberg, D.W. Marion, and L.W. Jenkins, 
Biochemical, cellular, and molecular mechanisms in the evolution of secondary 
damage after severe traumatic brain injury in infants and children: Lessons learned 
from the bedside. Pediatr Crit Care Med, 2000. 1(1): p. 4-19. 
20. Elmore, S., Apoptosis: a review of programmed cell death. Toxicol Pathol, 2007. 
35(4): p. 495-516. 
21. Kim, J.Y., N. Kim, Z. Zheng, J.E. Lee, and M.A. Yenari, The 70 kDa heat shock 
protein protects against experimental traumatic brain injury. Neurobiol Dis, 2013. 
58C: p. 289-295. 
22. Shohami, E., E. BeitYannai, M. Horowitz, and R. Kohen, Oxidative stress in closed-
head injury: Brain antioxidant capacity as an indicator of functional outcome. Journal 
of Cerebral Blood Flow and Metabolism, 1997. 17(10): p. 1007-1019. 
23. Shohami, E., A. Cohen-Yeshurun, L. Magid, M. Algali, and R. Mechoulam, 
Endocannabinoids and traumatic brain injury. Br J Pharmacol, 2011. 163(7): p. 
1402-10. 
24. Mammis, A., T.K. Mclntosh, and A.H. Maniker, Erythropoietin as a neuroprotective 
agent in traumatic brain injury Review. Surgical Neurology, 2009. 71(5): p. 527-531. 
25. Stein, D.G., Brain damage, sex hormones and recovery: a new role for progesterone 
and estrogen? Trends Neurosci, 2001. 24(7): p. 386-91. 
26. Langlois, J.A., W. Rutland-Brown, and M.M. Wald, The epidemiology and impact of 
traumatic brain injury: a brief overview. J Head Trauma Rehabil, 2006. 21(5): p. 375-
8. 
27. Shively, S., A.I. Scher, D.P. Perl, and R. Diaz-Arrastia, Dementia resulting from 
traumatic brain injury: what is the pathology? Arch Neurol, 2012. 69(10): p. 1245-
51. 
28. Fleminger, S., D.L. Oliver, S. Lovestone, S. Rabe-Hesketh, and A. Giora, Head injury 
as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial 
replication. J Neurol Neurosurg Psychiatry, 2003. 74(7): p. 857-62. 
29. Molloy, C., R.M. Conroy, D.R. Cotter, and M. Cannon, Is traumatic brain injury a 
risk factor for schizophrenia? A meta-analysis of case-controlled population-based 
studies. Schizophr Bull, 2011. 37(6): p. 1104-10. 
30. Bryant, R.A., M.L. O'Donnell, M. Creamer, A.C. McFarlane, C.R. Clark, and D. 
Silove, The psychiatric sequelae of traumatic injury. Am J Psychiatry, 2010. 167(3): 
p. 312-20. 
31. Schouten, J.W., Neuroprotection in traumatic brain injury: a complex struggle 
against the biology of nature. Curr Opin Crit Care, 2007. 13(2): p. 134-42. 
32. Ghajar, J., Traumatic brain injury. Lancet, 2000. 356(9233): p. 923-9. 
33. Teasdale, G. and B. Jennett, Assessment of coma and impaired consciousness. A 
practical scale. Lancet, 1974. 2(7872): p. 81-4. 
34. Balestreri, M., M. Czosnyka, D.A. Chatfield, L.A. Steiner, E.A. Schmidt, P. 
Smielewski, B. Matta, and J.D. Pickard, Predictive value of Glasgow Coma Scale 
after brain trauma: change in trend over the past ten years. J Neurol Neurosurg 
Psychiatry, 2004. 75(1): p. 161-2. 
35. Marshall, L.F., S.B. Marshall, M.R. Klauber, M.V. Clark, H.M. Eisenberg, J.A. Jane, 
T.G. Luerssen, A. Marmarou, and M.A. Foulkes, A New Classification of Head-Injury 
Based on Computerized-Tomography. Journal of Neurosurgery, 1991. 75: p. S14-S20. 
36. Mazzeo, A.T., A. Beat, A. Singh, and M.R. Bullock, The role of mitochondrial 
transition pore, and its modulation, in traumatic brain injury and delayed 
neurodegeneration after TBI. Exp Neurol, 2009. 218(2): p. 363-70. 
References 
 
Page 148 of 170 
 
37. Wang, K.K., S.F. Larner, G. Robinson, and R.L. Hayes, Neuroprotection targets after 
traumatic brain injury. Curr Opin Neurol, 2006. 19(6): p. 514-9. 
38. Bayir, H., R.S. Clark, and P.M. Kochanek, Promising strategies to minimize 
secondary brain injury after head trauma. Crit Care Med, 2003. 31(1 Suppl): p. S112-
7. 
39. Song, S.S. and P.D. Lyden, Overview of Therapeutic Hypothermia. Curr Treat 
Options Neurol, 2012. 
40. Maier, C.M., G.H. Sun, D. Cheng, M.A. Yenari, P.H. Chan, and G.K. Steinberg, 
Effects of mild hypothermia on superoxide anion production, superoxide dismutase 
expression, and activity following transient focal cerebral ischemia. Neurobiol Dis, 
2002. 11(1): p. 28-42. 
41. Karibe, H., S.F. Chen, G.J. Zarow, J. Gafni, S.H. Graham, P.H. Chan, and P.R. 
Weinstein, Mild intraischemic hypothermia suppresses consumption of endogenous 
antioxidants after temporary focal ischemia in rats. Brain Res, 1994. 649(1-2): p. 12-
8. 
42. Metz, C., M. Holzschuh, T. Bein, C. Woertgen, A. Frey, I. Frey, K. Taeger, and A. 
Brawanski, Moderate hypothermia in patients with severe head injury: cerebral and 
extracerebral effects. Journal of Neurosurgery, 1996. 85(4): p. 533-41. 
43. Peterson, K., S. Carson, and N. Carney, Hypothermia treatment for traumatic brain 
injury: a systematic review and meta-analysis. J Neurotrauma, 2008. 25(1): p. 62-71. 
44. Sydenham, E., I. Roberts, and P. Alderson, Hypothermia for traumatic head injury. 
Cochrane Database Syst Rev, 2009(2): p. CD001048. 
45. Clifton, G.L., A. Valadka, D. Zygun, C.S. Coffey, P. Drever, S. Fourwinds, L.S. 
Janis, E. Wilde, P. Taylor, K. Harshman, A. Conley, A. Puccio, H.S. Levin, S.R. 
McCauley, R.D. Bucholz, K.R. Smith, J.H. Schmidt, J.N. Scott, H. Yonas, and D.O. 
Okonkwo, Very early hypothermia induction in patients with severe brain injury (the 
National Acute Brain Injury Study: Hypothermia II): a randomised trial. Lancet 
Neurol, 2011. 10(2): p. 131-9. 
46. Ikonomidou, C. and L. Turski, Why did NMDA receptor antagonists fail clinical trials 
for stroke and traumatic brain injury? Lancet Neurol, 2002. 1(6): p. 383-6. 
47. Wilhelm, S., D. Ma, M. Maze, and N.P. Franks, Effects of xenon on in vitro and in 
vivo models of neuronal injury. Anesthesiology, 2002. 96(6): p. 1485-91. 
48. Wright, D.W., A.L. Kellermann, V.S. Hertzberg, P.L. Clark, M. Frankel, F.C. 
Goldstein, J.P. Salomone, L.L. Dent, O.A. Harris, D.S. Ander, D.W. Lowery, M.M. 
Patel, D.D. Denson, A.B. Gordon, M.M. Wald, S. Gupta, S.W. Hoffman, and D.G. 
Stein, ProTECT: a randomized clinical trial of progesterone for acute traumatic 
brain injury. Ann Emerg Med, 2007. 49(4): p. 391-402, 402 e1-2. 
49. Stein, D.G., D.W. Wright, and A.L. Kellermann, Does progesterone have 
neuroprotective properties? Ann Emerg Med, 2008. 51(2): p. 164-72. 
50. Coburn, M., M. Maze, and N.P. Franks, The neuroprotective effects of xenon and 
helium in an in vitro model of traumatic brain injury. Crit Care Med, 2008. 36(2): p. 
588-95. 
51. Loetscher, P.D., J. Rossaint, R. Rossaint, J. Weis, M. Fries, A. Fahlenkamp, Y.M. 
Ryang, O. Grottke, and M. Coburn, Argon: neuroprotection in in vitro models of 
cerebral ischemia and traumatic brain injury. Crit Care, 2009. 13(6): p. R206. 
52. Frizzell, J.P., Acute stroke: pathophysiology, diagnosis, and treatment. AACN Clin 
Issues, 2005. 16(4): p. 421-40; quiz 597-8. 
53. Bramlett, H.M. and W.D. Dietrich, Pathophysiology of cerebral ischemia and brain 
trauma: similarities and differences. J Cereb Blood Flow Metab, 2004. 24(2): p. 133-
50. 
References 
 
Page 149 of 170 
 
54. Turner, R.C., S.C. Dodson, C.L. Rosen, and J.D. Huber, The science of cerebral 
ischemia and the quest for neuroprotection: navigating past failure to future success. 
Journal of Neurosurgery, 2013. 118(5): p. 1072-85. 
55. Starkov, A.A., C. Chinopoulos, and G. Fiskum, Mitochondrial calcium and oxidative 
stress as mediators of ischemic brain injury. Cell Calcium, 2004. 36(3-4): p. 257-64. 
56. Broughton, B.R., D.C. Reutens, and C.G. Sobey, Apoptotic mechanisms after 
cerebral ischemia. Stroke, 2009. 40(5): p. e331-9. 
57. Lee, J.M., G.J. Zipfel, and D.W. Choi, The changing landscape of ischaemic brain 
injury mechanisms. Nature, 1999. 399(6738 Suppl): p. A7-14. 
58. Hobbs, C., M. Thoresen, A. Tucker, K. Aquilina, E. Chakkarapani, and J. Dingley, 
Xenon and hypothermia combine additively, offering long-term functional and 
histopathologic neuroprotection after neonatal hypoxia/ischemia. Stroke, 2008. 39(4): 
p. 1307-13. 
59. Lawrence, J.H., W.F. Loomis, and et al., Preliminary observations on the narcotic 
effect of xenon with a review of values for solubilities of gases in water and oils. J 
Physiol, 1946. 105(6): p. 197-204. 
60. Cullen, S.C. and E.G. Gross, The anesthetic properties of xenon in animals and 
human beings, with additional observations on krypton. Science, 1951. 113(2942): p. 
580-2. 
61. Cullen, S.C., E.I. Eger, 2nd, B.F. Cullen, and P. Gregory, Observations on the 
anesthetic effect of the combination of xenon and halothane. Anesthesiology, 1969. 
31(4): p. 305-9. 
62. Nakata, Y., T. Goto, Y. Ishiguro, K. Terui, H. Kawakami, M. Santo, Y. Niimi, and S. 
Morita, Minimum alveolar concentration (MAC) of xenon with sevoflurane in 
humans. Anesthesiology, 2001. 94(4): p. 611-4. 
63. Harris, P.D. and R. Barnes, The uses of helium and xenon in current clinical practice. 
Anaesthesia, 2008. 63(3): p. 284-93. 
64. Sanders, R.D., N.P. Franks, and M. Maze, Xenon: no stranger to anaesthesia. Br J 
Anaesth, 2003. 91(5): p. 709-17. 
65. Chakkarapani, E., J. Dingley, X. Liu, N. Hoque, K. Aquilina, H. Porter, and M. 
Thoresen, Xenon enhances hypothermic neuroprotection in asphyxiated newborn 
pigs. Ann Neurol, 2010. 68(3): p. 330-41. 
66. Thoresen, M., C.E. Hobbs, T. Wood, E. Chakkarapani, and J. Dingley, Cooling 
combined with immediate or delayed xenon inhalation provides equivalent long-term 
neuroprotection after neonatal hypoxia-ischemia. J Cereb Blood Flow Metab, 2009. 
29(4): p. 707-14. 
67. Dingley, J., J. Tooley, H. Porter, and M. Thoresen, Xenon provides short-term 
neuroprotection in neonatal rats when administered after hypoxia-ischemia. Stroke, 
2006. 37(2): p. 501-6. 
68. Banks, P., N.P. Franks, and R. Dickinson, Competitive inhibition at the glycine site of 
the N-methyl-D-aspartate receptor mediates xenon neuroprotection against hypoxia-
ischemia. Anesthesiology, 2010. 112(3): p. 614-22. 
69. Preckel, B., N.C. Weber, R.D. Sanders, M. Maze, and W. Schlack, Molecular 
mechanisms transducing the anesthetic, analgesic, and organ-protective actions of 
xenon. Anesthesiology, 2006. 105(1): p. 187-97. 
70. Georgiev, S.K., H. Furue, H. Baba, and T. Kohno, Xenon inhibits excitatory but not 
inhibitory transmission in rat spinal cord dorsal horn neurons. Mol Pain, 2010. 6: p. 
25. 
71. Franks, N.P., R. Dickinson, S.L. de Sousa, A.C. Hall, and W.R. Lieb, How does 
xenon produce anaesthesia? Nature, 1998. 396(6709): p. 324. 
References 
 
Page 150 of 170 
 
72. Haseneder, R., S. Kratzer, E. Kochs, V.S. Eckle, W. Zieglgansberger, and G. 
Rammes, Xenon reduces N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor-mediated synaptic transmission in the 
amygdala. Anesthesiology, 2008. 109(6): p. 998-1006. 
73. Yamakura, T. and R.A. Harris, Effects of gaseous anesthetics nitrous oxide and xenon 
on ligand-gated ion channels. Comparison with isoflurane and ethanol. 
Anesthesiology, 2000. 93(4): p. 1095-101. 
74. Dickinson, R. and N.P. Franks, Bench-to-bedside review: Molecular pharmacology 
and clinical use of inert gases in anesthesia and neuroprotection. Crit Care, 2010. 
14(4): p. 229. 
75. White, I.L., N.P. Franks, and R. Dickinson, Effects of isoflurane and xenon on Ba2+-
currents mediated by N-type calcium channels. Br J Anaesth, 2005. 94(6): p. 784-90. 
76. Dickinson, R., B.K. Peterson, P. Banks, C. Simillis, J.C. Martin, C.A. Valenzuela, M. 
Maze, and N.P. Franks, Competitive inhibition at the glycine site of the N-methyl-D-
aspartate receptor by the anesthetics xenon and isoflurane: evidence from molecular 
modeling and electrophysiology. Anesthesiology, 2007. 107(5): p. 756-67. 
77. Armstrong, S.P., P.J. Banks, T.J. McKitrick, C.H. Geldart, C.J. Edge, R. Babla, C. 
Simillis, N.P. Franks, and R. Dickinson, Identification of two mutations (F758W and 
F758Y) in the N-methyl-D-aspartate receptor glycine-binding site that selectively 
prevent competitive inhibition by xenon without affecting glycine binding. 
Anesthesiology, 2012. 117(1): p. 38-47. 
78. Gruss, M., T.J. Bushell, D.P. Bright, W.R. Lieb, A. Mathie, and N.P. Franks, Two-
pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous 
oxide, and cyclopropane. Mol Pharmacol, 2004. 65(2): p. 443-52. 
79. Bantel, C., M. Maze, and S. Trapp, Neuronal preconditioning by inhalational 
anesthetics: evidence for the role of plasmalemmal adenosine triphosphate-sensitive 
potassium channels. Anesthesiology, 2009. 110(5): p. 986-95. 
80. Bantel, C., M. Maze, and S. Trapp, Noble gas xenon is a novel adenosine 
triphosphate-sensitive potassium channel opener. Anesthesiology, 2010. 112(3): p. 
623-30. 
81. Suzuki, T., K. Ueta, M. Sugimoto, I. Uchida, and T. Mashimo, Nitrous oxide and 
xenon inhibit the human (alpha 7)5 nicotinic acetylcholine receptor expressed in 
Xenopus oocyte. Anesth Analg, 2003. 96(2): p. 443-8, table of contents. 
82. Suzuki, T., H. Koyama, M. Sugimoto, I. Uchida, and T. Mashimo, The diverse actions 
of volatile and gaseous anesthetics on human-cloned 5-hydroxytryptamine3 receptors 
expressed in Xenopus oocytes. Anesthesiology, 2002. 96(3): p. 699-704. 
83. Luo, Y., D. Ma, E. Ieong, R.D. Sanders, B. Yu, M. Hossain, and M. Maze, Xenon and 
sevoflurane protect against brain injury in a neonatal asphyxia model. 
Anesthesiology, 2008. 109(5): p. 782-9. 
84. David, H.N., B. Haelewyn, C. Rouillon, M. Lecoq, L. Chazalviel, G. Apiou, J.J. 
Risso, M. Lemaire, and J.H. Abraini, Neuroprotective effects of xenon: a therapeutic 
window of opportunity in rats subjected to transient cerebral ischemia. FASEB J, 
2008. 22(4): p. 1275-86. 
85. Ma, D., M. Hossain, A. Chow, M. Arshad, R.M. Battson, R.D. Sanders, H. Mehmet, 
A.D. Edwards, N.P. Franks, and M. Maze, Xenon and hypothermia combine to 
provide neuroprotection from neonatal asphyxia. Ann Neurol, 2005. 58(2): p. 182-93. 
86. Petzelt, C., P. Blom, W. Schmehl, J. Muller, and W.J. Kox, Prevention of 
neurotoxicity in hypoxic cortical neurons by the noble gas xenon. Life Sci, 2003. 
72(17): p. 1909-18. 
References 
 
Page 151 of 170 
 
87. Ma, D., S. Wilhelm, M. Maze, and N.P. Franks, Neuroprotective and neurotoxic 
properties of the 'inert' gas, xenon. Br J Anaesth, 2002. 89(5): p. 739-46. 
88. Fries, M., K.W. Nolte, M. Coburn, S. Rex, A. Timper, K. Kottmann, K. Siepmann, M. 
Hausler, J. Weis, and R. Rossaint, Xenon reduces neurohistopathological damage and 
improves the early neurological deficit after cardiac arrest in pigs. Crit Care Med, 
2008. 36(8): p. 2420-6. 
89. Homi, H.M., N. Yokoo, D. Ma, D.S. Warner, N.P. Franks, M. Maze, and H.P. 
Grocott, The neuroprotective effect of xenon administration during transient middle 
cerebral artery occlusion in mice. Anesthesiology, 2003. 99(4): p. 876-81. 
90. Limatola, V., P. Ward, D. Cattano, J. Gu, F. Giunta, M. Maze, and D. Ma, Xenon 
preconditioning confers neuroprotection regardless of gender in a mouse model of 
transient middle cerebral artery occlusion. Neuroscience, 2010. 165(3): p. 874-81. 
91. Martin, J.L., D. Ma, M. Hossain, J. Xu, R.D. Sanders, N.P. Franks, and M. Maze, 
Asynchronous administration of xenon and hypothermia significantly reduces brain 
infarction in the neonatal rat. Br J Anaesth, 2007. 98(2): p. 236-40. 
92. Dickinson, R., W.R. Lieb, and N.P. Franks, The effects of temperature on the 
interactions between volatile general anaesthetics and a neuronal nicotinic 
acetylcholine receptor. Br J Pharmacol, 1995. 116(7): p. 2949-56. 
93. McKenzie, J.D., P. Calow, J. Clyde, A. Miles, R. Dickinson, W.R. Lieb, and N.P. 
Franks, Effects of temperature on the anaesthetic potency of halothane, enflurane and 
ethanol in Daphnia magna (Cladocera: Crustacea). Comp Biochem Physiol C, 1992. 
101(1): p. 15-9. 
94. Dickinson, R., N.P. Franks, and W.R. Lieb, Thermodynamics of anesthetic/protein 
interactions. Temperature studies on firefly luciferase. Biophys J, 1993. 64(4): p. 
1264-71. 
95. Jawad, N., M. Rizvi, J. Gu, O. Adeyi, G. Tao, M. Maze, and D. Ma, Neuroprotection 
(and lack of neuroprotection) afforded by a series of noble gases in an in vitro model 
of neuronal injury. Neurosci Lett, 2009. 460(3): p. 232-6. 
96. Seto, T., H. Isogai, M. Ozaki, and S. Nosaka, Noble gas binding to human serum 
albumin using docking simulation: nonimmobilizers and anesthetics bind to different 
sites. Anesth Analg, 2008. 107(4): p. 1223-8. 
97. Trudell, J.R., D.D. Koblin, and E.I. Eger, 2nd, A molecular description of how noble 
gases and nitrogen bind to a model site of anesthetic action. Anesth Analg, 1998. 
87(2): p. 411-8. 
98. Pan, Y., H. Zhang, D.R. VanDeripe, S. Cruz-Flores, and W.M. Panneton, Heliox and 
oxygen reduce infarct volume in a rat model of focal ischemia. Exp Neurol, 2007. 
205(2): p. 587-90. 
99. David, H.N., B. Haelewyn, L. Chazalviel, M. Lecocq, M. Degoulet, J.J. Risso, and 
J.H. Abraini, Post-ischemic helium provides neuroprotection in rats subjected to 
middle cerebral artery occlusion-induced ischemia by producing hypothermia. J 
Cereb Blood Flow Metab, 2009. 29(6): p. 1159-65. 
100. Ryang, Y.M., A.V. Fahlenkamp, R. Rossaint, D. Wesp, P.D. Loetscher, C. Beyer, and 
M. Coburn, Neuroprotective effects of argon in an in vivo model of transient middle 
cerebral artery occlusion in rats. Crit Care Med, 2011. 39(6): p. 1448-53. 
101. David, H.N., B. Haelewyn, M. Degoulet, D.G. Colomb, Jr., J.J. Risso, and J.H. 
Abraini, Ex vivo and in vivo neuroprotection induced by argon when given after an 
excitotoxic or ischemic insult. PLoS One, 2012. 7(2): p. e30934. 
102. Brucken, A., A. Cizen, C. Fera, A. Meinhardt, J. Weis, K. Nolte, R. Rossaint, T. Pufe, 
G. Marx, and M. Fries, Argon reduces neurohistopathological damage and preserves 
References 
 
Page 152 of 170 
 
functional recovery after cardiac arrest in rats. Br J Anaesth, 2013. 110 Suppl 1: p. 
i106-12. 
103. Sanders, R.D., D. Ma, and M. Maze, Argon neuroprotection. Crit Care, 2010. 14(1): 
p. 117. 
104. Gahwiler, B.H., Organotypic cultures of neural tissue. Trends Neurosci, 1988. 
11(11): p. 484-9. 
105. Gahwiler, B.H., M. Capogna, D. Debanne, R.A. McKinney, and S.M. Thompson, 
Organotypic slice cultures: a technique has come of age. Trends Neurosci, 1997. 
20(10): p. 471-7. 
106. De Simoni, A., C.B. Griesinger, and F.A. Edwards, Development of rat CA1 neurones 
in acute versus organotypic slices: role of experience in synaptic morphology and 
activity. J Physiol, 2003. 550(Pt 1): p. 135-47. 
107. Kotapka, M.J., D.I. Graham, J.H. Adams, and T.A. Gennarelli, Hippocampal 
pathology in fatal non-missile human head injury. Acta Neuropathol, 1992. 83(5): p. 
530-4. 
108. Watanabe, M., M. Fukaya, K. Sakimura, T. Manabe, M. Mishina, and Y. Inoue, 
Selective scarcity of NMDA receptor channel subunits in the stratum lucidum (mossy 
fibre-recipient layer) of the mouse hippocampal CA3 subfield. Eur J Neurosci, 1998. 
10(2): p. 478-87. 
109. Stoppini, L., P.A. Buchs, and D. Muller, A simple method for organotypic cultures of 
nervous tissue. J Neurosci Methods, 1991. 37(2): p. 173-82. 
110. Morrison, B., 3rd, H.L. Cater, C.D. Benham, and L.E. Sundstrom, An in vitro model 
of traumatic brain injury utilising two-dimensional stretch of organotypic 
hippocampal slice cultures. J Neurosci Methods, 2006. 150(2): p. 192-201. 
111. Morrison, B., 3rd, B.S. Elkin, J.P. Dolle, and M.L. Yarmush, In vitro models of 
traumatic brain injury. Annu Rev Biomed Eng, 2011. 13: p. 91-126. 
112. Adamchik, Y., M.V. Frantseva, M. Weisspapir, P.L. Carlen, and J.L. Perez 
Velazquez, Methods to induce primary and secondary traumatic damage in 
organotypic hippocampal slice cultures. Brain Res Brain Res Protoc, 2000. 5(2): p. 
153-8. 
113. Adembri, C., A. Bechi, E. Meli, E. Gramigni, L. Venturi, F. Moroni, A.R. De Gaudio, 
and D.E. Pellegrini-Giampietro, Erythropoietin attenuates post-traumatic injury in 
organotypic hippocampal slices. J Neurotrauma, 2004. 21(8): p. 1103-12. 
114. Macklis, J.D. and R.D. Madison, Progressive incorporation of propidium iodide in 
cultured mouse neurons correlates with declining electrophysiological status: a 
fluorescence scale of membrane integrity. J Neurosci Methods, 1990. 31(1): p. 43-6. 
115. Noraberg, J., B.W. Kristensen, and J. Zimmer, Markers for neuronal degeneration in 
organotypic slice cultures. Brain Res Brain Res Protoc, 1999. 3(3): p. 278-90. 
116. Downie, D.L., A.C. Hall, W.R. Lieb, and N.P. Franks, Effects of inhalational general 
anaesthetics on native glycine receptors in rat medullary neurones and recombinant 
glycine receptors in Xenopus oocytes. Br J Pharmacol, 1996. 118(3): p. 493-502. 
117. Cho, S., A. Wood, and M.R. Bowlby, Brain slices as models for neurodegenerative 
disease and screening platforms to identify novel therapeutics. Curr Neuropharmacol, 
2007. 5(1): p. 19-33. 
118. Hailer, N.P., J.D. Jarhult, and R. Nitsch, Resting microglial cells in vitro: analysis of 
morphology and adhesion molecule expression in organotypic hippocampal slice 
cultures. Glia, 1996. 18(4): p. 319-31. 
119. Mewes, A., H. Franke, and D. Singer, Organotypic Brain Slice Cultures of Adult 
Transgenic P301S Mice-A Model for Tauopathy Studies. PLoS One, 2012. 7(9): p. 
e45017. 
References 
 
Page 153 of 170 
 
120. del Rio, J.A., B. Heimrich, E. Soriano, H. Schwegler, and M. Frotscher, Proliferation 
and differentiation of glial fibrillary acidic protein-immunoreactive glial cells in 
organotypic slice cultures of rat hippocampus. Neuroscience, 1991. 43(2-3): p. 335-
47. 
121. Morrison, B., 3rd, K.E. Saatman, D.F. Meaney, and T.K. McIntosh, In vitro central 
nervous system models of mechanically induced trauma: a review. J Neurotrauma, 
1998. 15(11): p. 911-28. 
122. Su, T., B. Paradiso, Y.S. Long, W.P. Liao, and M. Simonato, Evaluation of cell 
damage in organotypic hippocampal slice culture from adult mouse: a potential 
model system to study neuroprotection. Brain Res, 2011. 1385: p. 68-76. 
123. Blaha, M., J. Schwab, O. Vajnerova, M. Bednar, L. Vajner, and T. Michal, 
Intracranial pressure and experimental model of diffuse brain injury in rats. J Korean 
Neurosurg Soc, 2010. 47(1): p. 7-10. 
124. Adelson, P.D., P. Robichaud, R.L. Hamilton, and P.M. Kochanek, A model of diffuse 
traumatic brain injury in the immature rat. Journal of Neurosurgery, 1996. 85(5): p. 
877-84. 
125. Finley, M., D. Fairman, D. Liu, P. Li, A. Wood, and S. Cho, Functional validation of 
adult hippocampal organotypic cultures as an in vitro model of brain injury. Brain 
Res, 2004. 1001(1-2): p. 125-32. 
126. Newell, D.W., A. Barth, V. Papermaster, and A.T. Malouf, Glutamate and non-
glutamate receptor mediated toxicity caused by oxygen and glucose deprivation in 
organotypic hippocampal cultures. J Neurosci, 1995. 15(11): p. 7702-11. 
127. Colicos, M.A., C.E. Dixon, and P.K. Dash, Delayed, selective neuronal death 
following experimental cortical impact injury in rats: possible role in memory 
deficits. Brain Res, 1996. 739(1-2): p. 111-9. 
128. Hall, E.D., P.G. Sullivan, T.R. Gibson, K.M. Pavel, B.M. Thompson, and S.W. 
Scheff, Spatial and temporal characteristics of neurodegeneration after controlled 
cortical impact in mice: more than a focal brain injury. J Neurotrauma, 2005. 22(2): 
p. 252-65. 
129. Monaghan, D.T. and C.W. Cotman, Distribution of N-methyl-D-aspartate-sensitive L-
[3H]glutamate-binding sites in rat brain. J Neurosci, 1985. 5(11): p. 2909-19. 
130. Kristensen, B.W., J. Noraberg, and J. Zimmer, Comparison of excitotoxic profiles of 
ATPA, AMPA, KA and NMDA in organotypic hippocampal slice cultures. Brain Res, 
2001. 917(1): p. 21-44. 
131. Miller, K.W., M.W. Wilson, and R.A. Smith, Pressure resolves two sites of action of 
inert gases. Mol Pharmacol, 1978. 14(5): p. 950-9. 
132. Miller, K.W. and M.W. Wilson, The pressure reversal of a variety of anesthetic 
agents in mice. Anesthesiology, 1978. 48(2): p. 104-10. 
133. Brucken, A., P. Kurnaz, C. Bleilevens, M. Derwall, J. Weis, K. Nolte, R. Rossaint, 
and M. Fries, Dose dependent neuroprotection of the noble gas argon after cardiac 
arrest in rats is not mediated by K-Channel opening. Resuscitation, 2014. 
134. Zhuang, L., T. Yang, H. Zhao, A.R. Fidalgo, M.P. Vizcaychipi, R.D. Sanders, B. Yu, 
M. Takata, M.R. Johnson, and D. Ma, The protective profile of argon, helium, and 
xenon in a model of neonatal asphyxia in rats. Crit Care Med, 2012. 40(6): p. 1724-
30. 
135. Pan, Y., H.B. Zhang, D.R. VanDeripe, S. Cruz-Flores, and W.M. Panneton, Heliox 
and oxygen reduce infarct volume in a rat model of focal ischemia. Experimental 
Neurology, 2007. 205(2): p. 587-590. 
References 
 
Page 154 of 170 
 
136. Pan, Y., H. Zhang, A.B. Acharya, S. Cruz-Flores, and W.M. Panneton, The effect of 
heliox treatment in a rat model of focal transient cerebral ischemia. Neurosci Lett, 
2011. 497(2): p. 144-7. 
137. Pagel, P.S., J.G. Krolikowski, Y.H. Shim, S. Venkatapuram, J.R. Kersten, D. 
Weihrauch, D.C. Warltier, and P.F. Pratt, Jr., Noble gases without anesthetic 
properties protect myocardium against infarction by activating prosurvival signaling 
kinases and inhibiting mitochondrial permeability transition in vivo. Anesth Analg, 
2007. 105(3): p. 562-9. 
138. Wallis, R.A., K.L. Panizzon, and J.P. Nolan, Glycine-induced CA1 excitotoxicity in 
the rat hippocampal slice. Brain Res, 1994. 664(1-2): p. 115-25. 
139. Barth, A., L.B. Nguyen, L. Barth, and D.W. Newell, Glycine-induced neurotoxicity in 
organotypic hippocampal slice cultures. Exp Brain Res, 2005. 161(3): p. 351-7. 
140. McNamara, D. and R. Dingledine, Dual effect of glycine on NMDA-induced 
neurotoxicity in rat cortical cultures. J Neurosci, 1990. 10(12): p. 3970-6. 
141. Newell, D.W., A. Barth, and A.T. Malouf, Glycine site NMDA receptor antagonists 
provide protection against ischemia-induced neuronal damage in hippocampal slice 
cultures. Brain Res, 1995. 675(1-2): p. 38-44. 
142. Katsuki, H., Y. Watanabe, S. Fujimoto, T. Kume, and A. Akaike, Contribution of 
endogenous glycine and d-serine to excitotoxic and ischemic cell death in rat 
cerebrocortical slice cultures. Life Sci, 2007. 81(9): p. 740-9. 
143. Obrenovitch, T.P., A.M. Hardy, and J. Urenjak, High extracellular glycine does not 
potentiate N-methyl-D-aspartate-evoked depolarization in vivo. Brain Res, 1997. 
746(1-2): p. 190-4. 
144. Ogita, K. and Y. Yoneda, 6,7-Dichloroquinoxaline-2,3-dione is a competitive 
antagonist specific to strychnine-insensitive [3H]glycine binding sites on the N-
methyl-D-aspartate receptor complex. J Neurochem, 1990. 54(2): p. 699-702. 
145. Foster, A.C. and J.A. Kemp, HA-966 antagonizes N-methyl-D-aspartate receptors 
through a selective interaction with the glycine modulatory site. J Neurosci, 1989. 
9(6): p. 2191-6. 
146. Drejer, J., M. Sheardown, E.O. Nielsen, and T. Honore, Glycine reverses the effect of 
HA-966 on NMDA responses in cultured rat cortical neurons and in chick retina. 
Neurosci Lett, 1989. 98(3): p. 333-8. 
147. Huettner, J.E., Competitive antagonism of glycine at the N-methyl-D-aspartate 
(NMDA) receptor. Biochem Pharmacol, 1991. 41(1): p. 9-16. 
148. Mothet, J.P., A.T. Parent, H. Wolosker, R.O. Brady, Jr., D.J. Linden, C.D. Ferris, 
M.A. Rogawski, and S.H. Snyder, D-serine is an endogenous ligand for the glycine 
site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A, 2000. 97(9): p. 
4926-31. 
149. Shleper, M., E. Kartvelishvily, and H. Wolosker, D-serine is the dominant 
endogenous coagonist for NMDA receptor neurotoxicity in organotypic hippocampal 
slices. J Neurosci, 2005. 25(41): p. 9413-7. 
150. Rosenberg, D., S. Artoul, A.C. Segal, G. Kolodney, I. Radzishevsky, E. Dikopoltsev, 
V.N. Foltyn, R. Inoue, H. Mori, J.M. Billard, and H. Wolosker, Neuronal D-serine 
and glycine release via the Asc-1 transporter regulates NMDA receptor-dependent 
synaptic activity. J Neurosci, 2013. 33(8): p. 3533-44. 
151. Yashiro, K. and B.D. Philpot, Regulation of NMDA receptor subunit expression and 
its implications for LTD, LTP, and metaplasticity. Neuropharmacology, 2008. 55(7): 
p. 1081-94. 
152. Haseneder, R., S. Kratzer, E. Kochs, D. Hofelmann, Y. Auberson, M. Eder, and G. 
Rammes, The xenon-mediated antagonism against the NMDA receptor is non-
References 
 
Page 155 of 170 
 
selective for receptors containing either NR2A or NR2B subunits in the mouse 
amygdala. Eur J Pharmacol, 2009. 619(1-3): p. 33-7. 
153. Kratzer, S., C. Mattusch, E. Kochs, M. Eder, R. Haseneder, and G. Rammes, Xenon 
Attenuates Hippocampal Long-term Potentiation by Diminishing Synaptic and 
Extrasynaptic N-methyl-D-aspartate Receptor Currents. Anesthesiology, 2012. 
154. Hardingham, G.E. and H. Bading, The Yin and Yang of NMDA receptor signalling. 
Trends Neurosci, 2003. 26(2): p. 81-9. 
155. Stoffel, M., N. Plesnila, J. Eriskat, M. Furst, and A. Baethmann, Release of excitatory 
amino acids in the penumbra of a focal cortical necrosis. J Neurotrauma, 2002. 19(4): 
p. 467-77. 
156. Ballanyi, K., Protective role of neuronal KATP channels in brain hypoxia. J Exp Biol, 
2004. 207(Pt 18): p. 3201-12. 
157. Yamada, K., J.J. Ji, H. Yuan, T. Miki, S. Sato, N. Horimoto, T. Shimizu, S. Seino, 
and N. Inagaki, Protective role of ATP-sensitive potassium channels in hypoxia-
induced generalized seizure. Science, 2001. 292(5521): p. 1543-6. 
158. Heurteaux, C., N. Guy, C. Laigle, N. Blondeau, F. Duprat, M. Mazzuca, L. Lang-
Lazdunski, C. Widmann, M. Zanzouri, G. Romey, and M. Lazdunski, TREK-1, a K+ 
channel involved in neuroprotection and general anesthesia. EMBO J, 2004. 23(13): 
p. 2684-95. 
159. Fahlenkamp, A.V., M. Coburn, H. Haase, M. Kipp, Y.M. Ryang, R. Rossaint, and C. 
Beyer, Xenon enhances LPS-induced IL-1beta expression in microglia via the 
extracellular signal-regulated kinase 1/2 pathway. J Mol Neurosci, 2011. 45(1): p. 
48-59. 
160. Deng, J., C. Lei, Y. Chen, Z. Fang, Q. Yang, H. Zhang, M. Cai, L. Shi, H. Dong, and 
L. Xiong, Neuroprotective gases - Fantasy or reality for clinical use? Prog Neurobiol, 
2014. 
161. Fahlenkamp, A.V., R. Rossaint, H. Haase, H. Al Kassam, Y.M. Ryang, C. Beyer, and 
M. Coburn, The noble gas argon modifies extracellular signal-regulated kinase 1/2 
signaling in neurons and glial cells. Eur J Pharmacol, 2012. 674(2-3): p. 104-11. 
162. Abraini, J.H., B. Kriem, N. Balon, J.C. Rostain, and J.J. Risso, Gamma-aminobutyric 
acid neuropharmacological investigations on narcosis produced by nitrogen, argon, 
or nitrous oxide. Anesth Analg, 2003. 96(3): p. 746-9, table of contents. 
163. Bickler, P.E., D.S. Warner, G. Stratmann, and J.A. Schuyler, gamma-Aminobutyric 
acid-A receptors contribute to isoflurane neuroprotection in organotypic 
hippocampal cultures. Anesth Analg, 2003. 97(2): p. 564-71, table of contents. 
164. Schwartz-Bloom, R.D., K.A. Miller, D.A. Evenson, B.J. Crain, and J.V. Nadler, 
Benzodiazepines protect hippocampal neurons from degeneration after transient 
cerebral ischemia: an ultrastructural study. Neuroscience, 2000. 98(3): p. 471-84. 
165. Zhang, F., C. Li, R. Wang, D. Han, Q.G. Zhang, C. Zhou, H.M. Yu, and G.Y. Zhang, 
Activation of GABA receptors attenuates neuronal apoptosis through inhibiting the 
tyrosine phosphorylation of NR2A by Src after cerebral ischemia and reperfusion. 
Neuroscience, 2007. 150(4): p. 938-49. 
166. Xu, J., C. Li, X.H. Yin, and G.Y. Zhang, Additive neuroprotection of GABA A and 
GABA B receptor agonists in cerebral ischemic injury via PI-3K/Akt pathway 
inhibiting the ASK1-JNK cascade. Neuropharmacology, 2008. 54(7): p. 1029-40. 
167. Galeffi, F., S. Sinnar, and R.D. Schwartz-Bloom, Diazepam promotes ATP recovery 
and prevents cytochrome c release in hippocampal slices after in vitro ischemia. J 
Neurochem, 2000. 75(3): p. 1242-9. 
168. Vannucci, R.C. and J.M. Perlman, Interventions for perinatal hypoxic-ischemic 
encephalopathy. Pediatrics, 1997. 100(6): p. 1004-14. 
References 
 
Page 156 of 170 
 
169. Ma, D.Q., M. Hossain, G.K.J. Pettet, Y. Luo, T. Lim, S. Akimov, R.D. Sanders, N.P. 
Franks, and M. Maze, Xenon preconditioning reduces brain damage from neonatal 
asphyxia in rats. Journal of Cerebral Blood Flow and Metabolism, 2006. 26(2): p. 
199-208. 
170. Luo, Y., D.Q. Ma, E. Leong, R.D. Sanders, B.W. Yu, M. Hossain, and M. Maze, 
Xenon and Sevoflurane Protect against Brain Injury in a Neonatal Asphyxia Model. 
Anesthesiology, 2008. 109(5): p. 782-789. 
171. Fries, M., A. Brucken, A. Cizen, M. Westerkamp, C. Lower, J. Deike-Glindemann, 
N.K. Schnorrenberger, S. Rex, M. Coburn, K.W. Nolte, J. Weis, R. Rossaint, and M. 
Derwall, Combining xenon and mild therapeutic hypothermia preserves neurological 
function after prolonged cardiac arrest in pigs*. Crit Care Med, 2012. 40(4): p. 1297-
303. 
172. Busto, R., M.Y. Globus, W.D. Dietrich, E. Martinez, I. Valdes, and M.D. Ginsberg, 
Effect of mild hypothermia on ischemia-induced release of neurotransmitters and free 
fatty acids in rat brain. Stroke, 1989. 20(7): p. 904-10. 
173. Yenari, M.A., S. Iwayama, D. Cheng, G.H. Sun, M. Fujimura, Y. Morita-Fujimura, 
P.H. Chan, and G.K. Steinberg, Mild hypothermia attenuates cytochrome c release 
but does not alter Bcl-2 expression or caspase activation after experimental stroke. J 
Cereb Blood Flow Metab, 2002. 22(1): p. 29-38. 
174. Ji, X., Y. Luo, F. Ling, R.A. Stetler, J. Lan, G. Cao, and J. Chen, Mild hypothermia 
diminishes oxidative DNA damage and pro-death signaling events after cerebral 
ischemia: a mechanism for neuroprotection. Front Biosci, 2007. 12: p. 1737-47. 
175. Ooboshi, H., S. Ibayashi, K. Takano, S. Sadoshima, A. Kondo, H. Uchimura, and M. 
Fujishima, Hypothermia inhibits ischemia-induced efflux of amino acids and neuronal 
damage in the hippocampus of aged rats. Brain Res, 2000. 884(1--2): p. 23-30. 
176. Hynd, M.R., H.L. Scott, and P.R. Dodd, Glutamate-mediated excitotoxicity and 
neurodegeneration in Alzheimer's disease. Neurochem Int, 2004. 45(5): p. 583-95. 
177. Muir, K.W., Glutamate-based therapeutic approaches: clinical trials with NMDA 
antagonists. Curr Opin Pharmacol, 2006. 6(1): p. 53-60. 
178. Sacco, R.L., J.T. DeRosa, E.C. Haley, Jr., B. Levin, P. Ordronneau, S.J. Phillips, T. 
Rundek, R.G. Snipes, and J.L. Thompson, Glycine antagonist in neuroprotection for 
patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA, 
2001. 285(13): p. 1719-28. 
179. Lees, K.R., K. Asplund, A. Carolei, S.M. Davis, H.C. Diener, M. Kaste, J.M. 
Orgogozo, and J. Whitehead, Glycine antagonist (gavestinel) in neuroprotection 
(GAIN International) in patients with acute stroke: a randomised controlled trial. 
GAIN International Investigators. Lancet, 2000. 355(9219): p. 1949-54. 
180. Hoke, J.F., A.G. Dyker, R.J. Barnaby, and K.R. Lees, Pharmacokinetics of a glycine 
site antagonist (gavestinel) following multiple dosing in patients with acute stroke. 
Eur J Clin Pharmacol, 2000. 55(11-12): p. 867-72. 
181. Rawat, S. and J. Dingley, Closed-circuit xenon delivery using a standard anesthesia 
workstation. Anesth Analg, 2010. 110(1): p. 101-9. 
182. Karadottir, R. and D. Attwell, Neurotransmitter receptors in the life and death of 
oligodendrocytes. Neuroscience, 2007. 145(4): p. 1426-38. 
183. Salter, M.G. and R. Fern, NMDA receptors are expressed in developing 
oligodendrocyte processes and mediate injury. Nature, 2005. 438(7071): p. 1167-71. 
184. Karadottir, R., P. Cavelier, L.H. Bergersen, and D. Attwell, NMDA receptors are 
expressed in oligodendrocytes and activated in ischaemia. Nature, 2005. 438(7071): 
p. 1162-6. 
References 
 
Page 157 of 170 
 
185. Micu, I., Q. Jiang, E. Coderre, A. Ridsdale, L. Zhang, J. Woulfe, X. Yin, B.D. Trapp, 
J.E. McRory, R. Rehak, G.W. Zamponi, W. Wang, and P.K. Stys, NMDA receptors 
mediate calcium accumulation in myelin during chemical ischaemia. Nature, 2006. 
439(7079): p. 988-92. 
186. Bakiri, Y., N.B. Hamilton, R. Karadottir, and D. Attwell, Testing NMDA receptor 
block as a therapeutic strategy for reducing ischaemic damage to CNS white matter. 
Glia, 2008. 56(2): p. 233-40. 
187. Lotocki, G., J.P. de Rivero Vaccari, O. Alonso, J.S. Molano, R. Nixon, P. Safavi, 
W.D. Dietrich, and H.M. Bramlett, Oligodendrocyte vulnerability following traumatic 
brain injury in rats. Neurosci Lett, 2011. 499(3): p. 143-8. 
188. Berger, T. and M. Frotscher, Distribution and morphological characteristics of 
oligodendrocytes in the rat hippocampus in situ and in vitro: an immunocytochemical 
study with the monoclonal Rip antibody. J Neurocytol, 1994. 23(1): p. 61-74. 
 
Appendix 
 
Page 158 of 170 
 
APPENDIX 
Appendix A    
 
The data presented in this thesis was published in Anesthesiology, 2013 Nov;119(5):1137-48 
 
Appendix 
 
Page 159 of 170 
 
Appendix 
 
Page 160 of 170 
 
Appendix 
 
Page 161 of 170 
 
Appendix 
 
Page 162 of 170 
 
Appendix 
 
Page 163 of 170 
 
Appendix 
 
Page 164 of 170 
 
Appendix 
 
Page 165 of 170 
 
Appendix 
 
Page 166 of 170 
 
Appendix 
 
Page 167 of 170 
 
Appendix 
 
Page 168 of 170 
 
Appendix 
 
Page 169 of 170 
 
Appendix 
 
Page 170 of 170 
 
 
 
